|
|
Download Full Issue
Show Outline
Highlights
•
Systemic metabolism affects immune cell metabolism
•
Hypercholesterolemia suppresses the PPP and Nrf2 pathway in macrophages
•
PPP inhibition and hypercholesterolemia deactivate inflammatory macrophage responses
•
The Nrf2 pathway regulates the PPP in an LXR-independent manner
Summary
Metabolic reprogramming has emerged as a crucial regulator of immune cell activation, but how systemic metabolism influences immune cell metabolism and function remains to be investigated. To investigate the effect of dyslipidemia on immune cell metabolism, we performed in-depth transcriptional, metabolic, and functional characterization of macrophages isolated from hypercholesterolemic mice. Systemic metabolic changes in such mice alter cellular macrophage metabolism and attenuate inflammatory macrophage responses. In addition to diminished maximal mitochondrial respiration, hypercholesterolemia reduces the LPS-mediated induction of the pentose phosphate pathway (PPP) and the Nrf2-mediated oxidative stress response. Our observation that suppression of the PPP diminishes LPS-induced cytokine secretion supports the notion that this pathway contributes to inflammatory macrophage responses. Overall, this study reveals that systemic and cellular metabolism are strongly interconnected, together dictating macrophage phenotype and function.
전신 대사가 면역 세포 대사에 영향을 미침
Systemic metabolism affects immune cell metabolism
고콜레스테롤혈증은 대식세포에서 PPP 및 Nrf2 경로를 억제함
Hypercholesterolemia suppresses the PPP and Nrf2 pathway in macrophages
PPP 억제 및 고콜레스테롤혈증은 염증성 대식세포 반응을 비활성화함
PPP inhibition and hypercholesterolemia deactivate inflammatory macrophage responses
Nrf2 경로는 LXR 독립적인 방식으로 PPP를 조절함
요약
대사 재프로그래밍 Metabolic reprogramming은
면역 세포 활성화의 핵심 조절자로 부상했으나,
전신 대사가 면역 세포 대사와 기능에 미치는 영향은 아직 연구가 필요한 분야이다.
이상지질혈증이 면역 세포 대사에 미치는 영향을 조사하기 위해,
고콜레스테롤혈증 마우스에서 분리된 대식세포의 전사체, 대사 및 기능적 특성을
심층 분석하였다.
이러한 마우스의 전신 대사 변화는
세포 내 대식세포 대사를 변형시키고
염증성 대식세포 반응을 약화시킨다.
고콜레스테롤혈증은
최대 미토콘드리아 호흡 감소 외에도,
LPS 매개 오탄당인산경로(PPP) 유도 및 Nrf2 매개 산화 스트레스 반응을 감소시킵니다.
PPP 억제가
LPS 유도 사이토카인 분비를 감소시킨다는 우리의 관찰은
이 경로가 염증성 대식세포 반응에 기여한다는 개념을 뒷받침합니다.
종합적으로,
본 연구는 전신 및 세포 대사가 강력하게 상호 연결되어
대식세포 표현형과 기능을 함께 결정한다는 사실을 밝힙니다.
Graphical Abstract
Keywords
Introduction
In recent years, metabolic reprogramming arose as a crucial controller of macrophage activation (Van den Bossche et al., 2016, 2017). For instance, in response to pro-inflammatory stimuli such as the Toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS), macrophages show increased glycolysis, as demonstrated by an enhanced extracellular acidification rate (ECAR) (Van den Bossche et al., 2016). Moreover, LPS reconfigures the tricarboxylic acid (TCA) cycle in macrophages and induces itaconate and succinate accumulation (Jha et al., 2015; Tannahill et al., 2013). Itaconate is a key controller of inflammatory macrophage responses through its regulatory effect on succinate dehydrogenase and its activation of the anti-oxidant transcription factor Nrf2 (Lampropoulou et al., 2016; Michelucci et al., 2013; Mills et al., 2018). Succinate promotes inflammation by inducing interleukin 1β (IL-1β) expression (Mills et al., 2016; Tannahill et al., 2013) and can activate immune cells in the local environment upon secretion (Littlewood-Evans et al., 2016). Furthermore, the activity of the pentose phosphate pathway (PPP) is enhanced in LPS-stimulated macrophages, supplying precursors for nucleotide synthesis and nicotinamide adenine dinucleotide phosphate (NADPH), which is used for reactive oxygen species (ROS) production by NADPH oxidase, fatty acid synthesis, and anti-oxidant cellular defense (Nagy and Haschemi, 2015; Wu et al., 2008). So far, most knowledge regarding macrophage immunometabolism was obtained with in vitro-cultured bone marrow-derived macrophages and largely ignored the possible systemic and micro-environmental effects on macrophage metabolism and function in vivo (Norata et al., 2015). Exploring this neglected aspect of immunometabolism might identify therapeutic strategies to dampen chronic inflammatory diseases such as atherosclerosis, in which lipid-laden macrophage “foam cells” are crucial during all stages of the disease. Elevated levels of circulating low-density lipoprotein (LDL) cholesterol, as observed in patients with familial hypercholesterolemia (FH), are a prominent risk factor for developing atherosclerosis (Ference et al., 2017). FH is predominantly caused by loss-of-function mutations in the LDL receptor (LDLR) gene, leading to impaired hepatic uptake of LDL and, consequently, elevated levels of plasma LDL (Reiner, 2015). It has been shown that hypercholesterolemia affects the lipidome of macrophages and deactivates part of their inflammatory responses via activation of LXR (Spann et al., 2012). However, LXR-independent repression mechanisms still need to be defined. Here we confirm that hypercholesterolemia attenuates LPS-induced inflammatory macrophage responses and show that this deactivated phenotype is accompanied by a diminished Nrf2-mediated oxidative stress response and LXR-independent suppression of the PPP, indicating that systemic and cellular metabolism are directly intertwined, together regulating macrophage function.
최근 몇 년간 대사 재프로그래밍이
대식세포 활성화의 핵심 조절자로 부상했습니다(Van den Bossche et al., 2016, 2017).
| IL-4 재자극 시 마우스 및 인간 M1 대식세포의 M2 재분극 실패 LPS + IFNγ 처리는 대식세포의 미토콘드리아 산화 호흡을 억제함 M2 표현형으로의 재분극에는 미토콘드리아 기능이 필요함 NO는 미토콘드리아 호흡을 둔화시키고 M1 대식세포의 가소성을 방해함 요약 대식세포는 미세환경에 반응하여 다양한 활성화 상태를 취하는 선천성 면역 세포이다. 염증성(M1) 대식세포를 항염증성(M2) 대식세포로 재분극화시켜 염증성 질환을 완화하는 대식세포 활성화 조절은 매우 중요한 연구 주제이다. 본 연구에서는 생체 내외에서 IL-4 노출 시 마우스 및 인간 M1 대식세포가 M2 세포로 전환되지 않음을 확인하였다. 대조적으로, M2 대식세포는 가소성이 더 높아 염증성 M1 상태로 쉽게 재분극된다. 우리는 M1→M2 재분극을 방해하는 요인으로 M1 관련 미토콘드리아 산화적 인산화 억제를 확인했다. M1 세포의 핵심 효과 분자인 산화질소 생성을 억제하면 미토콘드리아 기능 저하가 완화되어 M2 대식세포로의 대사적·형질적 재프로그래밍이 개선된다. 따라서 염증성 대식세포 활성화는 산화적 인산화 작용을 둔화시켜 재분극을 방해한다. 치료적으로 미토콘드리아 기능을 회복시키는 것은 염증성 대식세포를 항염증성 세포로 재프로그래밍하여 질환을 제어하는 데 유용할 수 있다. |
예를 들어,
Toll-like receptor 4 (TLR4) 리간드인 리포폴리사카라이드(LPS)와 같은 프로염증성 자극에 반응하여
대식세포는 세포외 산성화 속도(ECAR)의 증가로 입증된 바와 같이
당분해 증가를 보입니다(Van den Bossche et al., 2016).
또한,
LPS는 대식세포에서 트리카르복실산(TCA) 사이클을 재구성하고
이타코네이트와 숙시네이트 축적을 유도합니다(Jha et al., 2015; Tannahill et al., 2013).
이타코네이트는
숙신산 탈수소효소에 대한 조절 효과와 항산화 전사 인자 Nrf2의 활성화를 통해
염증성 대식세포 반응의 핵심 조절자 역할을 합니다(Lampropoulou et al., 2016; Michelucci et al., 2013; Mills et al., 2018).
숙시네이트는
인터루킨 1β(IL-1β) 발현을 유도하여 염증을 촉진하며(Mills et al., 2016; Tannahill et al., 2013),
분비 시 국소 환경에서 면역 세포를 활성화할 수 있습니다(Littlewood-Evans et al., 2016).
또한,
LPS에 자극받은 대식세포에서는
오탄당 인산 경로(PPP)의 활성이 증가하여,
뉴클레오티드 합성과
니코틴아미드 아데닌 디뉴클레오티드 포스페이트(NADPH)의 전구체를 공급합니다.
NADPH는
NADPH 산화효소에 의한 활성산소종(ROS) 생성,
지방산 합성 및 항산화 세포 방어에 사용됩니다(Nagy and Haschemi, 2015; Wu et al., 2008).
지금까지 대식세포 면역대사 관련 지식 대부분은 in vitro 배양된 골수유래 대식세포를 통해 얻어졌으며, in vivo에서 대식세포 대사와 기능에 미칠 수 있는 전신적 및 미세환경적 영향은 대체로 간과되어 왔다(Norata et al., 2015).
이러한 간과된 면역대사 측면을 탐구함으로써,
지질로 가득 찬 대식세포인 “거품세포”가 질병 전 단계에서 핵심적인 역할을 하는 죽상경화증과 같은
만성 염증성 질환을 완화할 수 있는 치료 전략을 규명할 수 있을 것이다.
가족성 고콜레스테롤혈증(FH) 환자에서 관찰되는
순환 저밀도 지단백(LDL) 콜레스테롤 수치의 상승은
죽상경화증 발병의 주요 위험 요인이다(Ference et al., 2017).
FH는
주로 LDL 수용체(LDLR) 유전자의 기능 상실 돌연변이로 인해 발생하며,
이는 간에서의 LDL 흡수를 저해하고 결과적으로 혈장 LDL 수치를 상승시킵니다(Reiner, 2015).
고콜레스테롤혈증이
대식세포의 지질체(lipidome)에 영향을 미치고
LXR 활성화를 통해 대식세포의 염증 반응 일부를 비활성화한다는 것이 밝혀졌습니다(Spann et al., 2012) .
그러나
LXR 독립적 억제 기전은 아직 규명되지 않았다.
본 연구에서는
고콜레스테롤혈증이 LPS 유발 대식세포 염증 반응을 약화시킨다는 점을 확인하고,
이러한 비활성화된 표현형이 Nrf2 매개 산화 스트레스 반응 감소 및 LXR 독립적 PPP 억제와 동반됨을 보여주었다.
이는 전신 및 세포 대사가
직접적으로 상호 연관되어 대식세포 기능을 공동 조절함을 시사한다.
Results
Hypercholesterolemia Translates into Altered Immune Cell Metabolism
Ingenuity Pathway Analysis (IPA) of published FH patient microarray data (GEO: GSE13985; characteristics in Table S1) identified oxidative phosphorylation (OXPHOS) and mitochondrial dysfunction among the top-ranked enriched canonical pathways (Figure 1A), and most differentially expressed genes belonging to those pathways were downregulated in leukocytes of FH patients (Figure 1B).

Figure 1 Hypercholesterolemia Affects Immune Cell Metabolism
Show full captionFigure viewer
To study the effects of systemic metabolic changes on immune cell metabolism in more detail, Ldlrko mice were fed a high-fat diet (HFD) to induce hypercholesterolemia and hypertriglyceridemia or a normal-fat control diet (NFD) (Figures S1A–S1C). Peritoneal macrophages from HFD mice were elicited as a validated in vivo model and source of foam cells (Spann et al., 2012). CD11b+F4/80+ peritoneal macrophages isolated from the HFD group were lipid-laden foam cells (hereafter referred to as “HFD macrophages”; Figures S1D and S1E) and compared with “NFD macrophages” to evaluate the effect of systemic metabolism on macrophage metabolism independent of microenvironmental cues present in atherosclerotic lesions. To study the effects of these different lipid environments on glycolysis and mitochondrial function in macrophages, we performed an extracellular flux analysis and revealed similar basal glycolysis and mitochondrial respiration in macrophages isolated from mice fed either diet (Figure 1C). Interestingly, HFD macrophages demonstrated lower maximal mitochondrial respiration and a reduced spare respiratory capacity (SRC) (Figure 1D) but showed no differences in non-mitochondrial oxygen consumption, ATP production, and proton leak (Figure S2A). Furthermore, both macrophage types showed similar fuel dependencies, with fatty acids being the main drivers of mitochondrial oxygen consumption (Figure 1E).
Because reduced mitochondrial mass results in decreased SRC in T cells (van der Windt et al., 2012), we assessed whether a lower mitochondrial abundance could explain the reduced SRC in HFD macrophages. Supporting this notion, HFD macrophages indeed showed a lower mitochondrial mass, as demonstrated by MitoTracker Green staining, mitochondrial DNA:genomic DNA ratio, and mitochondrial complex immunoblotting (Figures 1F and 1G and S2B). Together with the observation that similar amounts of mitochondria isolated from NFD or HFD macrophages display equal respiration (Figure 1H), our data strongly suggest that the reduced maximal respiration in HFD macrophages is mainly due to a decrease in mitochondrial mass. RNA sequencing revealed that genes related to mitochondrial biogenesis and dynamics were not altered in HFD macrophages; this was further confirmed by qPCR and immunoblotting (Figures S2C–S2E). Pathway analysis indicated that the top most enriched pathways were related to cholesterol biosynthesis, and associated genes were downregulated in HFD macrophages (Figures 1I and 1J).
Given the importance of metabolites such as itaconate, succinate, and α-ketoglutarate in regulating macrophage function (Lampropoulou et al., 2016; Liu et al., 2017; Michelucci et al., 2013; Mills et al., 2016, 2018; Tannahill et al., 2013), we next measured the levels of an extensive set of 63 metabolites. Partial least square discriminant (PLS-DA) analysis was used to discriminate NFD and HFD macrophages based on the measured metabolites. Interestingly, the abundance of several metabolites varied among NFD and HFD macrophages, with itaconate as the most distinctive metabolite (Figure 1K), whose abundance was lower in HFD macrophages (Table S2). Overall, hypercholesterolemia is associated with reduced mitochondrial mass and maximal respiration and affects the levels of metabolites such as itaconate.
Hypercholesterolemia Attenuates Inflammatory Macrophage Responses without Major Changes in Glycolysis or the TCA Cycle
Because itaconate regulates inflammatory macrophage responses (Jha et al., 2015; Mills et al., 2018) and was reduced in naive HFD macrophages, we investigated the effects of hypercholesterolemia on LPS-induced inflammatory macrophage activation. In parallel to the previously reported decreased expression of several inflammatory genes, we identified reduced secretion of pro-inflammatory cytokines as well as lower nitric oxide (NO) and lower ROS levels in HFD macrophages (Figures 2A–2C). Both types of macrophages exhibited similar phagocytic activity and comparable expression of Il10 and IL-4-induced genes and surface proteins (Figures 2D, S3A, and S3B). Together, this does not indicate a general inhibition of macrophage activation in the HFD group but shows that these cells undergo a deactivation process during which foam cells lose part of their LPS-induced inflammatory properties. Likewise, short exposure to oxidized or acetylated LDL in vitro also decreased subsequent LPS-induced tumor necrosis factor (TNF), IL-6, and NO secretion in NFD macrophages (Figure S3C).

Figure 2 Hypercholesterolemia Attenuates the Inflammatory Phenotype of Macrophages without Reconfiguring Glycolysis and the TCA Cycle
Show full captionFigure viewer
To address whether distinct LPS-induced metabolic rewiring underlies the deactivated phenotype of HFD foam cells, we measured glycolysis upon acute and 24-hr LPS exposure. NFD and HFD macrophages showed comparable glycolytic rates and glucose uptake (Figure 2E, 2F, and S3D), indicating that the attenuated inflammatory phenotype of HFD macrophages is probably not caused by reduced glycolysis.
Next we examined whether differences in succinate, itaconate, α-ketoglutarate, or other metabolites could explain the attenuated pro-inflammatory function of LPS-stimulated HFD macrophages. PLS-DA identified distinct metabolic profiles upon LPS stimulation in macrophages from both groups (Figure 2G). We observed that LPS induced itaconate, succinate, and oxaloacetate levels to a similar extent in both NFD and HFD macrophages (Figure 2H). This suggests that the reduced inflammatory phenotype observed in HFD macrophages is not caused by a distinct LPS-induced TCA cycle reconfiguration. In addition to altered levels of different amino acids (Figures 2I) and increased levels of NADH in HFD macrophages (Table S2), several metabolites related to the PPP (marked with asterisks in Figure 2I) strongly contributed to the differential metabolic profile in LPS-stimulated NFD and HFD macrophages.
Hypercholesterolemia Diminishes the NRF2 and PPP in Macrophages
Metabolic analysis demonstrated an increased abundance of several PPP metabolites, including ribose-5P or ribulose-5P, sedoheptulose-7P, and glyceraldehyde 3-P upon LPS stimulation (Figure 3A). Interestingly, LPS-induced ribose-5P or ribulose-5P and sedoheptulose-7P levels were lower in HFD macrophages. Analyzing the two genes that encode glucose-6-phosphate dehydrogenase (G6PD) as the rate-limiting enzyme of the PPP in mice (Huminiecki and Wolfe, 2004) revealed that the LPS-induced elevation of G6pd2, but not G6pdx, was absent in HFD macrophages (Figures 3B and 3C). Moreover, Pgd (encoding 6-phosphogluconate dehydrogenase, which converts 6-phosphogluconate into ribulose 5-P in the PPP) was reduced in both naive and LPS-stimulated HFD macrophages (Figure 3B), whereas Pgd protein levels were only suppressed in naive HFD macrophages (Figure S4A). To validate whether suppression of the PPP in HFD macrophages (Figure 3D) could explain their attenuated LPS-induced inflammatory responses, we pharmacologically inhibited G6PD with dehydroepiandrosterone (DHEA) or 6-aminonicotinamide (6-AN). Supporting this notion, blockade of the PPP diminished the LPS-induced production of pro-inflammatory mediators in macrophages (Figure 3E). Because desmosterol-driven LXR activation regulates at least a part of the inflammatory phenotype of foam cells (Spann et al., 2012), we studied whether this pathway controls the PPP. Activation of LXR and its target genes with GW3965 did not affect PPP genes and metabolites (Figures S4B–S4D), backing the idea that both LXR-dependent and independent mechanisms contribute to the diminished inflammatory phenotype of foam cells (Spann et al., 2012).

Figure 3 Hypercholesterolemia Reduces LPS-Mediated Induction of the PPP in Macrophages
Show full captionFigure viewer
To uncover the LXR-independent mechanistic link between hypercholesterolemia, suppressed PPP, and inflammation, we further explored our RNA sequencing (RNA-seq) dataset. Pathways analysis revealed that the Nrf2 pathway was the most differentially regulated pathway between LPS-stimulated NFD and HFD macrophages (Figure 3F), and most genes of this pathway were downregulated in HFD macrophages (Figure 3G). Accordingly, Nrf2 protein levels were reduced in LPS-treated HFD macrophages (Figure 3H). Importantly, Nrf2 was found to be a regulator of the PPP in cancer cells (Mitsuishi et al., 2012) and analyzing expression data from Nrf2-deficient macrophages (GEO: GSE71695) revealed that several PPP genes, including Pgd, are downregulated in Nrf2-deficient macrophages (Figure S4E). Moreover, analysis of published chromatin immunoprecipitation (ChIP-seq) data (DDBJ: DRA003771) revealed binding of Nrf2 4 kb upstream of the Pgd locus (Figure 3I), suggesting a direct link between reduced Nrf2 activity and Pgd expression in HFD macrophages. Indeed, Pgd is suppressed in Nrf2-deficient macrophages and increased in macrophages that have lower levels of the Nrf2 repressor protein KEAP1 (Figure 3J). Accordingly, the LPS-induced production of sedoheptulose-7P and ribose-5P or ribulose-5P downstream of Pgd in the PPP was blunted in the absence of Nrf2 (Figure S4F). This suppressed Nrf2 signaling acts in parallel with other pathways, like the LXR pathway (Spann et al., 2012), and manipulating one branch does not recapitulate the deactivated phenotype observed in HFD macrophages. Indeed, Nrf2-deficient macrophages did not show overall suppressed LPS responses (Figure S4G).
Together, this demonstrates a link between reduced Nrf2 and a defective PPP in HFD macrophages and that the latter pathway supports inflammatory responses.
Discussion
Recent findings in the rapidly expanding field of immunometabolism underscored the importance of metabolic reprogramming during macrophage activation (Van den Bossche et al., 2017). However, most knowledge regarding this metabolic-immunologic crosstalk has emerged from in vitro-cultured macrophages, excluding different (e.g., microenvironmental and systemic) layers of regulation that are at play in vivo. This gave us the incentive to explore the influences of different systemic lipid environments on cellular macrophage metabolism and function.
Leukocytes from FH patients demonstrated reduced expression of genes related to OXPHOS. In mice, hypercholesterolemia was associated with reduced cholesterol biosynthesis in macrophages. Differences in cell type (total leukocytes versus macrophages) or species (human versus mouse) might underlie this discrepancy. Dhcr24, which encodes 24-dehydrocholesterol reductase, which converts desmosterol into cholesterol, was the most suppressed gene related to cholesterol biosynthesis in macrophages from HFD mice. This finding is in agreement with a previous study, and diminished Dhcr24 expression was found to result in the accumulation of desmosterol in HFD macrophages (Spann et al., 2012).
Isolated macrophages from hypercholesterolemic mice showed reduced maximal respiration and SRC. In T cells, SRC is positively correlated with their survival (van der Windt et al., 2012). Therefore, decreased SRC might increase the susceptibly to apoptosis in macrophage foam cells, potentially contributing to necrotic core development in atherosclerotic lesions (Moore et al., 2013).
It is well-accepted that atherosclerosis is a chronic inflammatory disease driven by elevated LDL cholesterol levels. The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial provides strong evidence in support of the inflammation hypothesis and demonstrated that neutralizing the pro-inflammatory cytokine IL-1β significantly reduces the rate of recurrent cardiovascular events (Ridker et al., 2017).
Confirming previous literature (Spann et al., 2012), we now observed that the LPS-induced secretion of inflammatory mediators was reduced in macrophages isolated from hypercholesterolemic mice. This might appear to be inconsistent with the inflammation hypothesis of atherogenesis. However, it is important to note that both in vivo-elicited HFD foam cells and in vitro LDL-exposed macrophages still produce considerable amounts of inflammatory cytokines upon activation, albeit to a lower extend than “normal” macrophages. Another explanation for the observed deactivated phenotype of foam cells could be the phenotypic diversity detected in plaques (Cochain et al., 2018). Not all plaque macrophages exhibit a pro-inflammatory phenotype, and there is a substantial subpopulation of macrophages with anti-inflammatory features (Kadl et al., 2010). In agreement with our observations, recent transcriptome analysis of macrophages from atherosclerotic aortae revealed that lipid-loaded plaque macrophages are less inflammatory than their non-foamy counterparts (Kim et al., 2018). We therefore favor the theory that, in addition to the systemic metabolic environment, microenvironmental cues regulate macrophage phenotypes in plaques (Spann et al., 2012) to promote the chronic inflammatory responses that are demonstrably driving atherogenesis.
Accumulation of cellular cholesterol leads to specific oxysterols and sterols that regulate the activity of LXR (Spann et al., 2012). LXRs bind to and prevent the removal of repressor complexes at TLR4-responsive genes, blunting their expression and exerting anti-inflammatory effects (Ghisletti et al., 2007). We now show that, in addition to LXR (Spann et al., 2012), LXR-independent impairment of the PPP contributes to the suppressed inflammatory responses in macrophage foam cells during hypercholesterolemia.
Interestingly, we discovered that 6-phosphogluconate dehydrogenase (Pgd) gene expression and downstream metabolites were blunted in HFD macrophages. In accordance, knockdown of PGD was found to reduce the oxidative PPP flux, NADPH:NADP+ ratio, and ribulose-5P and ribose-5P levels in human cancer cells (Lin et al., 2015). NADPH and ribose-5P generated in the PPP can support the inflammatory macrophage responses in different ways, including ROS production, anti-oxidant cellular defense, fatty acid synthesis, and nucleotide production (Nagy and Haschemi, 2015). Thus, reduced flux through the PPP as observed in HFD macrophages can cause attenuated inflammatory responses and ROS production. Furthermore, Pgd expression was already reduced in naive HFD macrophages, possibly creating a condition that causes impaired future LPS responses. Vice versa, the lower PPP might also be a consequence of an attenuated inflammatory phenotype in HFD macrophages and the consecutive lower demand for PPP-derived products that regulate inflammation and anti-oxidant cellular defense.
We identified the Nrf2-mediated oxidative stress response as the most suppressed pathway in LPS-stimulated HFD macrophages. Nrf2 emerged as a crucial regulator of the inflammatory responses in macrophages (Kobayashi et al., 2016; Mills et al., 2018). Interestingly, several PPP genes were previously identified as Nrf2 target genes in cancer cells (Mitsuishi et al., 2012). Here we emphasized the importance of the Nrf2 pathway in the regulation of the PPP in macrophages. Importantly, suppressed Nrf2 is not the only mediator of the HFD macrophage phenotype and probably acts in parallel with other mechanisms, like the desmosterol-induced LXR pathway that was described earlier (Spann et al., 2012). Indeed, LXR activation or Nrf2 deletion as such did not result in the deactivated HFD macrophage phenotype. Our observations agree with previous studies demonstrating normal IL-1β, TNF, and IL-6 expression in the absence of Nrf2 (Mills et al., 2018; Bambouskova et al., 2018; Kobayashi et al., 2016). Conversely, activation of Nrf2 in macrophages by pharmacological or genetic (low KEAP1 expression) means clearly dampens inflammatory responses (Kobayashi et al., 2016) and mediates the anti-inflammatory effects of the metabolite itaconate (Mills et al., 2018). Thus, low levels of Nrf2 do not affect LPS responses as such, but Nrf2 activation is clearly anti-inflammatory. It will be of interest to define the mechanism responsible for Nrf2 repression in macrophage foam cells.
Together, these observations show that hypercholesterolemia suppresses the Nrf2 and PPP in macrophages and deactivates their inflammatory phenotype. We demonstrate that systemic metabolic changes translate into rewired intracellular metabolic pathways in macrophages that are tailored to support their effector functions. This highlights the intricate interplay between inflammatory signaling and metabolic pathways.
STAR★MethodsKey Resources Table
REAGENT or RESOURCESOURCEIDENTIFIER
| Antibodies | ||
| anti-actin | Millipore | Cat# MAB1501; RRID:AB_2223041 |
| anti-mitofusin 1 (MFN1) | Abcam | Cat# ab57602; RRID:AB_2142624 |
| anti-mitofusin 2 (MFN2) | Sigma | Cat# WH0009927M3; RRID:AB_1842440 |
| anti-OPA1 | BD Biosciences | Cat# 612606; RRID:AB_612606 |
| anti-NRF2 | Cell Signaling | Cat# 12721; RRID:AB_2715528 |
| anti-PGD | Abcam | Cat# ab129199; RRID:AB_11144133 |
| Total OXPHOS Rodent WB Antibody Cocktail | Abcam | Cat# ab110413; RRID:AB_2629281 |
| anti-rabbit IgG/HRP (secondary) | Thermo Fisher Scientific | Cat# 32260; RRID:AB_1965959 |
| anti-mouse IgG/HRP (secondary) | Thermo Fisher Scientific | Cat# 32230; RRID:AB_1965958 |
| anti-mouse CD71-PE | BD PharMingen | Cat# 553267; RRID:AB_394744 |
| anti-mouse CD206-APC | Biolegend | Cat# 141707; RRID:AB_10896057 |
| anti-mouse CD273-PE | BD PharMingen | Cat# 557796; RRID:AB_396874 |
| anti-mouse CD301-Alexa Fluor-647 | Serotec | Cat# MCA2392A647T; RRID:AB_1101873 |
| rat IgG2a-PE (isotype control) | BioLegend | Cat# 400507 |
| rat IgG2a-APC (isotype control) | BioLegend | Cat# 400511 |
| anti-mouse CD11b-PE-Cy7 | BD PharMingen | Cat# 552850; RRID:AB_394491 |
| anti-mouse F4/80-APC-eFluor780 | eBioscience | Cat# 47-4801; RRID:AB_2637188 |
| anti-mouse CD16/CD32 (Fc-block) | eBioscience | Cat# 14-0161; RRID:AB_467132 |
| Chemicals, Peptides, and Recombinant Proteins | ||
| Penicillin-Streptomycin | Thermo Fisher Scientific | Cat# 15140-122 |
| L-glutamine | Thermo Fisher Scientific | Cat# 25030024 |
| Recombinant murine IL-4 | PeproTech | Cat# 214-14 |
| Lipopolysaccharides (LPS) | Sigma | Cat# L2637 |
| Oil Red O | Sigma | Cat# O0625 |
| Hematoxylin | Merck | Cat# 1.05175.2500 |
| Oligomycin (OM) | Sigma | Cat# 75351 |
| 2-deoxyglucose (2-DG) | Sigma | Cat# D6134 |
| Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) | Sigma | Cat# C2920 |
| Rotenone | Sigma | Cat# R8875 |
| Antimycin A | Sigma | Cat# A8674 |
| Pyruvic acid | Sigma | Cat# 107360 |
| Malic acid | Sigma | Cat# M0875 |
| Adenosine diphosphate (ADP) | Sigma | Cat# A5285 |
| MitoTracker Green FM | Thermo Fisher Scientific | Cat# M7514 |
| CM-H2DCFDA | Thermo Fisher Scientific | Cat# C6827 |
| 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) | Thermo Fisher Scientific | Cat# N13195 |
| RNA-free DNase | QIAGEN | Cat# 79254 |
| 6-Aminonicotinamide (6-AN) | Sigma | Cat# A68203 |
| Dehydroepiandrosterone (DHEA) | Sigma | Cat# D063 |
| GW3965 | Sigma | Cat# G6295 |
| Critical Commercial Assays | ||
| IL-6 ELISA | Life Technologies | Cat# CMC0063 |
| TNF ELISA | Life Technologies | Cat# CMC3013 |
| Griess reaction | Sigma | Cat# G4410 |
| BCA Protein Assay kit | Thermo Fisher Scientific | Cat# 23225 |
| RNeasy Mini Kit | QIAGEN | Cat# 74106 |
| Ovation Mouse RNA-Seq System | NuGEN | Cat# 0348-32 |
| High Pure RNA Isolation Kit | Roche | Cat# 11828665001 |
| iScript cDNA Synthesis Kit | Bio-Rad | Cat# 170-8891 |
| Quick-gDNA MiniPrep | Zymo Research | Cat# D3024 |
| Deposited Data | ||
| RNA-sequencing data | This paper | GEO: GSE107412 |
| Experimental Models: Organisms/Strains | ||
| Mouse: LdlrKO: B6.129S7-Ldlrtm1Her/J | The Jackson Laboratory | JAX:002207 |
| Mouse: Nrf2KO: B6.129P3-Nf2l2tm1Mym | Itoh et al., 1997 | N/A |
| Mouse: Keap1KD: B6.129P3-Keap1tm2Mym | Taguchi et al., 2010 | N/A |
| Mouse: WT: C57BL/6J | The Jackson Laboratory | JAX:000664 |
| Oligonucleotides | ||
| Primer sequences | This paper (Table S3) | N/A |
| Software and Algorithms | ||
| FlowJo | ThreeStar | N/A |
| GraphPad Prism 7 | GraphPad Software | N/A |
| Seahorse Wave | Agilent | N/A |
| Ingenuity Pathway Analysis | QIAGEN | N/A |
| R package: ggplot2 | Wickham, 2016 | https://cran.r-project.org/web/packages/ggplot2 |
| R package: ropls | Thévenot et al. (2015) | http://www.bioconductor.org/packages/release/bioc/html/ropls.html |
| R package: mixOmics | Rohart et al. (2017) | http://mixomics.org |
| STAR 2.5.2b | Dobin et al. (2013) | https://github.com/alexdobin/STAR/releases |
| SAM tools | Li et al. (2009) | http://samtools.sourceforge.net |
| HOMER | Heinz et al. (2010) | http://homer.ucsd.edu/homer |
| R package: DESeq2 | Love et al. (2014) | https://bioconductor.org/packages/release/bioc/html/DESeq2.html |
| R package: limma | Ritchie et al. (2015) | https://bioconductor.org/packages/release/bioc/html/limma.html |
| Other | ||
| Control normal fat diet (NFD) | Harlan Laboratories (Envigo) | Cat# 2016 (Teklad global 16% protein) |
| High fat diet (HFD) | Special diet Services | Code 824199 |
| 0.5 μM Fluoresbrite YG microspheres | Polysciences | Cat# 17152 |
| Thioglycollate medium | Fisher Scientific | Cat# 11782834 |
| RPMI-1640 medium | Thermo Fisher Scientific | Cat# 52400041 |
| RPMI-1640 Medium, no glucose | Thermo Fisher Scientific | Cat# 11879020 |
| Fetal Bovine Serum | Thermo Fisher Scientific | Cat# 10500 |
| NP-40 cell lysis buffer | Thermo Fisher Scientific | Cat# FNN0021 |
| Protease Inhibitor Cocktail | Sigma | Cat# 11873580001 |
| PhosSTOP | Sigma | Cat# 4906837001 |
| Bolt 4-12% Bis-Tris Plus Gels | Thermo Fisher Scientific | Cat# NW04120BOX |
| Nitrocellulose Membrane | Bio-Rad | Cat# 162-0094 |
| TWEEN 20 | Sigma | Cat# P1379 |
| SuperSignal West Pico PLUS Chemiluminescent Substrate | Thermo Fisher Scientific | Cat# 34580 |
| Fast SYBR Green Master Mix | Applied Biosytems | Cat# 4385618 |
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jan Van den Bossche (j.vandenbossche@vumc.nl).
Experimental Model and Subject DetailsMice
Female and male LdlrKO mice were obtained from Jackson Laboratory. LdlrKO mice were housed at the Animal Research Institute AMC (ARIA) and all animal experiments were conducted after approval (permit: DBC102861) by the Committee for Animal Welfare of the Academic Medical Center, University of Amsterdam. 6-month old adult mice were used for experiments and put on a control normal fat diet (NFD, 4% fat, Harlan Laboratories) or a high fat, high cholesterol diet (HFD, 16% fat, 0,25% cholesterol, Special Diet Services) for 10 weeks. Nrf2-knockout (Nrf2KO) (Itoh et al., 1997) and Keap1-knockdown (Keap1KD) (Taguchi et al., 2010) mice, and their wild-type (WT) counterparts, all 8-12-week old females on the C57BL/6 genetic background, were bred and maintained in the Medical School Resource Unit of the University of Dundee. Mice of the same sex were randomly assigned to both experimental groups in disposable Innovive 101 IVC cages in groups of 3 or 4.
Method DetailsIsolation of macrophages
After 10 weeks of NFD or HFD, LldrKO mice were euthanized by CO2 asphyxiation. Four days prior to sacrifice, mice were intraperitoneally injected with 3% thioglycollate medium (Fisher Scientific). Upon sacrifice, the peritoneum was flushed with 10 mL ice-cold PBS and collected peritoneal cells were cultured in RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin (GIBCO). After 3 h, non-adherent cells were washed away and adhered cells (typically consisting of 90%–95% CD11b+ F4/80+ macrophages, Figure S1D) were stimulated for 24 hours with 10 ng/ml LPS (Sigma) or 100 U/ml IL-4 (Peprotech), or were left untreated, and were used for further analyses. Blood cholesterol and triglyceride levels were measured by enzymatic methods using available kits (Roche). To determine lipid accumulated in peritoneal macrophages, tissue slides with cells were fixed in 4% formalin for 10 minutes and washed two times with PBS (with magnesium and chloride) before and after fixation. Subsequently, tissue slides were incubated in 60% isopropanol for 15 minutes before staining for 45 minutes with fresh 0.3% Oil Red O in 60% isopropanol. After staining, tissue slides were rinsed in 60% isopropanol, washed in distilled water, incubated for 1 minute with hematoxylin blued in tap water and rinsed with distilled water. Bone-marrow derived (BMDM) macrophages were generated from femurs and tibia from WT, Nrf2KO and Keap1KD mice and differentiated in RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin and 15% L929-conditioned medium for 7 days.
Metabolic extracellular flux analysis
Macrophages (1x105 cells/well) were plated on XF-96-cell culture plates (Seahorse Bioscience) and treated as specified. OCR and ECAR were assessed using the XF-96 Flux Analyzer (Seahorse Bioscience) as detailed before (Van den Bossche et al., 2015). Changes in ECAR in response to glucose (10 mM), OM (1.5 μM) and 2-DG (100 mM) injection were used to calculate all glycolysis parameters and OXPHOS characteristics were calculated from the OCR changes in response to OM (1.5 μM), FCCP (1.5 μM) and rotenone (1.25 μM) + antimycin A (2.5 μM) injection (Van den Bossche et al., 2015; Van den Bossche et al., 2016). The Seahorse Bioscience Mito Fuel Flex Test Kit was used to determine the dependency of cells for glucose, glutamine or fatty acid oxidation.
Respiratory measurements of isolated mitochondria
To isolate mitochondria, cell pellets were resuspended in 1 mL of MTE buffer (250 mM mannitol, 5 mM TRIS, 0.5 mM EDTA, pH 7.4). Macrophages were lysed using 10 passages through the cell cracker (European Molecular Biology Laboratory, Heidelberg, Germany). The homogenate was centrifuged 10 min at 1000 g, after which the supernatant was transferred to a new tube and centrifuged at 10000 g. The resulting supernatant was considered the cytosolic fraction. The final pellet containing the mitochondrial fraction was washed with 1 mL MTE buffer, centrifuged at 3600 g and resuspended in a minimal volume of MTE buffer. Equal amounts of mitochondria (0.5 μg well) were resuspended in MAS buffer (70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, and 1 mM EGTA; pH 7.2, plus 10 mM pyruvate and 1 mM malate as substrates), transferred to XF-96-cell culture plates, centrifuged at 2000 g for 20 min at 4°C and measured using a XF-96 Flux Analyzer (Seahorse Bioscience) to assess basal oxygen consumption (state 2), maximal coupled respiration or state 3 after injection of 4 mM ADP, state 4o after injection of 1.5 μM OM, maximal uncoupled respiration (state 3u) after injection of 4 μM FCCP and the respiratory control ratio (RCR = state 3/state 4o) in accordance to an established protocol (Rogers et al., 2011).
Liquid chromatography - mass spectrometry
Macrophages (5x105 cells/well) in 24 well plates were washed three times with 0,9% NaCl. Metabolism was quenched by adding 1 mL ice-cold methanol/water (1/1; v/v). The following internal standards were added, D3-aspartic acid, D3-serine, D5-glutamine, D3-glutamate, 13C3-pyruvate, 13C6-isoleucine, 13C6-glucose, 13C6-fructose-1,6-biphosphate, 13C6-glucose-6-phosphate, adenosine-15N5-monophosphate and guanosine-15N5-monophosphate (5 μM). 1 mL of chloroform was added, vortexed and centrifuged for 5 minutes at 14.000 rpm at 4°C. ∼800 μL of the “polar” top layer was transferred to a 1.5 mL tube, dried to dryness in a vacuum concentrator and dissolved in 100 μL methanol/water (6/4; v/v). For the analysis, we used a Thermo Scientific (U)HPLC system coupled to a Thermo Q Exactive (Plus) Orbitrap mass spectrometer (Waltman) with a SeQuant ZIC-cHILIC column at 15°C (PEEK 100 × 2.1 mm, 3.0 μm particle size, Merck). The mobile phase composed of (A) 9/1 acetonitrile/water with 5 mM ammonium acetate; pH 6.8 and (B) 1/9 acetonitrile/water with 5 mM ammonium acetate; pH 6.8, respectively. The LC program started with 100% (A) hold 0-3 min; ramping 3-24 min to 20% (A); hold from 24-27 min at 20% (A); ramping from 27-28 min to 100% (A); and re-equilibrate from 28-35 min with 100% (A), flow rate was 0.250 mL/min. The MS data were acquired in full scan, negative ionization mode with a mass resolution of 140.000. Interpretation of the data was performed in the Xcalibur software (ThermoFisher). Subsequent analyses were done in a R environment using the ggplot2, ropls and mixOmics packages (Rohart et al., 2017; Thévenot et al., 2015; Wickham, 2016).
Flow cytometry
To assess surface marker expression, cells (1.5x105 cells/well) in 96 well plates were deateched with citrate and transferred to V-bottom 96 well plates and stained with CD71, CD206, CD273, CD301 or isotype controls (all 1:250 diluted in PBS with 0,5% BSA and 2.5 mM EDTA) for 20 minutes at room temperature in the dark. After labeling, cells were washed with PBS with 0,5% BSA and 2.5 mM EDTA and finally resuspend in PBS with 0,5% BSA and 2.5 mM EDTA and measured on BD FACSCanto or a Beckman Coulter CytoFLEX, and analyzed using FlowJo (TreeStar). In order to quantify mitochondrial mass and ROS production, macrophages (105 cells/well) in 96 well plates were detached using citrate buffer (17 mM tri-Sodium citrate dehydrate and 135 mM potassium chloride in water) transferred to V-bottom 96 well plates and washed with PBS. Next, cells were resuspended in PBS with 200 nm MitoTracker Green or 20 μM CM-H2DCFDA (both ThermoFisher) and incubated for 30 minutes at 37°C (5% CO2). After incubation, cells were washed with PBS and mitochondrial mass and ROS production was measured using flow cytometry. To determine glucose uptake, macrophages (105 cells/well) were cultured in 96 well plates for two hours in RPMI-1640 lacking glucose and serum. Subsequently, 2-NBDG (ThermoFisher) was added for an additional incubation of 20 minutes in a final concentration of 25 μM. Next, cells were detached with citrate buffer, transferred to V-bottom 96 well plates and washed with PBS and analyzed using flow cytometry. To assess phagocytic activity, 105 macrophages were cultured for 1 h at 37°C (or 4°C as a control, Figure S3E) in the presence of Fluoresbrite YG microspheres (0.5 μM, Polysciences).
Immunoblotting
Immunoblotting for NRF2 and mitochondrial complexes was performed as detailed by (Mills et al., 2018) and (Wüst et al., 2016), respectively. For MFN1, MFN2, OPA1 and PGD immunoblotting, macrophages (1x106 cells/well) in 12 well plates were lysed in NP40 cell lysis buffer (ThermoFisher) supplemented with protease inhibitor cocktail (Sigma-Aldrich) and PhosSTOP (Sigma-Aldrich). Lysates were equalized on protein concentration after quantification with the BCA assay (ThermoFisher), separated on Bolt 4%–12% Bis-Tris gels (ThermoFisher) and transferred onto nitrocellulose membranes (Bio-Rad). After blocking for 1 hour with 5% milk powder (Campina) in Tris-buffered saline, TWEEN 20 (TBS-T), membranes were incubated overnight with primary antibodies against MFN1 (1:1000 dilution), MFN2 (1:200), OPA1 (1:1000) and PGD (1:1000) in 5% milk, TBS-T, followed by incubation for 1 hour with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:2000) in 5% milk, TBS-T and visualization with SuperSignal West Pico Chemiluminescent PLUS Substrate (Thermo Fisher Scientific).
Cytokine and NO production
IL-6 and TNF levels in the supernatant were measured by ELISA (Life Technologies) and NO production was assessed by a Griess reaction (Sigma-Aldrich) according to the supplier’s protocol.
RNA sequencing
Total RNA was isolated from peritoneal macrophages using a RNeasy Mini Kit with DNase treatment (QIAGEN). Strand-specific libraries were constructed from 100 ng total RNA using ‘Ovation RNA-Seq system’ following manufacturer instructions (NuGen Technologies). Samples were pooled and diluted to 10 nM and sequenced on an Illumina HiSeq 4000 instrument (Illumina) to a depth of ± 20 million single-ended 50 bp reads.
Bioinformatics
Reads were aligned to the mouse genome mm10 by STAR 2.5.2b with default settings (Dobin et al., 2013). BAM files were indexed and filtered on MAPQ > 15 with SAMTools 1.3.1 (Li et al., 2009). Raw tag counts and RPKM (reads per kilobase per million mapped reads) values per gene were summed using HOMER2′s analyzeRepeats.pl script with default settings and the -noadj or –rpkm options for raw counts and RPKM reporting, respectively (Heinz et al., 2010). Differential expression was assessed using the DESeq2 bioconductor package in an R 3.3.1 environment with gene expression called differential with a p value < 0.05 and an average RPKM > 1 in at least one group (Love et al., 2014). Presented RPKM values in scatterplots were tested using one-way ANOVA followed by Bonferroni’s post hoc comparisons test. Differential expression analysis on available microarray data (GEO: GSE13985) was executed using the limma package and gene expression was called differential with a p value < 0.05 (Ritchie et al., 2015). Differential expressed genes were analyzed in Ingenuity Pathway Analysis (Qiaqen) to identify deregulated pathways.
qPCR
RNA was isolated with High Pure RNA Isolation kits (Roche), cDNA was synthesized with iScript (Bio-Rad), and qPCR was performed using SYBR Green Fast mix (Applied Biosytems) on a ViiA7 (Applied Biosystems). Housekeeping genes Rplp0 and Ppia were used for normalization and used primer sequences are noted in the Table S3. DNA was extracted using the Quick-gDNA MiniPrep (Zymo Research) kit and primers for mt-Co1 and Ndufv1 were used to determine the mtDNA/gDNA ratio.
Quantification and Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). Number (n) and type (biological or technical) of replicates are indicated in the figure legends. Data were tested using a two-tailed Student’s t test (when comparing two groups) or one-way ANOVA followed by Bonferroni’s post hoc comparison to test multiple groups in GraphPad Prism version 7.0 software, as indicated in the figure legends. p values < 0.05 were considered significant, with levels of significance being indicated as follows: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant.
Data and Software Availability
The accession number for the RNA sequencing data reported in this paper is GEO: GSE107412.
Acknowledgments
J.V.d.B. received a VENI grant from ZonMW (91615052) and a Netherlands Heart Foundation junior postdoctoral grant (2013T003) and senior fellowship (2017T048). M.P.J.d.W. is an established investigator of the Netherlands Heart Foundation, is supported by grants from the Netherlands Heart Foundation and Spark-Holding BV (2015B002), the European Union (ITN grant EPIMAC and REPROGRAM [EU Horizon 2020]), and Fondation Leducq (16CVD-01), and holds an AMC fellowship. We acknowledge support from the Netherlands CardioVascular Research Initiative, Dutch Federation of University Medical Centers, the Netherlands Organisation for Health Research and Development, the Royal Netherlands Academy of Sciences (CVON 2011-19 and CVON 2017-20) and Cancer Research UK (C20953/A18644). We thank Tadeja Rezen, Peter Juvan, and Damjana Rozman for the GEO: GSE13985 dataset details.
Author Contributions
Conceptualization, J.V.d.B.; Methodology, J.V.d.B.; Formal Analysis, J.B., S.G.S.V., M.v.W., K.H.M.P., and J.V.d.B.; Investigation, J.B., S.v.d.V., S.G.S.V., D.G.R., R.C.I.W., A.E.N., S.W.D., M.E.W., E.V.K., and J.V.d.B.; Writing – Original Draft, J.B.; Writing – Review & Editing, J.B., S.G.S.V., D.S., R.H.H., L.A.O., A.T.D.-K., E.L., M.P.J.d.W., and J.V.d.B.; Visualization, J.B., M.v.W., and J.V.d.B.; Supervision, M.P.J.d.W. and J.V.d.B.; Funding Acquisition, M.P.J.d.W. and J.V.d.B. All authors read and approved the final manuscript.
Declaration of Interests
The authors declare no competing interests.
Supplemental Information (2)
Download all
Document S1. Figures S1–S4 and Tables S1–S3
Document S2. Article plus Supplemental Information
References
Bambouskova, M. ∙ Gorvel, L. ∙ Lampropoulou, V. ...
Electrophilic properties of itaconate and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis
Nature. 2018; 556:501-504
Cochain, C. ∙ Vafadarnejad, E. ∙ Arampatzi, P. ...
Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis
Circ. Res. 2018; 122:1661-1674
Dobin, A. ∙ Davis, C.A. ∙ Schlesinger, F. ...
STAR: ultrafast universal RNA-seq aligner
Bioinformatics. 2013; 29:15-21
Ference, B.A. ∙ Ginsberg, H.N. ∙ Graham, I. ...
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Eur. Heart J. 2017; 38:2459-2472
Ghisletti, S. ∙ Huang, W. ∙ Ogawa, S. ...
Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma
Mol. Cell. 2007; 25:57-70
Heinz, S. ∙ Benner, C. ∙ Spann, N. ...
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities
ReportVolume 25, Issue 8p2044-2052.e5November 20, 2018Open access
Download Full Issue
A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia
Jeroen Baardman1 ∙ Sanne G.S. Verberk2,9 ∙ Koen H.M. Prange1,9 ∙ … ∙ Esther Lutgens1,8 ∙ Menno P.J. de Winther1,8,9 ∙ Jan Van den Bossche1,2,9,10 j.vandenbossche@vumc.nl … Show more
Affiliations & NotesArticle Info

Download Full Issue
Show Outline
Highlights
•
Systemic metabolism affects immune cell metabolism
•
Hypercholesterolemia suppresses the PPP and Nrf2 pathway in macrophages
•
PPP inhibition and hypercholesterolemia deactivate inflammatory macrophage responses
•
The Nrf2 pathway regulates the PPP in an LXR-independent manner
Summary
Metabolic reprogramming has emerged as a crucial regulator of immune cell activation, but how systemic metabolism influences immune cell metabolism and function remains to be investigated. To investigate the effect of dyslipidemia on immune cell metabolism, we performed in-depth transcriptional, metabolic, and functional characterization of macrophages isolated from hypercholesterolemic mice. Systemic metabolic changes in such mice alter cellular macrophage metabolism and attenuate inflammatory macrophage responses. In addition to diminished maximal mitochondrial respiration, hypercholesterolemia reduces the LPS-mediated induction of the pentose phosphate pathway (PPP) and the Nrf2-mediated oxidative stress response. Our observation that suppression of the PPP diminishes LPS-induced cytokine secretion supports the notion that this pathway contributes to inflammatory macrophage responses. Overall, this study reveals that systemic and cellular metabolism are strongly interconnected, together dictating macrophage phenotype and function.
Graphical Abstract

Keywords
Introduction
In recent years, metabolic reprogramming arose as a crucial controller of macrophage activation (Van den Bossche et al., 2016, 2017). For instance, in response to pro-inflammatory stimuli such as the Toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS), macrophages show increased glycolysis, as demonstrated by an enhanced extracellular acidification rate (ECAR) (Van den Bossche et al., 2016). Moreover, LPS reconfigures the tricarboxylic acid (TCA) cycle in macrophages and induces itaconate and succinate accumulation (Jha et al., 2015; Tannahill et al., 2013). Itaconate is a key controller of inflammatory macrophage responses through its regulatory effect on succinate dehydrogenase and its activation of the anti-oxidant transcription factor Nrf2 (Lampropoulou et al., 2016; Michelucci et al., 2013; Mills et al., 2018). Succinate promotes inflammation by inducing interleukin 1β (IL-1β) expression (Mills et al., 2016; Tannahill et al., 2013) and can activate immune cells in the local environment upon secretion (Littlewood-Evans et al., 2016). Furthermore, the activity of the pentose phosphate pathway (PPP) is enhanced in LPS-stimulated macrophages, supplying precursors for nucleotide synthesis and nicotinamide adenine dinucleotide phosphate (NADPH), which is used for reactive oxygen species (ROS) production by NADPH oxidase, fatty acid synthesis, and anti-oxidant cellular defense (Nagy and Haschemi, 2015; Wu et al., 2008). So far, most knowledge regarding macrophage immunometabolism was obtained with in vitro-cultured bone marrow-derived macrophages and largely ignored the possible systemic and micro-environmental effects on macrophage metabolism and function in vivo (Norata et al., 2015). Exploring this neglected aspect of immunometabolism might identify therapeutic strategies to dampen chronic inflammatory diseases such as atherosclerosis, in which lipid-laden macrophage “foam cells” are crucial during all stages of the disease. Elevated levels of circulating low-density lipoprotein (LDL) cholesterol, as observed in patients with familial hypercholesterolemia (FH), are a prominent risk factor for developing atherosclerosis (Ference et al., 2017). FH is predominantly caused by loss-of-function mutations in the LDL receptor (LDLR) gene, leading to impaired hepatic uptake of LDL and, consequently, elevated levels of plasma LDL (Reiner, 2015). It has been shown that hypercholesterolemia affects the lipidome of macrophages and deactivates part of their inflammatory responses via activation of LXR (Spann et al., 2012). However, LXR-independent repression mechanisms still need to be defined. Here we confirm that hypercholesterolemia attenuates LPS-induced inflammatory macrophage responses and show that this deactivated phenotype is accompanied by a diminished Nrf2-mediated oxidative stress response and LXR-independent suppression of the PPP, indicating that systemic and cellular metabolism are directly intertwined, together regulating macrophage function.
ResultsHypercholesterolemia Translates into Altered Immune Cell Metabolism
Ingenuity Pathway Analysis (IPA) of published FH patient microarray data (GEO: GSE13985; characteristics in Table S1) identified oxidative phosphorylation (OXPHOS) and mitochondrial dysfunction among the top-ranked enriched canonical pathways (Figure 1A), and most differentially expressed genes belonging to those pathways were downregulated in leukocytes of FH patients (Figure 1B).

Figure 1 Hypercholesterolemia Affects Immune Cell Metabolism
Show full captionFigure viewer
To study the effects of systemic metabolic changes on immune cell metabolism in more detail, Ldlrko mice were fed a high-fat diet (HFD) to induce hypercholesterolemia and hypertriglyceridemia or a normal-fat control diet (NFD) (Figures S1A–S1C). Peritoneal macrophages from HFD mice were elicited as a validated in vivo model and source of foam cells (Spann et al., 2012). CD11b+F4/80+ peritoneal macrophages isolated from the HFD group were lipid-laden foam cells (hereafter referred to as “HFD macrophages”; Figures S1D and S1E) and compared with “NFD macrophages” to evaluate the effect of systemic metabolism on macrophage metabolism independent of microenvironmental cues present in atherosclerotic lesions. To study the effects of these different lipid environments on glycolysis and mitochondrial function in macrophages, we performed an extracellular flux analysis and revealed similar basal glycolysis and mitochondrial respiration in macrophages isolated from mice fed either diet (Figure 1C). Interestingly, HFD macrophages demonstrated lower maximal mitochondrial respiration and a reduced spare respiratory capacity (SRC) (Figure 1D) but showed no differences in non-mitochondrial oxygen consumption, ATP production, and proton leak (Figure S2A). Furthermore, both macrophage types showed similar fuel dependencies, with fatty acids being the main drivers of mitochondrial oxygen consumption (Figure 1E).
Because reduced mitochondrial mass results in decreased SRC in T cells (van der Windt et al., 2012), we assessed whether a lower mitochondrial abundance could explain the reduced SRC in HFD macrophages. Supporting this notion, HFD macrophages indeed showed a lower mitochondrial mass, as demonstrated by MitoTracker Green staining, mitochondrial DNA:genomic DNA ratio, and mitochondrial complex immunoblotting (Figures 1F and 1G and S2B). Together with the observation that similar amounts of mitochondria isolated from NFD or HFD macrophages display equal respiration (Figure 1H), our data strongly suggest that the reduced maximal respiration in HFD macrophages is mainly due to a decrease in mitochondrial mass. RNA sequencing revealed that genes related to mitochondrial biogenesis and dynamics were not altered in HFD macrophages; this was further confirmed by qPCR and immunoblotting (Figures S2C–S2E). Pathway analysis indicated that the top most enriched pathways were related to cholesterol biosynthesis, and associated genes were downregulated in HFD macrophages (Figures 1I and 1J).
Given the importance of metabolites such as itaconate, succinate, and α-ketoglutarate in regulating macrophage function (Lampropoulou et al., 2016; Liu et al., 2017; Michelucci et al., 2013; Mills et al., 2016, 2018; Tannahill et al., 2013), we next measured the levels of an extensive set of 63 metabolites. Partial least square discriminant (PLS-DA) analysis was used to discriminate NFD and HFD macrophages based on the measured metabolites. Interestingly, the abundance of several metabolites varied among NFD and HFD macrophages, with itaconate as the most distinctive metabolite (Figure 1K), whose abundance was lower in HFD macrophages (Table S2). Overall, hypercholesterolemia is associated with reduced mitochondrial mass and maximal respiration and affects the levels of metabolites such as itaconate.
Hypercholesterolemia Attenuates Inflammatory Macrophage Responses without Major Changes in Glycolysis or the TCA Cycle
Because itaconate regulates inflammatory macrophage responses (Jha et al., 2015; Mills et al., 2018) and was reduced in naive HFD macrophages, we investigated the effects of hypercholesterolemia on LPS-induced inflammatory macrophage activation. In parallel to the previously reported decreased expression of several inflammatory genes, we identified reduced secretion of pro-inflammatory cytokines as well as lower nitric oxide (NO) and lower ROS levels in HFD macrophages (Figures 2A–2C). Both types of macrophages exhibited similar phagocytic activity and comparable expression of Il10 and IL-4-induced genes and surface proteins (Figures 2D, S3A, and S3B). Together, this does not indicate a general inhibition of macrophage activation in the HFD group but shows that these cells undergo a deactivation process during which foam cells lose part of their LPS-induced inflammatory properties. Likewise, short exposure to oxidized or acetylated LDL in vitro also decreased subsequent LPS-induced tumor necrosis factor (TNF), IL-6, and NO secretion in NFD macrophages (Figure S3C).

Figure 2 Hypercholesterolemia Attenuates the Inflammatory Phenotype of Macrophages without Reconfiguring Glycolysis and the TCA Cycle
Show full captionFigure viewer
To address whether distinct LPS-induced metabolic rewiring underlies the deactivated phenotype of HFD foam cells, we measured glycolysis upon acute and 24-hr LPS exposure. NFD and HFD macrophages showed comparable glycolytic rates and glucose uptake (Figure 2E, 2F, and S3D), indicating that the attenuated inflammatory phenotype of HFD macrophages is probably not caused by reduced glycolysis.
Next we examined whether differences in succinate, itaconate, α-ketoglutarate, or other metabolites could explain the attenuated pro-inflammatory function of LPS-stimulated HFD macrophages. PLS-DA identified distinct metabolic profiles upon LPS stimulation in macrophages from both groups (Figure 2G). We observed that LPS induced itaconate, succinate, and oxaloacetate levels to a similar extent in both NFD and HFD macrophages (Figure 2H). This suggests that the reduced inflammatory phenotype observed in HFD macrophages is not caused by a distinct LPS-induced TCA cycle reconfiguration. In addition to altered levels of different amino acids (Figures 2I) and increased levels of NADH in HFD macrophages (Table S2), several metabolites related to the PPP (marked with asterisks in Figure 2I) strongly contributed to the differential metabolic profile in LPS-stimulated NFD and HFD macrophages.
Hypercholesterolemia Diminishes the NRF2 and PPP in Macrophages
Metabolic analysis demonstrated an increased abundance of several PPP metabolites, including ribose-5P or ribulose-5P, sedoheptulose-7P, and glyceraldehyde 3-P upon LPS stimulation (Figure 3A). Interestingly, LPS-induced ribose-5P or ribulose-5P and sedoheptulose-7P levels were lower in HFD macrophages. Analyzing the two genes that encode glucose-6-phosphate dehydrogenase (G6PD) as the rate-limiting enzyme of the PPP in mice (Huminiecki and Wolfe, 2004) revealed that the LPS-induced elevation of G6pd2, but not G6pdx, was absent in HFD macrophages (Figures 3B and 3C). Moreover, Pgd (encoding 6-phosphogluconate dehydrogenase, which converts 6-phosphogluconate into ribulose 5-P in the PPP) was reduced in both naive and LPS-stimulated HFD macrophages (Figure 3B), whereas Pgd protein levels were only suppressed in naive HFD macrophages (Figure S4A). To validate whether suppression of the PPP in HFD macrophages (Figure 3D) could explain their attenuated LPS-induced inflammatory responses, we pharmacologically inhibited G6PD with dehydroepiandrosterone (DHEA) or 6-aminonicotinamide (6-AN). Supporting this notion, blockade of the PPP diminished the LPS-induced production of pro-inflammatory mediators in macrophages (Figure 3E). Because desmosterol-driven LXR activation regulates at least a part of the inflammatory phenotype of foam cells (Spann et al., 2012), we studied whether this pathway controls the PPP. Activation of LXR and its target genes with GW3965 did not affect PPP genes and metabolites (Figures S4B–S4D), backing the idea that both LXR-dependent and independent mechanisms contribute to the diminished inflammatory phenotype of foam cells (Spann et al., 2012).

Figure 3 Hypercholesterolemia Reduces LPS-Mediated Induction of the PPP in Macrophages
Show full captionFigure viewer
To uncover the LXR-independent mechanistic link between hypercholesterolemia, suppressed PPP, and inflammation, we further explored our RNA sequencing (RNA-seq) dataset. Pathways analysis revealed that the Nrf2 pathway was the most differentially regulated pathway between LPS-stimulated NFD and HFD macrophages (Figure 3F), and most genes of this pathway were downregulated in HFD macrophages (Figure 3G). Accordingly, Nrf2 protein levels were reduced in LPS-treated HFD macrophages (Figure 3H). Importantly, Nrf2 was found to be a regulator of the PPP in cancer cells (Mitsuishi et al., 2012) and analyzing expression data from Nrf2-deficient macrophages (GEO: GSE71695) revealed that several PPP genes, including Pgd, are downregulated in Nrf2-deficient macrophages (Figure S4E). Moreover, analysis of published chromatin immunoprecipitation (ChIP-seq) data (DDBJ: DRA003771) revealed binding of Nrf2 4 kb upstream of the Pgd locus (Figure 3I), suggesting a direct link between reduced Nrf2 activity and Pgd expression in HFD macrophages. Indeed, Pgd is suppressed in Nrf2-deficient macrophages and increased in macrophages that have lower levels of the Nrf2 repressor protein KEAP1 (Figure 3J). Accordingly, the LPS-induced production of sedoheptulose-7P and ribose-5P or ribulose-5P downstream of Pgd in the PPP was blunted in the absence of Nrf2 (Figure S4F). This suppressed Nrf2 signaling acts in parallel with other pathways, like the LXR pathway (Spann et al., 2012), and manipulating one branch does not recapitulate the deactivated phenotype observed in HFD macrophages. Indeed, Nrf2-deficient macrophages did not show overall suppressed LPS responses (Figure S4G).
Together, this demonstrates a link between reduced Nrf2 and a defective PPP in HFD macrophages and that the latter pathway supports inflammatory responses.
Discussion
Recent findings in the rapidly expanding field of immunometabolism underscored the importance of metabolic reprogramming during macrophage activation (Van den Bossche et al., 2017). However, most knowledge regarding this metabolic-immunologic crosstalk has emerged from in vitro-cultured macrophages, excluding different (e.g., microenvironmental and systemic) layers of regulation that are at play in vivo. This gave us the incentive to explore the influences of different systemic lipid environments on cellular macrophage metabolism and function.
Leukocytes from FH patients demonstrated reduced expression of genes related to OXPHOS. In mice, hypercholesterolemia was associated with reduced cholesterol biosynthesis in macrophages. Differences in cell type (total leukocytes versus macrophages) or species (human versus mouse) might underlie this discrepancy. Dhcr24, which encodes 24-dehydrocholesterol reductase, which converts desmosterol into cholesterol, was the most suppressed gene related to cholesterol biosynthesis in macrophages from HFD mice. This finding is in agreement with a previous study, and diminished Dhcr24 expression was found to result in the accumulation of desmosterol in HFD macrophages (Spann et al., 2012).
Isolated macrophages from hypercholesterolemic mice showed reduced maximal respiration and SRC. In T cells, SRC is positively correlated with their survival (van der Windt et al., 2012). Therefore, decreased SRC might increase the susceptibly to apoptosis in macrophage foam cells, potentially contributing to necrotic core development in atherosclerotic lesions (Moore et al., 2013).
It is well-accepted that atherosclerosis is a chronic inflammatory disease driven by elevated LDL cholesterol levels. The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial provides strong evidence in support of the inflammation hypothesis and demonstrated that neutralizing the pro-inflammatory cytokine IL-1β significantly reduces the rate of recurrent cardiovascular events (Ridker et al., 2017).
Confirming previous literature (Spann et al., 2012), we now observed that the LPS-induced secretion of inflammatory mediators was reduced in macrophages isolated from hypercholesterolemic mice. This might appear to be inconsistent with the inflammation hypothesis of atherogenesis. However, it is important to note that both in vivo-elicited HFD foam cells and in vitro LDL-exposed macrophages still produce considerable amounts of inflammatory cytokines upon activation, albeit to a lower extend than “normal” macrophages. Another explanation for the observed deactivated phenotype of foam cells could be the phenotypic diversity detected in plaques (Cochain et al., 2018). Not all plaque macrophages exhibit a pro-inflammatory phenotype, and there is a substantial subpopulation of macrophages with anti-inflammatory features (Kadl et al., 2010). In agreement with our observations, recent transcriptome analysis of macrophages from atherosclerotic aortae revealed that lipid-loaded plaque macrophages are less inflammatory than their non-foamy counterparts (Kim et al., 2018). We therefore favor the theory that, in addition to the systemic metabolic environment, microenvironmental cues regulate macrophage phenotypes in plaques (Spann et al., 2012) to promote the chronic inflammatory responses that are demonstrably driving atherogenesis.
Accumulation of cellular cholesterol leads to specific oxysterols and sterols that regulate the activity of LXR (Spann et al., 2012). LXRs bind to and prevent the removal of repressor complexes at TLR4-responsive genes, blunting their expression and exerting anti-inflammatory effects (Ghisletti et al., 2007). We now show that, in addition to LXR (Spann et al., 2012), LXR-independent impairment of the PPP contributes to the suppressed inflammatory responses in macrophage foam cells during hypercholesterolemia.
Interestingly, we discovered that 6-phosphogluconate dehydrogenase (Pgd) gene expression and downstream metabolites were blunted in HFD macrophages. In accordance, knockdown of PGD was found to reduce the oxidative PPP flux, NADPH:NADP+ ratio, and ribulose-5P and ribose-5P levels in human cancer cells (Lin et al., 2015). NADPH and ribose-5P generated in the PPP can support the inflammatory macrophage responses in different ways, including ROS production, anti-oxidant cellular defense, fatty acid synthesis, and nucleotide production (Nagy and Haschemi, 2015). Thus, reduced flux through the PPP as observed in HFD macrophages can cause attenuated inflammatory responses and ROS production. Furthermore, Pgd expression was already reduced in naive HFD macrophages, possibly creating a condition that causes impaired future LPS responses. Vice versa, the lower PPP might also be a consequence of an attenuated inflammatory phenotype in HFD macrophages and the consecutive lower demand for PPP-derived products that regulate inflammation and anti-oxidant cellular defense.
We identified the Nrf2-mediated oxidative stress response as the most suppressed pathway in LPS-stimulated HFD macrophages. Nrf2 emerged as a crucial regulator of the inflammatory responses in macrophages (Kobayashi et al., 2016; Mills et al., 2018). Interestingly, several PPP genes were previously identified as Nrf2 target genes in cancer cells (Mitsuishi et al., 2012). Here we emphasized the importance of the Nrf2 pathway in the regulation of the PPP in macrophages. Importantly, suppressed Nrf2 is not the only mediator of the HFD macrophage phenotype and probably acts in parallel with other mechanisms, like the desmosterol-induced LXR pathway that was described earlier (Spann et al., 2012). Indeed, LXR activation or Nrf2 deletion as such did not result in the deactivated HFD macrophage phenotype. Our observations agree with previous studies demonstrating normal IL-1β, TNF, and IL-6 expression in the absence of Nrf2 (Mills et al., 2018; Bambouskova et al., 2018; Kobayashi et al., 2016). Conversely, activation of Nrf2 in macrophages by pharmacological or genetic (low KEAP1 expression) means clearly dampens inflammatory responses (Kobayashi et al., 2016) and mediates the anti-inflammatory effects of the metabolite itaconate (Mills et al., 2018). Thus, low levels of Nrf2 do not affect LPS responses as such, but Nrf2 activation is clearly anti-inflammatory. It will be of interest to define the mechanism responsible for Nrf2 repression in macrophage foam cells.
Together, these observations show that hypercholesterolemia suppresses the Nrf2 and PPP in macrophages and deactivates their inflammatory phenotype. We demonstrate that systemic metabolic changes translate into rewired intracellular metabolic pathways in macrophages that are tailored to support their effector functions. This highlights the intricate interplay between inflammatory signaling and metabolic pathways.
STAR★MethodsKey Resources Table
REAGENT or RESOURCESOURCEIDENTIFIER
| Antibodies | ||
| anti-actin | Millipore | Cat# MAB1501; RRID:AB_2223041 |
| anti-mitofusin 1 (MFN1) | Abcam | Cat# ab57602; RRID:AB_2142624 |
| anti-mitofusin 2 (MFN2) | Sigma | Cat# WH0009927M3; RRID:AB_1842440 |
| anti-OPA1 | BD Biosciences | Cat# 612606; RRID:AB_612606 |
| anti-NRF2 | Cell Signaling | Cat# 12721; RRID:AB_2715528 |
| anti-PGD | Abcam | Cat# ab129199; RRID:AB_11144133 |
| Total OXPHOS Rodent WB Antibody Cocktail | Abcam | Cat# ab110413; RRID:AB_2629281 |
| anti-rabbit IgG/HRP (secondary) | Thermo Fisher Scientific | Cat# 32260; RRID:AB_1965959 |
| anti-mouse IgG/HRP (secondary) | Thermo Fisher Scientific | Cat# 32230; RRID:AB_1965958 |
| anti-mouse CD71-PE | BD PharMingen | Cat# 553267; RRID:AB_394744 |
| anti-mouse CD206-APC | Biolegend | Cat# 141707; RRID:AB_10896057 |
| anti-mouse CD273-PE | BD PharMingen | Cat# 557796; RRID:AB_396874 |
| anti-mouse CD301-Alexa Fluor-647 | Serotec | Cat# MCA2392A647T; RRID:AB_1101873 |
| rat IgG2a-PE (isotype control) | BioLegend | Cat# 400507 |
| rat IgG2a-APC (isotype control) | BioLegend | Cat# 400511 |
| anti-mouse CD11b-PE-Cy7 | BD PharMingen | Cat# 552850; RRID:AB_394491 |
| anti-mouse F4/80-APC-eFluor780 | eBioscience | Cat# 47-4801; RRID:AB_2637188 |
| anti-mouse CD16/CD32 (Fc-block) | eBioscience | Cat# 14-0161; RRID:AB_467132 |
| Chemicals, Peptides, and Recombinant Proteins | ||
| Penicillin-Streptomycin | Thermo Fisher Scientific | Cat# 15140-122 |
| L-glutamine | Thermo Fisher Scientific | Cat# 25030024 |
| Recombinant murine IL-4 | PeproTech | Cat# 214-14 |
| Lipopolysaccharides (LPS) | Sigma | Cat# L2637 |
| Oil Red O | Sigma | Cat# O0625 |
| Hematoxylin | Merck | Cat# 1.05175.2500 |
| Oligomycin (OM) | Sigma | Cat# 75351 |
| 2-deoxyglucose (2-DG) | Sigma | Cat# D6134 |
| Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) | Sigma | Cat# C2920 |
| Rotenone | Sigma | Cat# R8875 |
| Antimycin A | Sigma | Cat# A8674 |
| Pyruvic acid | Sigma | Cat# 107360 |
| Malic acid | Sigma | Cat# M0875 |
| Adenosine diphosphate (ADP) | Sigma | Cat# A5285 |
| MitoTracker Green FM | Thermo Fisher Scientific | Cat# M7514 |
| CM-H2DCFDA | Thermo Fisher Scientific | Cat# C6827 |
| 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) | Thermo Fisher Scientific | Cat# N13195 |
| RNA-free DNase | QIAGEN | Cat# 79254 |
| 6-Aminonicotinamide (6-AN) | Sigma | Cat# A68203 |
| Dehydroepiandrosterone (DHEA) | Sigma | Cat# D063 |
| GW3965 | Sigma | Cat# G6295 |
| Critical Commercial Assays | ||
| IL-6 ELISA | Life Technologies | Cat# CMC0063 |
| TNF ELISA | Life Technologies | Cat# CMC3013 |
| Griess reaction | Sigma | Cat# G4410 |
| BCA Protein Assay kit | Thermo Fisher Scientific | Cat# 23225 |
| RNeasy Mini Kit | QIAGEN | Cat# 74106 |
| Ovation Mouse RNA-Seq System | NuGEN | Cat# 0348-32 |
| High Pure RNA Isolation Kit | Roche | Cat# 11828665001 |
| iScript cDNA Synthesis Kit | Bio-Rad | Cat# 170-8891 |
| Quick-gDNA MiniPrep | Zymo Research | Cat# D3024 |
| Deposited Data | ||
| RNA-sequencing data | This paper | GEO: GSE107412 |
| Experimental Models: Organisms/Strains | ||
| Mouse: LdlrKO: B6.129S7-Ldlrtm1Her/J | The Jackson Laboratory | JAX:002207 |
| Mouse: Nrf2KO: B6.129P3-Nf2l2tm1Mym | Itoh et al., 1997 | N/A |
| Mouse: Keap1KD: B6.129P3-Keap1tm2Mym | Taguchi et al., 2010 | N/A |
| Mouse: WT: C57BL/6J | The Jackson Laboratory | JAX:000664 |
| Oligonucleotides | ||
| Primer sequences | This paper (Table S3) | N/A |
| Software and Algorithms | ||
| FlowJo | ThreeStar | N/A |
| GraphPad Prism 7 | GraphPad Software | N/A |
| Seahorse Wave | Agilent | N/A |
| Ingenuity Pathway Analysis | QIAGEN | N/A |
| R package: ggplot2 | Wickham, 2016 | https://cran.r-project.org/web/packages/ggplot2 |
| R package: ropls | Thévenot et al. (2015) | http://www.bioconductor.org/packages/release/bioc/html/ropls.html |
| R package: mixOmics | Rohart et al. (2017) | http://mixomics.org |
| STAR 2.5.2b | Dobin et al. (2013) | https://github.com/alexdobin/STAR/releases |
| SAM tools | Li et al. (2009) | http://samtools.sourceforge.net |
| HOMER | Heinz et al. (2010) | http://homer.ucsd.edu/homer |
| R package: DESeq2 | Love et al. (2014) | https://bioconductor.org/packages/release/bioc/html/DESeq2.html |
| R package: limma | Ritchie et al. (2015) | https://bioconductor.org/packages/release/bioc/html/limma.html |
| Other | ||
| Control normal fat diet (NFD) | Harlan Laboratories (Envigo) | Cat# 2016 (Teklad global 16% protein) |
| High fat diet (HFD) | Special diet Services | Code 824199 |
| 0.5 μM Fluoresbrite YG microspheres | Polysciences | Cat# 17152 |
| Thioglycollate medium | Fisher Scientific | Cat# 11782834 |
| RPMI-1640 medium | Thermo Fisher Scientific | Cat# 52400041 |
| RPMI-1640 Medium, no glucose | Thermo Fisher Scientific | Cat# 11879020 |
| Fetal Bovine Serum | Thermo Fisher Scientific | Cat# 10500 |
| NP-40 cell lysis buffer | Thermo Fisher Scientific | Cat# FNN0021 |
| Protease Inhibitor Cocktail | Sigma | Cat# 11873580001 |
| PhosSTOP | Sigma | Cat# 4906837001 |
| Bolt 4-12% Bis-Tris Plus Gels | Thermo Fisher Scientific | Cat# NW04120BOX |
| Nitrocellulose Membrane | Bio-Rad | Cat# 162-0094 |
| TWEEN 20 | Sigma | Cat# P1379 |
| SuperSignal West Pico PLUS Chemiluminescent Substrate | Thermo Fisher Scientific | Cat# 34580 |
| Fast SYBR Green Master Mix | Applied Biosytems | Cat# 4385618 |
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jan Van den Bossche (j.vandenbossche@vumc.nl).
Experimental Model and Subject DetailsMice
Female and male LdlrKO mice were obtained from Jackson Laboratory. LdlrKO mice were housed at the Animal Research Institute AMC (ARIA) and all animal experiments were conducted after approval (permit: DBC102861) by the Committee for Animal Welfare of the Academic Medical Center, University of Amsterdam. 6-month old adult mice were used for experiments and put on a control normal fat diet (NFD, 4% fat, Harlan Laboratories) or a high fat, high cholesterol diet (HFD, 16% fat, 0,25% cholesterol, Special Diet Services) for 10 weeks. Nrf2-knockout (Nrf2KO) (Itoh et al., 1997) and Keap1-knockdown (Keap1KD) (Taguchi et al., 2010) mice, and their wild-type (WT) counterparts, all 8-12-week old females on the C57BL/6 genetic background, were bred and maintained in the Medical School Resource Unit of the University of Dundee. Mice of the same sex were randomly assigned to both experimental groups in disposable Innovive 101 IVC cages in groups of 3 or 4.
Method DetailsIsolation of macrophages
After 10 weeks of NFD or HFD, LldrKO mice were euthanized by CO2 asphyxiation. Four days prior to sacrifice, mice were intraperitoneally injected with 3% thioglycollate medium (Fisher Scientific). Upon sacrifice, the peritoneum was flushed with 10 mL ice-cold PBS and collected peritoneal cells were cultured in RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin (GIBCO). After 3 h, non-adherent cells were washed away and adhered cells (typically consisting of 90%–95% CD11b+ F4/80+ macrophages, Figure S1D) were stimulated for 24 hours with 10 ng/ml LPS (Sigma) or 100 U/ml IL-4 (Peprotech), or were left untreated, and were used for further analyses. Blood cholesterol and triglyceride levels were measured by enzymatic methods using available kits (Roche). To determine lipid accumulated in peritoneal macrophages, tissue slides with cells were fixed in 4% formalin for 10 minutes and washed two times with PBS (with magnesium and chloride) before and after fixation. Subsequently, tissue slides were incubated in 60% isopropanol for 15 minutes before staining for 45 minutes with fresh 0.3% Oil Red O in 60% isopropanol. After staining, tissue slides were rinsed in 60% isopropanol, washed in distilled water, incubated for 1 minute with hematoxylin blued in tap water and rinsed with distilled water. Bone-marrow derived (BMDM) macrophages were generated from femurs and tibia from WT, Nrf2KO and Keap1KD mice and differentiated in RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin and 15% L929-conditioned medium for 7 days.
Metabolic extracellular flux analysis
Macrophages (1x105 cells/well) were plated on XF-96-cell culture plates (Seahorse Bioscience) and treated as specified. OCR and ECAR were assessed using the XF-96 Flux Analyzer (Seahorse Bioscience) as detailed before (Van den Bossche et al., 2015). Changes in ECAR in response to glucose (10 mM), OM (1.5 μM) and 2-DG (100 mM) injection were used to calculate all glycolysis parameters and OXPHOS characteristics were calculated from the OCR changes in response to OM (1.5 μM), FCCP (1.5 μM) and rotenone (1.25 μM) + antimycin A (2.5 μM) injection (Van den Bossche et al., 2015; Van den Bossche et al., 2016). The Seahorse Bioscience Mito Fuel Flex Test Kit was used to determine the dependency of cells for glucose, glutamine or fatty acid oxidation.
Respiratory measurements of isolated mitochondria
To isolate mitochondria, cell pellets were resuspended in 1 mL of MTE buffer (250 mM mannitol, 5 mM TRIS, 0.5 mM EDTA, pH 7.4). Macrophages were lysed using 10 passages through the cell cracker (European Molecular Biology Laboratory, Heidelberg, Germany). The homogenate was centrifuged 10 min at 1000 g, after which the supernatant was transferred to a new tube and centrifuged at 10000 g. The resulting supernatant was considered the cytosolic fraction. The final pellet containing the mitochondrial fraction was washed with 1 mL MTE buffer, centrifuged at 3600 g and resuspended in a minimal volume of MTE buffer. Equal amounts of mitochondria (0.5 μg well) were resuspended in MAS buffer (70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, and 1 mM EGTA; pH 7.2, plus 10 mM pyruvate and 1 mM malate as substrates), transferred to XF-96-cell culture plates, centrifuged at 2000 g for 20 min at 4°C and measured using a XF-96 Flux Analyzer (Seahorse Bioscience) to assess basal oxygen consumption (state 2), maximal coupled respiration or state 3 after injection of 4 mM ADP, state 4o after injection of 1.5 μM OM, maximal uncoupled respiration (state 3u) after injection of 4 μM FCCP and the respiratory control ratio (RCR = state 3/state 4o) in accordance to an established protocol (Rogers et al., 2011).
Liquid chromatography - mass spectrometry
Macrophages (5x105 cells/well) in 24 well plates were washed three times with 0,9% NaCl. Metabolism was quenched by adding 1 mL ice-cold methanol/water (1/1; v/v). The following internal standards were added, D3-aspartic acid, D3-serine, D5-glutamine, D3-glutamate, 13C3-pyruvate, 13C6-isoleucine, 13C6-glucose, 13C6-fructose-1,6-biphosphate, 13C6-glucose-6-phosphate, adenosine-15N5-monophosphate and guanosine-15N5-monophosphate (5 μM). 1 mL of chloroform was added, vortexed and centrifuged for 5 minutes at 14.000 rpm at 4°C. ∼800 μL of the “polar” top layer was transferred to a 1.5 mL tube, dried to dryness in a vacuum concentrator and dissolved in 100 μL methanol/water (6/4; v/v). For the analysis, we used a Thermo Scientific (U)HPLC system coupled to a Thermo Q Exactive (Plus) Orbitrap mass spectrometer (Waltman) with a SeQuant ZIC-cHILIC column at 15°C (PEEK 100 × 2.1 mm, 3.0 μm particle size, Merck). The mobile phase composed of (A) 9/1 acetonitrile/water with 5 mM ammonium acetate; pH 6.8 and (B) 1/9 acetonitrile/water with 5 mM ammonium acetate; pH 6.8, respectively. The LC program started with 100% (A) hold 0-3 min; ramping 3-24 min to 20% (A); hold from 24-27 min at 20% (A); ramping from 27-28 min to 100% (A); and re-equilibrate from 28-35 min with 100% (A), flow rate was 0.250 mL/min. The MS data were acquired in full scan, negative ionization mode with a mass resolution of 140.000. Interpretation of the data was performed in the Xcalibur software (ThermoFisher). Subsequent analyses were done in a R environment using the ggplot2, ropls and mixOmics packages (Rohart et al., 2017; Thévenot et al., 2015; Wickham, 2016).
Flow cytometry
To assess surface marker expression, cells (1.5x105 cells/well) in 96 well plates were deateched with citrate and transferred to V-bottom 96 well plates and stained with CD71, CD206, CD273, CD301 or isotype controls (all 1:250 diluted in PBS with 0,5% BSA and 2.5 mM EDTA) for 20 minutes at room temperature in the dark. After labeling, cells were washed with PBS with 0,5% BSA and 2.5 mM EDTA and finally resuspend in PBS with 0,5% BSA and 2.5 mM EDTA and measured on BD FACSCanto or a Beckman Coulter CytoFLEX, and analyzed using FlowJo (TreeStar). In order to quantify mitochondrial mass and ROS production, macrophages (105 cells/well) in 96 well plates were detached using citrate buffer (17 mM tri-Sodium citrate dehydrate and 135 mM potassium chloride in water) transferred to V-bottom 96 well plates and washed with PBS. Next, cells were resuspended in PBS with 200 nm MitoTracker Green or 20 μM CM-H2DCFDA (both ThermoFisher) and incubated for 30 minutes at 37°C (5% CO2). After incubation, cells were washed with PBS and mitochondrial mass and ROS production was measured using flow cytometry. To determine glucose uptake, macrophages (105 cells/well) were cultured in 96 well plates for two hours in RPMI-1640 lacking glucose and serum. Subsequently, 2-NBDG (ThermoFisher) was added for an additional incubation of 20 minutes in a final concentration of 25 μM. Next, cells were detached with citrate buffer, transferred to V-bottom 96 well plates and washed with PBS and analyzed using flow cytometry. To assess phagocytic activity, 105 macrophages were cultured for 1 h at 37°C (or 4°C as a control, Figure S3E) in the presence of Fluoresbrite YG microspheres (0.5 μM, Polysciences).
Immunoblotting
Immunoblotting for NRF2 and mitochondrial complexes was performed as detailed by (Mills et al., 2018) and (Wüst et al., 2016), respectively. For MFN1, MFN2, OPA1 and PGD immunoblotting, macrophages (1x106 cells/well) in 12 well plates were lysed in NP40 cell lysis buffer (ThermoFisher) supplemented with protease inhibitor cocktail (Sigma-Aldrich) and PhosSTOP (Sigma-Aldrich). Lysates were equalized on protein concentration after quantification with the BCA assay (ThermoFisher), separated on Bolt 4%–12% Bis-Tris gels (ThermoFisher) and transferred onto nitrocellulose membranes (Bio-Rad). After blocking for 1 hour with 5% milk powder (Campina) in Tris-buffered saline, TWEEN 20 (TBS-T), membranes were incubated overnight with primary antibodies against MFN1 (1:1000 dilution), MFN2 (1:200), OPA1 (1:1000) and PGD (1:1000) in 5% milk, TBS-T, followed by incubation for 1 hour with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:2000) in 5% milk, TBS-T and visualization with SuperSignal West Pico Chemiluminescent PLUS Substrate (Thermo Fisher Scientific).
Cytokine and NO production
IL-6 and TNF levels in the supernatant were measured by ELISA (Life Technologies) and NO production was assessed by a Griess reaction (Sigma-Aldrich) according to the supplier’s protocol.
RNA sequencing
Total RNA was isolated from peritoneal macrophages using a RNeasy Mini Kit with DNase treatment (QIAGEN). Strand-specific libraries were constructed from 100 ng total RNA using ‘Ovation RNA-Seq system’ following manufacturer instructions (NuGen Technologies). Samples were pooled and diluted to 10 nM and sequenced on an Illumina HiSeq 4000 instrument (Illumina) to a depth of ± 20 million single-ended 50 bp reads.
Bioinformatics
Reads were aligned to the mouse genome mm10 by STAR 2.5.2b with default settings (Dobin et al., 2013). BAM files were indexed and filtered on MAPQ > 15 with SAMTools 1.3.1 (Li et al., 2009). Raw tag counts and RPKM (reads per kilobase per million mapped reads) values per gene were summed using HOMER2′s analyzeRepeats.pl script with default settings and the -noadj or –rpkm options for raw counts and RPKM reporting, respectively (Heinz et al., 2010). Differential expression was assessed using the DESeq2 bioconductor package in an R 3.3.1 environment with gene expression called differential with a p value < 0.05 and an average RPKM > 1 in at least one group (Love et al., 2014). Presented RPKM values in scatterplots were tested using one-way ANOVA followed by Bonferroni’s post hoc comparisons test. Differential expression analysis on available microarray data (GEO: GSE13985) was executed using the limma package and gene expression was called differential with a p value < 0.05 (Ritchie et al., 2015). Differential expressed genes were analyzed in Ingenuity Pathway Analysis (Qiaqen) to identify deregulated pathways.
qPCR
RNA was isolated with High Pure RNA Isolation kits (Roche), cDNA was synthesized with iScript (Bio-Rad), and qPCR was performed using SYBR Green Fast mix (Applied Biosytems) on a ViiA7 (Applied Biosystems). Housekeeping genes Rplp0 and Ppia were used for normalization and used primer sequences are noted in the Table S3. DNA was extracted using the Quick-gDNA MiniPrep (Zymo Research) kit and primers for mt-Co1 and Ndufv1 were used to determine the mtDNA/gDNA ratio.
Quantification and Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). Number (n) and type (biological or technical) of replicates are indicated in the figure legends. Data were tested using a two-tailed Student’s t test (when comparing two groups) or one-way ANOVA followed by Bonferroni’s post hoc comparison to test multiple groups in GraphPad Prism version 7.0 software, as indicated in the figure legends. p values < 0.05 were considered significant, with levels of significance being indicated as follows: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant.
Data and Software Availability
The accession number for the RNA sequencing data reported in this paper is GEO: GSE107412.
Acknowledgments
J.V.d.B. received a VENI grant from ZonMW (91615052) and a Netherlands Heart Foundation junior postdoctoral grant (2013T003) and senior fellowship (2017T048). M.P.J.d.W. is an established investigator of the Netherlands Heart Foundation, is supported by grants from the Netherlands Heart Foundation and Spark-Holding BV (2015B002), the European Union (ITN grant EPIMAC and REPROGRAM [EU Horizon 2020]), and Fondation Leducq (16CVD-01), and holds an AMC fellowship. We acknowledge support from the Netherlands CardioVascular Research Initiative, Dutch Federation of University Medical Centers, the Netherlands Organisation for Health Research and Development, the Royal Netherlands Academy of Sciences (CVON 2011-19 and CVON 2017-20) and Cancer Research UK (C20953/A18644). We thank Tadeja Rezen, Peter Juvan, and Damjana Rozman for the GEO: GSE13985 dataset details.
Author Contributions
Conceptualization, J.V.d.B.; Methodology, J.V.d.B.; Formal Analysis, J.B., S.G.S.V., M.v.W., K.H.M.P., and J.V.d.B.; Investigation, J.B., S.v.d.V., S.G.S.V., D.G.R., R.C.I.W., A.E.N., S.W.D., M.E.W., E.V.K., and J.V.d.B.; Writing – Original Draft, J.B.; Writing – Review & Editing, J.B., S.G.S.V., D.S., R.H.H., L.A.O., A.T.D.-K., E.L., M.P.J.d.W., and J.V.d.B.; Visualization, J.B., M.v.W., and J.V.d.B.; Supervision, M.P.J.d.W. and J.V.d.B.; Funding Acquisition, M.P.J.d.W. and J.V.d.B. All authors read and approved the final manuscript.
Declaration of Interests
The authors declare no competing interests.
Supplemental Information (2)
Download all
Document S1. Figures S1–S4 and Tables S1–S3
Document S2. Article plus Supplemental Information
References
Bambouskova, M. ∙ Gorvel, L. ∙ Lampropoulou, V. ...
Electrophilic properties of itaconate and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis
Nature. 2018; 556:501-504
Cochain, C. ∙ Vafadarnejad, E. ∙ Arampatzi, P. ...
Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis
Circ. Res. 2018; 122:1661-1674
Dobin, A. ∙ Davis, C.A. ∙ Schlesinger, F. ...
STAR: ultrafast universal RNA-seq aligner
Bioinformatics. 2013; 29:15-21
Ference, B.A. ∙ Ginsberg, H.N. ∙ Graham, I. ...
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Eur. Heart J. 2017; 38:2459-2472
Ghisletti, S. ∙ Huang, W. ∙ Ogawa, S. ...
Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma
Mol. Cell. 2007; 25:57-70
Heinz, S. ∙ Benner, C. ∙ Spann, N. ...
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities
ReportVolume 25, Issue 8p2044-2052.e5November 20, 2018Open access
Download Full Issue
A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia
Jeroen Baardman1 ∙ Sanne G.S. Verberk2,9 ∙ Koen H.M. Prange1,9 ∙ … ∙ Esther Lutgens1,8 ∙ Menno P.J. de Winther1,8,9 ∙ Jan Van den Bossche1,2,9,10 j.vandenbossche@vumc.nl … Show more
Affiliations & NotesArticle Info

Download Full Issue
Show Outline
Highlights
•
Systemic metabolism affects immune cell metabolism
•
Hypercholesterolemia suppresses the PPP and Nrf2 pathway in macrophages
•
PPP inhibition and hypercholesterolemia deactivate inflammatory macrophage responses
•
The Nrf2 pathway regulates the PPP in an LXR-independent manner
Summary
Metabolic reprogramming has emerged as a crucial regulator of immune cell activation, but how systemic metabolism influences immune cell metabolism and function remains to be investigated. To investigate the effect of dyslipidemia on immune cell metabolism, we performed in-depth transcriptional, metabolic, and functional characterization of macrophages isolated from hypercholesterolemic mice. Systemic metabolic changes in such mice alter cellular macrophage metabolism and attenuate inflammatory macrophage responses. In addition to diminished maximal mitochondrial respiration, hypercholesterolemia reduces the LPS-mediated induction of the pentose phosphate pathway (PPP) and the Nrf2-mediated oxidative stress response. Our observation that suppression of the PPP diminishes LPS-induced cytokine secretion supports the notion that this pathway contributes to inflammatory macrophage responses. Overall, this study reveals that systemic and cellular metabolism are strongly interconnected, together dictating macrophage phenotype and function.
Graphical Abstract

Keywords
Introduction
In recent years, metabolic reprogramming arose as a crucial controller of macrophage activation (Van den Bossche et al., 2016, 2017). For instance, in response to pro-inflammatory stimuli such as the Toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS), macrophages show increased glycolysis, as demonstrated by an enhanced extracellular acidification rate (ECAR) (Van den Bossche et al., 2016). Moreover, LPS reconfigures the tricarboxylic acid (TCA) cycle in macrophages and induces itaconate and succinate accumulation (Jha et al., 2015; Tannahill et al., 2013). Itaconate is a key controller of inflammatory macrophage responses through its regulatory effect on succinate dehydrogenase and its activation of the anti-oxidant transcription factor Nrf2 (Lampropoulou et al., 2016; Michelucci et al., 2013; Mills et al., 2018). Succinate promotes inflammation by inducing interleukin 1β (IL-1β) expression (Mills et al., 2016; Tannahill et al., 2013) and can activate immune cells in the local environment upon secretion (Littlewood-Evans et al., 2016). Furthermore, the activity of the pentose phosphate pathway (PPP) is enhanced in LPS-stimulated macrophages, supplying precursors for nucleotide synthesis and nicotinamide adenine dinucleotide phosphate (NADPH), which is used for reactive oxygen species (ROS) production by NADPH oxidase, fatty acid synthesis, and anti-oxidant cellular defense (Nagy and Haschemi, 2015; Wu et al., 2008). So far, most knowledge regarding macrophage immunometabolism was obtained with in vitro-cultured bone marrow-derived macrophages and largely ignored the possible systemic and micro-environmental effects on macrophage metabolism and function in vivo (Norata et al., 2015). Exploring this neglected aspect of immunometabolism might identify therapeutic strategies to dampen chronic inflammatory diseases such as atherosclerosis, in which lipid-laden macrophage “foam cells” are crucial during all stages of the disease. Elevated levels of circulating low-density lipoprotein (LDL) cholesterol, as observed in patients with familial hypercholesterolemia (FH), are a prominent risk factor for developing atherosclerosis (Ference et al., 2017). FH is predominantly caused by loss-of-function mutations in the LDL receptor (LDLR) gene, leading to impaired hepatic uptake of LDL and, consequently, elevated levels of plasma LDL (Reiner, 2015). It has been shown that hypercholesterolemia affects the lipidome of macrophages and deactivates part of their inflammatory responses via activation of LXR (Spann et al., 2012). However, LXR-independent repression mechanisms still need to be defined. Here we confirm that hypercholesterolemia attenuates LPS-induced inflammatory macrophage responses and show that this deactivated phenotype is accompanied by a diminished Nrf2-mediated oxidative stress response and LXR-independent suppression of the PPP, indicating that systemic and cellular metabolism are directly intertwined, together regulating macrophage function.
ResultsHypercholesterolemia Translates into Altered Immune Cell Metabolism
Ingenuity Pathway Analysis (IPA) of published FH patient microarray data (GEO: GSE13985; characteristics in Table S1) identified oxidative phosphorylation (OXPHOS) and mitochondrial dysfunction among the top-ranked enriched canonical pathways (Figure 1A), and most differentially expressed genes belonging to those pathways were downregulated in leukocytes of FH patients (Figure 1B).

Figure 1 Hypercholesterolemia Affects Immune Cell Metabolism
Show full captionFigure viewer
To study the effects of systemic metabolic changes on immune cell metabolism in more detail, Ldlrko mice were fed a high-fat diet (HFD) to induce hypercholesterolemia and hypertriglyceridemia or a normal-fat control diet (NFD) (Figures S1A–S1C). Peritoneal macrophages from HFD mice were elicited as a validated in vivo model and source of foam cells (Spann et al., 2012). CD11b+F4/80+ peritoneal macrophages isolated from the HFD group were lipid-laden foam cells (hereafter referred to as “HFD macrophages”; Figures S1D and S1E) and compared with “NFD macrophages” to evaluate the effect of systemic metabolism on macrophage metabolism independent of microenvironmental cues present in atherosclerotic lesions. To study the effects of these different lipid environments on glycolysis and mitochondrial function in macrophages, we performed an extracellular flux analysis and revealed similar basal glycolysis and mitochondrial respiration in macrophages isolated from mice fed either diet (Figure 1C). Interestingly, HFD macrophages demonstrated lower maximal mitochondrial respiration and a reduced spare respiratory capacity (SRC) (Figure 1D) but showed no differences in non-mitochondrial oxygen consumption, ATP production, and proton leak (Figure S2A). Furthermore, both macrophage types showed similar fuel dependencies, with fatty acids being the main drivers of mitochondrial oxygen consumption (Figure 1E).
Because reduced mitochondrial mass results in decreased SRC in T cells (van der Windt et al., 2012), we assessed whether a lower mitochondrial abundance could explain the reduced SRC in HFD macrophages. Supporting this notion, HFD macrophages indeed showed a lower mitochondrial mass, as demonstrated by MitoTracker Green staining, mitochondrial DNA:genomic DNA ratio, and mitochondrial complex immunoblotting (Figures 1F and 1G and S2B). Together with the observation that similar amounts of mitochondria isolated from NFD or HFD macrophages display equal respiration (Figure 1H), our data strongly suggest that the reduced maximal respiration in HFD macrophages is mainly due to a decrease in mitochondrial mass. RNA sequencing revealed that genes related to mitochondrial biogenesis and dynamics were not altered in HFD macrophages; this was further confirmed by qPCR and immunoblotting (Figures S2C–S2E). Pathway analysis indicated that the top most enriched pathways were related to cholesterol biosynthesis, and associated genes were downregulated in HFD macrophages (Figures 1I and 1J).
Given the importance of metabolites such as itaconate, succinate, and α-ketoglutarate in regulating macrophage function (Lampropoulou et al., 2016; Liu et al., 2017; Michelucci et al., 2013; Mills et al., 2016, 2018; Tannahill et al., 2013), we next measured the levels of an extensive set of 63 metabolites. Partial least square discriminant (PLS-DA) analysis was used to discriminate NFD and HFD macrophages based on the measured metabolites. Interestingly, the abundance of several metabolites varied among NFD and HFD macrophages, with itaconate as the most distinctive metabolite (Figure 1K), whose abundance was lower in HFD macrophages (Table S2). Overall, hypercholesterolemia is associated with reduced mitochondrial mass and maximal respiration and affects the levels of metabolites such as itaconate.
Hypercholesterolemia Attenuates Inflammatory Macrophage Responses without Major Changes in Glycolysis or the TCA Cycle
Because itaconate regulates inflammatory macrophage responses (Jha et al., 2015; Mills et al., 2018) and was reduced in naive HFD macrophages, we investigated the effects of hypercholesterolemia on LPS-induced inflammatory macrophage activation. In parallel to the previously reported decreased expression of several inflammatory genes, we identified reduced secretion of pro-inflammatory cytokines as well as lower nitric oxide (NO) and lower ROS levels in HFD macrophages (Figures 2A–2C). Both types of macrophages exhibited similar phagocytic activity and comparable expression of Il10 and IL-4-induced genes and surface proteins (Figures 2D, S3A, and S3B). Together, this does not indicate a general inhibition of macrophage activation in the HFD group but shows that these cells undergo a deactivation process during which foam cells lose part of their LPS-induced inflammatory properties. Likewise, short exposure to oxidized or acetylated LDL in vitro also decreased subsequent LPS-induced tumor necrosis factor (TNF), IL-6, and NO secretion in NFD macrophages (Figure S3C).

Figure 2 Hypercholesterolemia Attenuates the Inflammatory Phenotype of Macrophages without Reconfiguring Glycolysis and the TCA Cycle
Show full captionFigure viewer
To address whether distinct LPS-induced metabolic rewiring underlies the deactivated phenotype of HFD foam cells, we measured glycolysis upon acute and 24-hr LPS exposure. NFD and HFD macrophages showed comparable glycolytic rates and glucose uptake (Figure 2E, 2F, and S3D), indicating that the attenuated inflammatory phenotype of HFD macrophages is probably not caused by reduced glycolysis.
Next we examined whether differences in succinate, itaconate, α-ketoglutarate, or other metabolites could explain the attenuated pro-inflammatory function of LPS-stimulated HFD macrophages. PLS-DA identified distinct metabolic profiles upon LPS stimulation in macrophages from both groups (Figure 2G). We observed that LPS induced itaconate, succinate, and oxaloacetate levels to a similar extent in both NFD and HFD macrophages (Figure 2H). This suggests that the reduced inflammatory phenotype observed in HFD macrophages is not caused by a distinct LPS-induced TCA cycle reconfiguration. In addition to altered levels of different amino acids (Figures 2I) and increased levels of NADH in HFD macrophages (Table S2), several metabolites related to the PPP (marked with asterisks in Figure 2I) strongly contributed to the differential metabolic profile in LPS-stimulated NFD and HFD macrophages.
Hypercholesterolemia Diminishes the NRF2 and PPP in Macrophages
Metabolic analysis demonstrated an increased abundance of several PPP metabolites, including ribose-5P or ribulose-5P, sedoheptulose-7P, and glyceraldehyde 3-P upon LPS stimulation (Figure 3A). Interestingly, LPS-induced ribose-5P or ribulose-5P and sedoheptulose-7P levels were lower in HFD macrophages. Analyzing the two genes that encode glucose-6-phosphate dehydrogenase (G6PD) as the rate-limiting enzyme of the PPP in mice (Huminiecki and Wolfe, 2004) revealed that the LPS-induced elevation of G6pd2, but not G6pdx, was absent in HFD macrophages (Figures 3B and 3C). Moreover, Pgd (encoding 6-phosphogluconate dehydrogenase, which converts 6-phosphogluconate into ribulose 5-P in the PPP) was reduced in both naive and LPS-stimulated HFD macrophages (Figure 3B), whereas Pgd protein levels were only suppressed in naive HFD macrophages (Figure S4A). To validate whether suppression of the PPP in HFD macrophages (Figure 3D) could explain their attenuated LPS-induced inflammatory responses, we pharmacologically inhibited G6PD with dehydroepiandrosterone (DHEA) or 6-aminonicotinamide (6-AN). Supporting this notion, blockade of the PPP diminished the LPS-induced production of pro-inflammatory mediators in macrophages (Figure 3E). Because desmosterol-driven LXR activation regulates at least a part of the inflammatory phenotype of foam cells (Spann et al., 2012), we studied whether this pathway controls the PPP. Activation of LXR and its target genes with GW3965 did not affect PPP genes and metabolites (Figures S4B–S4D), backing the idea that both LXR-dependent and independent mechanisms contribute to the diminished inflammatory phenotype of foam cells (Spann et al., 2012).

Figure 3 Hypercholesterolemia Reduces LPS-Mediated Induction of the PPP in Macrophages
Show full captionFigure viewer
To uncover the LXR-independent mechanistic link between hypercholesterolemia, suppressed PPP, and inflammation, we further explored our RNA sequencing (RNA-seq) dataset. Pathways analysis revealed that the Nrf2 pathway was the most differentially regulated pathway between LPS-stimulated NFD and HFD macrophages (Figure 3F), and most genes of this pathway were downregulated in HFD macrophages (Figure 3G). Accordingly, Nrf2 protein levels were reduced in LPS-treated HFD macrophages (Figure 3H). Importantly, Nrf2 was found to be a regulator of the PPP in cancer cells (Mitsuishi et al., 2012) and analyzing expression data from Nrf2-deficient macrophages (GEO: GSE71695) revealed that several PPP genes, including Pgd, are downregulated in Nrf2-deficient macrophages (Figure S4E). Moreover, analysis of published chromatin immunoprecipitation (ChIP-seq) data (DDBJ: DRA003771) revealed binding of Nrf2 4 kb upstream of the Pgd locus (Figure 3I), suggesting a direct link between reduced Nrf2 activity and Pgd expression in HFD macrophages. Indeed, Pgd is suppressed in Nrf2-deficient macrophages and increased in macrophages that have lower levels of the Nrf2 repressor protein KEAP1 (Figure 3J). Accordingly, the LPS-induced production of sedoheptulose-7P and ribose-5P or ribulose-5P downstream of Pgd in the PPP was blunted in the absence of Nrf2 (Figure S4F). This suppressed Nrf2 signaling acts in parallel with other pathways, like the LXR pathway (Spann et al., 2012), and manipulating one branch does not recapitulate the deactivated phenotype observed in HFD macrophages. Indeed, Nrf2-deficient macrophages did not show overall suppressed LPS responses (Figure S4G).
Together, this demonstrates a link between reduced Nrf2 and a defective PPP in HFD macrophages and that the latter pathway supports inflammatory responses.
Discussion
Recent findings in the rapidly expanding field of immunometabolism underscored the importance of metabolic reprogramming during macrophage activation (Van den Bossche et al., 2017). However, most knowledge regarding this metabolic-immunologic crosstalk has emerged from in vitro-cultured macrophages, excluding different (e.g., microenvironmental and systemic) layers of regulation that are at play in vivo. This gave us the incentive to explore the influences of different systemic lipid environments on cellular macrophage metabolism and function.
Leukocytes from FH patients demonstrated reduced expression of genes related to OXPHOS. In mice, hypercholesterolemia was associated with reduced cholesterol biosynthesis in macrophages. Differences in cell type (total leukocytes versus macrophages) or species (human versus mouse) might underlie this discrepancy. Dhcr24, which encodes 24-dehydrocholesterol reductase, which converts desmosterol into cholesterol, was the most suppressed gene related to cholesterol biosynthesis in macrophages from HFD mice. This finding is in agreement with a previous study, and diminished Dhcr24 expression was found to result in the accumulation of desmosterol in HFD macrophages (Spann et al., 2012).
Isolated macrophages from hypercholesterolemic mice showed reduced maximal respiration and SRC. In T cells, SRC is positively correlated with their survival (van der Windt et al., 2012). Therefore, decreased SRC might increase the susceptibly to apoptosis in macrophage foam cells, potentially contributing to necrotic core development in atherosclerotic lesions (Moore et al., 2013).
It is well-accepted that atherosclerosis is a chronic inflammatory disease driven by elevated LDL cholesterol levels. The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial provides strong evidence in support of the inflammation hypothesis and demonstrated that neutralizing the pro-inflammatory cytokine IL-1β significantly reduces the rate of recurrent cardiovascular events (Ridker et al., 2017).
Confirming previous literature (Spann et al., 2012), we now observed that the LPS-induced secretion of inflammatory mediators was reduced in macrophages isolated from hypercholesterolemic mice. This might appear to be inconsistent with the inflammation hypothesis of atherogenesis. However, it is important to note that both in vivo-elicited HFD foam cells and in vitro LDL-exposed macrophages still produce considerable amounts of inflammatory cytokines upon activation, albeit to a lower extend than “normal” macrophages. Another explanation for the observed deactivated phenotype of foam cells could be the phenotypic diversity detected in plaques (Cochain et al., 2018). Not all plaque macrophages exhibit a pro-inflammatory phenotype, and there is a substantial subpopulation of macrophages with anti-inflammatory features (Kadl et al., 2010). In agreement with our observations, recent transcriptome analysis of macrophages from atherosclerotic aortae revealed that lipid-loaded plaque macrophages are less inflammatory than their non-foamy counterparts (Kim et al., 2018). We therefore favor the theory that, in addition to the systemic metabolic environment, microenvironmental cues regulate macrophage phenotypes in plaques (Spann et al., 2012) to promote the chronic inflammatory responses that are demonstrably driving atherogenesis.
Accumulation of cellular cholesterol leads to specific oxysterols and sterols that regulate the activity of LXR (Spann et al., 2012). LXRs bind to and prevent the removal of repressor complexes at TLR4-responsive genes, blunting their expression and exerting anti-inflammatory effects (Ghisletti et al., 2007). We now show that, in addition to LXR (Spann et al., 2012), LXR-independent impairment of the PPP contributes to the suppressed inflammatory responses in macrophage foam cells during hypercholesterolemia.
Interestingly, we discovered that 6-phosphogluconate dehydrogenase (Pgd) gene expression and downstream metabolites were blunted in HFD macrophages. In accordance, knockdown of PGD was found to reduce the oxidative PPP flux, NADPH:NADP+ ratio, and ribulose-5P and ribose-5P levels in human cancer cells (Lin et al., 2015). NADPH and ribose-5P generated in the PPP can support the inflammatory macrophage responses in different ways, including ROS production, anti-oxidant cellular defense, fatty acid synthesis, and nucleotide production (Nagy and Haschemi, 2015). Thus, reduced flux through the PPP as observed in HFD macrophages can cause attenuated inflammatory responses and ROS production. Furthermore, Pgd expression was already reduced in naive HFD macrophages, possibly creating a condition that causes impaired future LPS responses. Vice versa, the lower PPP might also be a consequence of an attenuated inflammatory phenotype in HFD macrophages and the consecutive lower demand for PPP-derived products that regulate inflammation and anti-oxidant cellular defense.
We identified the Nrf2-mediated oxidative stress response as the most suppressed pathway in LPS-stimulated HFD macrophages. Nrf2 emerged as a crucial regulator of the inflammatory responses in macrophages (Kobayashi et al., 2016; Mills et al., 2018). Interestingly, several PPP genes were previously identified as Nrf2 target genes in cancer cells (Mitsuishi et al., 2012). Here we emphasized the importance of the Nrf2 pathway in the regulation of the PPP in macrophages. Importantly, suppressed Nrf2 is not the only mediator of the HFD macrophage phenotype and probably acts in parallel with other mechanisms, like the desmosterol-induced LXR pathway that was described earlier (Spann et al., 2012). Indeed, LXR activation or Nrf2 deletion as such did not result in the deactivated HFD macrophage phenotype. Our observations agree with previous studies demonstrating normal IL-1β, TNF, and IL-6 expression in the absence of Nrf2 (Mills et al., 2018; Bambouskova et al., 2018; Kobayashi et al., 2016). Conversely, activation of Nrf2 in macrophages by pharmacological or genetic (low KEAP1 expression) means clearly dampens inflammatory responses (Kobayashi et al., 2016) and mediates the anti-inflammatory effects of the metabolite itaconate (Mills et al., 2018). Thus, low levels of Nrf2 do not affect LPS responses as such, but Nrf2 activation is clearly anti-inflammatory. It will be of interest to define the mechanism responsible for Nrf2 repression in macrophage foam cells.
Together, these observations show that hypercholesterolemia suppresses the Nrf2 and PPP in macrophages and deactivates their inflammatory phenotype. We demonstrate that systemic metabolic changes translate into rewired intracellular metabolic pathways in macrophages that are tailored to support their effector functions. This highlights the intricate interplay between inflammatory signaling and metabolic pathways.
STAR★MethodsKey Resources Table
REAGENT or RESOURCESOURCEIDENTIFIER
| Antibodies | ||
| anti-actin | Millipore | Cat# MAB1501; RRID:AB_2223041 |
| anti-mitofusin 1 (MFN1) | Abcam | Cat# ab57602; RRID:AB_2142624 |
| anti-mitofusin 2 (MFN2) | Sigma | Cat# WH0009927M3; RRID:AB_1842440 |
| anti-OPA1 | BD Biosciences | Cat# 612606; RRID:AB_612606 |
| anti-NRF2 | Cell Signaling | Cat# 12721; RRID:AB_2715528 |
| anti-PGD | Abcam | Cat# ab129199; RRID:AB_11144133 |
| Total OXPHOS Rodent WB Antibody Cocktail | Abcam | Cat# ab110413; RRID:AB_2629281 |
| anti-rabbit IgG/HRP (secondary) | Thermo Fisher Scientific | Cat# 32260; RRID:AB_1965959 |
| anti-mouse IgG/HRP (secondary) | Thermo Fisher Scientific | Cat# 32230; RRID:AB_1965958 |
| anti-mouse CD71-PE | BD PharMingen | Cat# 553267; RRID:AB_394744 |
| anti-mouse CD206-APC | Biolegend | Cat# 141707; RRID:AB_10896057 |
| anti-mouse CD273-PE | BD PharMingen | Cat# 557796; RRID:AB_396874 |
| anti-mouse CD301-Alexa Fluor-647 | Serotec | Cat# MCA2392A647T; RRID:AB_1101873 |
| rat IgG2a-PE (isotype control) | BioLegend | Cat# 400507 |
| rat IgG2a-APC (isotype control) | BioLegend | Cat# 400511 |
| anti-mouse CD11b-PE-Cy7 | BD PharMingen | Cat# 552850; RRID:AB_394491 |
| anti-mouse F4/80-APC-eFluor780 | eBioscience | Cat# 47-4801; RRID:AB_2637188 |
| anti-mouse CD16/CD32 (Fc-block) | eBioscience | Cat# 14-0161; RRID:AB_467132 |
| Chemicals, Peptides, and Recombinant Proteins | ||
| Penicillin-Streptomycin | Thermo Fisher Scientific | Cat# 15140-122 |
| L-glutamine | Thermo Fisher Scientific | Cat# 25030024 |
| Recombinant murine IL-4 | PeproTech | Cat# 214-14 |
| Lipopolysaccharides (LPS) | Sigma | Cat# L2637 |
| Oil Red O | Sigma | Cat# O0625 |
| Hematoxylin | Merck | Cat# 1.05175.2500 |
| Oligomycin (OM) | Sigma | Cat# 75351 |
| 2-deoxyglucose (2-DG) | Sigma | Cat# D6134 |
| Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) | Sigma | Cat# C2920 |
| Rotenone | Sigma | Cat# R8875 |
| Antimycin A | Sigma | Cat# A8674 |
| Pyruvic acid | Sigma | Cat# 107360 |
| Malic acid | Sigma | Cat# M0875 |
| Adenosine diphosphate (ADP) | Sigma | Cat# A5285 |
| MitoTracker Green FM | Thermo Fisher Scientific | Cat# M7514 |
| CM-H2DCFDA | Thermo Fisher Scientific | Cat# C6827 |
| 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) | Thermo Fisher Scientific | Cat# N13195 |
| RNA-free DNase | QIAGEN | Cat# 79254 |
| 6-Aminonicotinamide (6-AN) | Sigma | Cat# A68203 |
| Dehydroepiandrosterone (DHEA) | Sigma | Cat# D063 |
| GW3965 | Sigma | Cat# G6295 |
| Critical Commercial Assays | ||
| IL-6 ELISA | Life Technologies | Cat# CMC0063 |
| TNF ELISA | Life Technologies | Cat# CMC3013 |
| Griess reaction | Sigma | Cat# G4410 |
| BCA Protein Assay kit | Thermo Fisher Scientific | Cat# 23225 |
| RNeasy Mini Kit | QIAGEN | Cat# 74106 |
| Ovation Mouse RNA-Seq System | NuGEN | Cat# 0348-32 |
| High Pure RNA Isolation Kit | Roche | Cat# 11828665001 |
| iScript cDNA Synthesis Kit | Bio-Rad | Cat# 170-8891 |
| Quick-gDNA MiniPrep | Zymo Research | Cat# D3024 |
| Deposited Data | ||
| RNA-sequencing data | This paper | GEO: GSE107412 |
| Experimental Models: Organisms/Strains | ||
| Mouse: LdlrKO: B6.129S7-Ldlrtm1Her/J | The Jackson Laboratory | JAX:002207 |
| Mouse: Nrf2KO: B6.129P3-Nf2l2tm1Mym | Itoh et al., 1997 | N/A |
| Mouse: Keap1KD: B6.129P3-Keap1tm2Mym | Taguchi et al., 2010 | N/A |
| Mouse: WT: C57BL/6J | The Jackson Laboratory | JAX:000664 |
| Oligonucleotides | ||
| Primer sequences | This paper (Table S3) | N/A |
| Software and Algorithms | ||
| FlowJo | ThreeStar | N/A |
| GraphPad Prism 7 | GraphPad Software | N/A |
| Seahorse Wave | Agilent | N/A |
| Ingenuity Pathway Analysis | QIAGEN | N/A |
| R package: ggplot2 | Wickham, 2016 | https://cran.r-project.org/web/packages/ggplot2 |
| R package: ropls | Thévenot et al. (2015) | http://www.bioconductor.org/packages/release/bioc/html/ropls.html |
| R package: mixOmics | Rohart et al. (2017) | http://mixomics.org |
| STAR 2.5.2b | Dobin et al. (2013) | https://github.com/alexdobin/STAR/releases |
| SAM tools | Li et al. (2009) | http://samtools.sourceforge.net |
| HOMER | Heinz et al. (2010) | http://homer.ucsd.edu/homer |
| R package: DESeq2 | Love et al. (2014) | https://bioconductor.org/packages/release/bioc/html/DESeq2.html |
| R package: limma | Ritchie et al. (2015) | https://bioconductor.org/packages/release/bioc/html/limma.html |
| Other | ||
| Control normal fat diet (NFD) | Harlan Laboratories (Envigo) | Cat# 2016 (Teklad global 16% protein) |
| High fat diet (HFD) | Special diet Services | Code 824199 |
| 0.5 μM Fluoresbrite YG microspheres | Polysciences | Cat# 17152 |
| Thioglycollate medium | Fisher Scientific | Cat# 11782834 |
| RPMI-1640 medium | Thermo Fisher Scientific | Cat# 52400041 |
| RPMI-1640 Medium, no glucose | Thermo Fisher Scientific | Cat# 11879020 |
| Fetal Bovine Serum | Thermo Fisher Scientific | Cat# 10500 |
| NP-40 cell lysis buffer | Thermo Fisher Scientific | Cat# FNN0021 |
| Protease Inhibitor Cocktail | Sigma | Cat# 11873580001 |
| PhosSTOP | Sigma | Cat# 4906837001 |
| Bolt 4-12% Bis-Tris Plus Gels | Thermo Fisher Scientific | Cat# NW04120BOX |
| Nitrocellulose Membrane | Bio-Rad | Cat# 162-0094 |
| TWEEN 20 | Sigma | Cat# P1379 |
| SuperSignal West Pico PLUS Chemiluminescent Substrate | Thermo Fisher Scientific | Cat# 34580 |
| Fast SYBR Green Master Mix | Applied Biosytems | Cat# 4385618 |
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jan Van den Bossche (j.vandenbossche@vumc.nl).
Experimental Model and Subject DetailsMice
Female and male LdlrKO mice were obtained from Jackson Laboratory. LdlrKO mice were housed at the Animal Research Institute AMC (ARIA) and all animal experiments were conducted after approval (permit: DBC102861) by the Committee for Animal Welfare of the Academic Medical Center, University of Amsterdam. 6-month old adult mice were used for experiments and put on a control normal fat diet (NFD, 4% fat, Harlan Laboratories) or a high fat, high cholesterol diet (HFD, 16% fat, 0,25% cholesterol, Special Diet Services) for 10 weeks. Nrf2-knockout (Nrf2KO) (Itoh et al., 1997) and Keap1-knockdown (Keap1KD) (Taguchi et al., 2010) mice, and their wild-type (WT) counterparts, all 8-12-week old females on the C57BL/6 genetic background, were bred and maintained in the Medical School Resource Unit of the University of Dundee. Mice of the same sex were randomly assigned to both experimental groups in disposable Innovive 101 IVC cages in groups of 3 or 4.
Method DetailsIsolation of macrophages
After 10 weeks of NFD or HFD, LldrKO mice were euthanized by CO2 asphyxiation. Four days prior to sacrifice, mice were intraperitoneally injected with 3% thioglycollate medium (Fisher Scientific). Upon sacrifice, the peritoneum was flushed with 10 mL ice-cold PBS and collected peritoneal cells were cultured in RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin (GIBCO). After 3 h, non-adherent cells were washed away and adhered cells (typically consisting of 90%–95% CD11b+ F4/80+ macrophages, Figure S1D) were stimulated for 24 hours with 10 ng/ml LPS (Sigma) or 100 U/ml IL-4 (Peprotech), or were left untreated, and were used for further analyses. Blood cholesterol and triglyceride levels were measured by enzymatic methods using available kits (Roche). To determine lipid accumulated in peritoneal macrophages, tissue slides with cells were fixed in 4% formalin for 10 minutes and washed two times with PBS (with magnesium and chloride) before and after fixation. Subsequently, tissue slides were incubated in 60% isopropanol for 15 minutes before staining for 45 minutes with fresh 0.3% Oil Red O in 60% isopropanol. After staining, tissue slides were rinsed in 60% isopropanol, washed in distilled water, incubated for 1 minute with hematoxylin blued in tap water and rinsed with distilled water. Bone-marrow derived (BMDM) macrophages were generated from femurs and tibia from WT, Nrf2KO and Keap1KD mice and differentiated in RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin and 15% L929-conditioned medium for 7 days.
Metabolic extracellular flux analysis
Macrophages (1x105 cells/well) were plated on XF-96-cell culture plates (Seahorse Bioscience) and treated as specified. OCR and ECAR were assessed using the XF-96 Flux Analyzer (Seahorse Bioscience) as detailed before (Van den Bossche et al., 2015). Changes in ECAR in response to glucose (10 mM), OM (1.5 μM) and 2-DG (100 mM) injection were used to calculate all glycolysis parameters and OXPHOS characteristics were calculated from the OCR changes in response to OM (1.5 μM), FCCP (1.5 μM) and rotenone (1.25 μM) + antimycin A (2.5 μM) injection (Van den Bossche et al., 2015; Van den Bossche et al., 2016). The Seahorse Bioscience Mito Fuel Flex Test Kit was used to determine the dependency of cells for glucose, glutamine or fatty acid oxidation.
Respiratory measurements of isolated mitochondria
To isolate mitochondria, cell pellets were resuspended in 1 mL of MTE buffer (250 mM mannitol, 5 mM TRIS, 0.5 mM EDTA, pH 7.4). Macrophages were lysed using 10 passages through the cell cracker (European Molecular Biology Laboratory, Heidelberg, Germany). The homogenate was centrifuged 10 min at 1000 g, after which the supernatant was transferred to a new tube and centrifuged at 10000 g. The resulting supernatant was considered the cytosolic fraction. The final pellet containing the mitochondrial fraction was washed with 1 mL MTE buffer, centrifuged at 3600 g and resuspended in a minimal volume of MTE buffer. Equal amounts of mitochondria (0.5 μg well) were resuspended in MAS buffer (70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, and 1 mM EGTA; pH 7.2, plus 10 mM pyruvate and 1 mM malate as substrates), transferred to XF-96-cell culture plates, centrifuged at 2000 g for 20 min at 4°C and measured using a XF-96 Flux Analyzer (Seahorse Bioscience) to assess basal oxygen consumption (state 2), maximal coupled respiration or state 3 after injection of 4 mM ADP, state 4o after injection of 1.5 μM OM, maximal uncoupled respiration (state 3u) after injection of 4 μM FCCP and the respiratory control ratio (RCR = state 3/state 4o) in accordance to an established protocol (Rogers et al., 2011).
Liquid chromatography - mass spectrometry
Macrophages (5x105 cells/well) in 24 well plates were washed three times with 0,9% NaCl. Metabolism was quenched by adding 1 mL ice-cold methanol/water (1/1; v/v). The following internal standards were added, D3-aspartic acid, D3-serine, D5-glutamine, D3-glutamate, 13C3-pyruvate, 13C6-isoleucine, 13C6-glucose, 13C6-fructose-1,6-biphosphate, 13C6-glucose-6-phosphate, adenosine-15N5-monophosphate and guanosine-15N5-monophosphate (5 μM). 1 mL of chloroform was added, vortexed and centrifuged for 5 minutes at 14.000 rpm at 4°C. ∼800 μL of the “polar” top layer was transferred to a 1.5 mL tube, dried to dryness in a vacuum concentrator and dissolved in 100 μL methanol/water (6/4; v/v). For the analysis, we used a Thermo Scientific (U)HPLC system coupled to a Thermo Q Exactive (Plus) Orbitrap mass spectrometer (Waltman) with a SeQuant ZIC-cHILIC column at 15°C (PEEK 100 × 2.1 mm, 3.0 μm particle size, Merck). The mobile phase composed of (A) 9/1 acetonitrile/water with 5 mM ammonium acetate; pH 6.8 and (B) 1/9 acetonitrile/water with 5 mM ammonium acetate; pH 6.8, respectively. The LC program started with 100% (A) hold 0-3 min; ramping 3-24 min to 20% (A); hold from 24-27 min at 20% (A); ramping from 27-28 min to 100% (A); and re-equilibrate from 28-35 min with 100% (A), flow rate was 0.250 mL/min. The MS data were acquired in full scan, negative ionization mode with a mass resolution of 140.000. Interpretation of the data was performed in the Xcalibur software (ThermoFisher). Subsequent analyses were done in a R environment using the ggplot2, ropls and mixOmics packages (Rohart et al., 2017; Thévenot et al., 2015; Wickham, 2016).
Flow cytometry
To assess surface marker expression, cells (1.5x105 cells/well) in 96 well plates were deateched with citrate and transferred to V-bottom 96 well plates and stained with CD71, CD206, CD273, CD301 or isotype controls (all 1:250 diluted in PBS with 0,5% BSA and 2.5 mM EDTA) for 20 minutes at room temperature in the dark. After labeling, cells were washed with PBS with 0,5% BSA and 2.5 mM EDTA and finally resuspend in PBS with 0,5% BSA and 2.5 mM EDTA and measured on BD FACSCanto or a Beckman Coulter CytoFLEX, and analyzed using FlowJo (TreeStar). In order to quantify mitochondrial mass and ROS production, macrophages (105 cells/well) in 96 well plates were detached using citrate buffer (17 mM tri-Sodium citrate dehydrate and 135 mM potassium chloride in water) transferred to V-bottom 96 well plates and washed with PBS. Next, cells were resuspended in PBS with 200 nm MitoTracker Green or 20 μM CM-H2DCFDA (both ThermoFisher) and incubated for 30 minutes at 37°C (5% CO2). After incubation, cells were washed with PBS and mitochondrial mass and ROS production was measured using flow cytometry. To determine glucose uptake, macrophages (105 cells/well) were cultured in 96 well plates for two hours in RPMI-1640 lacking glucose and serum. Subsequently, 2-NBDG (ThermoFisher) was added for an additional incubation of 20 minutes in a final concentration of 25 μM. Next, cells were detached with citrate buffer, transferred to V-bottom 96 well plates and washed with PBS and analyzed using flow cytometry. To assess phagocytic activity, 105 macrophages were cultured for 1 h at 37°C (or 4°C as a control, Figure S3E) in the presence of Fluoresbrite YG microspheres (0.5 μM, Polysciences).
Immunoblotting
Immunoblotting for NRF2 and mitochondrial complexes was performed as detailed by (Mills et al., 2018) and (Wüst et al., 2016), respectively. For MFN1, MFN2, OPA1 and PGD immunoblotting, macrophages (1x106 cells/well) in 12 well plates were lysed in NP40 cell lysis buffer (ThermoFisher) supplemented with protease inhibitor cocktail (Sigma-Aldrich) and PhosSTOP (Sigma-Aldrich). Lysates were equalized on protein concentration after quantification with the BCA assay (ThermoFisher), separated on Bolt 4%–12% Bis-Tris gels (ThermoFisher) and transferred onto nitrocellulose membranes (Bio-Rad). After blocking for 1 hour with 5% milk powder (Campina) in Tris-buffered saline, TWEEN 20 (TBS-T), membranes were incubated overnight with primary antibodies against MFN1 (1:1000 dilution), MFN2 (1:200), OPA1 (1:1000) and PGD (1:1000) in 5% milk, TBS-T, followed by incubation for 1 hour with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:2000) in 5% milk, TBS-T and visualization with SuperSignal West Pico Chemiluminescent PLUS Substrate (Thermo Fisher Scientific).
Cytokine and NO production
IL-6 and TNF levels in the supernatant were measured by ELISA (Life Technologies) and NO production was assessed by a Griess reaction (Sigma-Aldrich) according to the supplier’s protocol.
RNA sequencing
Total RNA was isolated from peritoneal macrophages using a RNeasy Mini Kit with DNase treatment (QIAGEN). Strand-specific libraries were constructed from 100 ng total RNA using ‘Ovation RNA-Seq system’ following manufacturer instructions (NuGen Technologies). Samples were pooled and diluted to 10 nM and sequenced on an Illumina HiSeq 4000 instrument (Illumina) to a depth of ± 20 million single-ended 50 bp reads.
Bioinformatics
Reads were aligned to the mouse genome mm10 by STAR 2.5.2b with default settings (Dobin et al., 2013). BAM files were indexed and filtered on MAPQ > 15 with SAMTools 1.3.1 (Li et al., 2009). Raw tag counts and RPKM (reads per kilobase per million mapped reads) values per gene were summed using HOMER2′s analyzeRepeats.pl script with default settings and the -noadj or –rpkm options for raw counts and RPKM reporting, respectively (Heinz et al., 2010). Differential expression was assessed using the DESeq2 bioconductor package in an R 3.3.1 environment with gene expression called differential with a p value < 0.05 and an average RPKM > 1 in at least one group (Love et al., 2014). Presented RPKM values in scatterplots were tested using one-way ANOVA followed by Bonferroni’s post hoc comparisons test. Differential expression analysis on available microarray data (GEO: GSE13985) was executed using the limma package and gene expression was called differential with a p value < 0.05 (Ritchie et al., 2015). Differential expressed genes were analyzed in Ingenuity Pathway Analysis (Qiaqen) to identify deregulated pathways.
qPCR
RNA was isolated with High Pure RNA Isolation kits (Roche), cDNA was synthesized with iScript (Bio-Rad), and qPCR was performed using SYBR Green Fast mix (Applied Biosytems) on a ViiA7 (Applied Biosystems). Housekeeping genes Rplp0 and Ppia were used for normalization and used primer sequences are noted in the Table S3. DNA was extracted using the Quick-gDNA MiniPrep (Zymo Research) kit and primers for mt-Co1 and Ndufv1 were used to determine the mtDNA/gDNA ratio.
Quantification and Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). Number (n) and type (biological or technical) of replicates are indicated in the figure legends. Data were tested using a two-tailed Student’s t test (when comparing two groups) or one-way ANOVA followed by Bonferroni’s post hoc comparison to test multiple groups in GraphPad Prism version 7.0 software, as indicated in the figure legends. p values < 0.05 were considered significant, with levels of significance being indicated as follows: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant.
Data and Software Availability
The accession number for the RNA sequencing data reported in this paper is GEO: GSE107412.
Acknowledgments
J.V.d.B. received a VENI grant from ZonMW (91615052) and a Netherlands Heart Foundation junior postdoctoral grant (2013T003) and senior fellowship (2017T048). M.P.J.d.W. is an established investigator of the Netherlands Heart Foundation, is supported by grants from the Netherlands Heart Foundation and Spark-Holding BV (2015B002), the European Union (ITN grant EPIMAC and REPROGRAM [EU Horizon 2020]), and Fondation Leducq (16CVD-01), and holds an AMC fellowship. We acknowledge support from the Netherlands CardioVascular Research Initiative, Dutch Federation of University Medical Centers, the Netherlands Organisation for Health Research and Development, the Royal Netherlands Academy of Sciences (CVON 2011-19 and CVON 2017-20) and Cancer Research UK (C20953/A18644). We thank Tadeja Rezen, Peter Juvan, and Damjana Rozman for the GEO: GSE13985 dataset details.
Author Contributions
Conceptualization, J.V.d.B.; Methodology, J.V.d.B.; Formal Analysis, J.B., S.G.S.V., M.v.W., K.H.M.P., and J.V.d.B.; Investigation, J.B., S.v.d.V., S.G.S.V., D.G.R., R.C.I.W., A.E.N., S.W.D., M.E.W., E.V.K., and J.V.d.B.; Writing – Original Draft, J.B.; Writing – Review & Editing, J.B., S.G.S.V., D.S., R.H.H., L.A.O., A.T.D.-K., E.L., M.P.J.d.W., and J.V.d.B.; Visualization, J.B., M.v.W., and J.V.d.B.; Supervision, M.P.J.d.W. and J.V.d.B.; Funding Acquisition, M.P.J.d.W. and J.V.d.B. All authors read and approved the final manuscript.
Declaration of Interests
The authors declare no competing interests.
Supplemental Information (2)
Download all
Document S1. Figures S1–S4 and Tables S1–S3
Document S2. Article plus Supplemental Information
References
Bambouskova, M. ∙ Gorvel, L. ∙ Lampropoulou, V. ...
Electrophilic properties of itaconate and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis
Nature. 2018; 556:501-504
Cochain, C. ∙ Vafadarnejad, E. ∙ Arampatzi, P. ...
Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis
Circ. Res. 2018; 122:1661-1674
Dobin, A. ∙ Davis, C.A. ∙ Schlesinger, F. ...
STAR: ultrafast universal RNA-seq aligner
Bioinformatics. 2013; 29:15-21
Ference, B.A. ∙ Ginsberg, H.N. ∙ Graham, I. ...
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Eur. Heart J. 2017; 38:2459-2472
Ghisletti, S. ∙ Huang, W. ∙ Ogawa, S. ...
Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma
Mol. Cell. 2007; 25:57-70
Heinz, S. ∙ Benner, C. ∙ Spann, N. ...
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities
ReportVolume 25, Issue 8p2044-2052.e5November 20, 2018Open access
Download Full Issue
A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia
Jeroen Baardman1 ∙ Sanne G.S. Verberk2,9 ∙ Koen H.M. Prange1,9 ∙ … ∙ Esther Lutgens1,8 ∙ Menno P.J. de Winther1,8,9 ∙ Jan Van den Bossche1,2,9,10 j.vandenbossche@vumc.nl … Show more
Affiliations & NotesArticle Info

Download Full Issue
Show Outline
Highlights
•
Systemic metabolism affects immune cell metabolism
•
Hypercholesterolemia suppresses the PPP and Nrf2 pathway in macrophages
•
PPP inhibition and hypercholesterolemia deactivate inflammatory macrophage responses
•
The Nrf2 pathway regulates the PPP in an LXR-independent manner
Summary
Metabolic reprogramming has emerged as a crucial regulator of immune cell activation, but how systemic metabolism influences immune cell metabolism and function remains to be investigated. To investigate the effect of dyslipidemia on immune cell metabolism, we performed in-depth transcriptional, metabolic, and functional characterization of macrophages isolated from hypercholesterolemic mice. Systemic metabolic changes in such mice alter cellular macrophage metabolism and attenuate inflammatory macrophage responses. In addition to diminished maximal mitochondrial respiration, hypercholesterolemia reduces the LPS-mediated induction of the pentose phosphate pathway (PPP) and the Nrf2-mediated oxidative stress response. Our observation that suppression of the PPP diminishes LPS-induced cytokine secretion supports the notion that this pathway contributes to inflammatory macrophage responses. Overall, this study reveals that systemic and cellular metabolism are strongly interconnected, together dictating macrophage phenotype and function.
Graphical Abstract

Keywords
Introduction
In recent years, metabolic reprogramming arose as a crucial controller of macrophage activation (Van den Bossche et al., 2016, 2017). For instance, in response to pro-inflammatory stimuli such as the Toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS), macrophages show increased glycolysis, as demonstrated by an enhanced extracellular acidification rate (ECAR) (Van den Bossche et al., 2016). Moreover, LPS reconfigures the tricarboxylic acid (TCA) cycle in macrophages and induces itaconate and succinate accumulation (Jha et al., 2015; Tannahill et al., 2013). Itaconate is a key controller of inflammatory macrophage responses through its regulatory effect on succinate dehydrogenase and its activation of the anti-oxidant transcription factor Nrf2 (Lampropoulou et al., 2016; Michelucci et al., 2013; Mills et al., 2018). Succinate promotes inflammation by inducing interleukin 1β (IL-1β) expression (Mills et al., 2016; Tannahill et al., 2013) and can activate immune cells in the local environment upon secretion (Littlewood-Evans et al., 2016). Furthermore, the activity of the pentose phosphate pathway (PPP) is enhanced in LPS-stimulated macrophages, supplying precursors for nucleotide synthesis and nicotinamide adenine dinucleotide phosphate (NADPH), which is used for reactive oxygen species (ROS) production by NADPH oxidase, fatty acid synthesis, and anti-oxidant cellular defense (Nagy and Haschemi, 2015; Wu et al., 2008). So far, most knowledge regarding macrophage immunometabolism was obtained with in vitro-cultured bone marrow-derived macrophages and largely ignored the possible systemic and micro-environmental effects on macrophage metabolism and function in vivo (Norata et al., 2015). Exploring this neglected aspect of immunometabolism might identify therapeutic strategies to dampen chronic inflammatory diseases such as atherosclerosis, in which lipid-laden macrophage “foam cells” are crucial during all stages of the disease. Elevated levels of circulating low-density lipoprotein (LDL) cholesterol, as observed in patients with familial hypercholesterolemia (FH), are a prominent risk factor for developing atherosclerosis (Ference et al., 2017). FH is predominantly caused by loss-of-function mutations in the LDL receptor (LDLR) gene, leading to impaired hepatic uptake of LDL and, consequently, elevated levels of plasma LDL (Reiner, 2015). It has been shown that hypercholesterolemia affects the lipidome of macrophages and deactivates part of their inflammatory responses via activation of LXR (Spann et al., 2012). However, LXR-independent repression mechanisms still need to be defined. Here we confirm that hypercholesterolemia attenuates LPS-induced inflammatory macrophage responses and show that this deactivated phenotype is accompanied by a diminished Nrf2-mediated oxidative stress response and LXR-independent suppression of the PPP, indicating that systemic and cellular metabolism are directly intertwined, together regulating macrophage function.
ResultsHypercholesterolemia Translates into Altered Immune Cell Metabolism
Ingenuity Pathway Analysis (IPA) of published FH patient microarray data (GEO: GSE13985; characteristics in Table S1) identified oxidative phosphorylation (OXPHOS) and mitochondrial dysfunction among the top-ranked enriched canonical pathways (Figure 1A), and most differentially expressed genes belonging to those pathways were downregulated in leukocytes of FH patients (Figure 1B).

Figure 1 Hypercholesterolemia Affects Immune Cell Metabolism
Show full captionFigure viewer
To study the effects of systemic metabolic changes on immune cell metabolism in more detail, Ldlrko mice were fed a high-fat diet (HFD) to induce hypercholesterolemia and hypertriglyceridemia or a normal-fat control diet (NFD) (Figures S1A–S1C). Peritoneal macrophages from HFD mice were elicited as a validated in vivo model and source of foam cells (Spann et al., 2012). CD11b+F4/80+ peritoneal macrophages isolated from the HFD group were lipid-laden foam cells (hereafter referred to as “HFD macrophages”; Figures S1D and S1E) and compared with “NFD macrophages” to evaluate the effect of systemic metabolism on macrophage metabolism independent of microenvironmental cues present in atherosclerotic lesions. To study the effects of these different lipid environments on glycolysis and mitochondrial function in macrophages, we performed an extracellular flux analysis and revealed similar basal glycolysis and mitochondrial respiration in macrophages isolated from mice fed either diet (Figure 1C). Interestingly, HFD macrophages demonstrated lower maximal mitochondrial respiration and a reduced spare respiratory capacity (SRC) (Figure 1D) but showed no differences in non-mitochondrial oxygen consumption, ATP production, and proton leak (Figure S2A). Furthermore, both macrophage types showed similar fuel dependencies, with fatty acids being the main drivers of mitochondrial oxygen consumption (Figure 1E).
Because reduced mitochondrial mass results in decreased SRC in T cells (van der Windt et al., 2012), we assessed whether a lower mitochondrial abundance could explain the reduced SRC in HFD macrophages. Supporting this notion, HFD macrophages indeed showed a lower mitochondrial mass, as demonstrated by MitoTracker Green staining, mitochondrial DNA:genomic DNA ratio, and mitochondrial complex immunoblotting (Figures 1F and 1G and S2B). Together with the observation that similar amounts of mitochondria isolated from NFD or HFD macrophages display equal respiration (Figure 1H), our data strongly suggest that the reduced maximal respiration in HFD macrophages is mainly due to a decrease in mitochondrial mass. RNA sequencing revealed that genes related to mitochondrial biogenesis and dynamics were not altered in HFD macrophages; this was further confirmed by qPCR and immunoblotting (Figures S2C–S2E). Pathway analysis indicated that the top most enriched pathways were related to cholesterol biosynthesis, and associated genes were downregulated in HFD macrophages (Figures 1I and 1J).
Given the importance of metabolites such as itaconate, succinate, and α-ketoglutarate in regulating macrophage function (Lampropoulou et al., 2016; Liu et al., 2017; Michelucci et al., 2013; Mills et al., 2016, 2018; Tannahill et al., 2013), we next measured the levels of an extensive set of 63 metabolites. Partial least square discriminant (PLS-DA) analysis was used to discriminate NFD and HFD macrophages based on the measured metabolites. Interestingly, the abundance of several metabolites varied among NFD and HFD macrophages, with itaconate as the most distinctive metabolite (Figure 1K), whose abundance was lower in HFD macrophages (Table S2). Overall, hypercholesterolemia is associated with reduced mitochondrial mass and maximal respiration and affects the levels of metabolites such as itaconate.
Hypercholesterolemia Attenuates Inflammatory Macrophage Responses without Major Changes in Glycolysis or the TCA Cycle
Because itaconate regulates inflammatory macrophage responses (Jha et al., 2015; Mills et al., 2018) and was reduced in naive HFD macrophages, we investigated the effects of hypercholesterolemia on LPS-induced inflammatory macrophage activation. In parallel to the previously reported decreased expression of several inflammatory genes, we identified reduced secretion of pro-inflammatory cytokines as well as lower nitric oxide (NO) and lower ROS levels in HFD macrophages (Figures 2A–2C). Both types of macrophages exhibited similar phagocytic activity and comparable expression of Il10 and IL-4-induced genes and surface proteins (Figures 2D, S3A, and S3B). Together, this does not indicate a general inhibition of macrophage activation in the HFD group but shows that these cells undergo a deactivation process during which foam cells lose part of their LPS-induced inflammatory properties. Likewise, short exposure to oxidized or acetylated LDL in vitro also decreased subsequent LPS-induced tumor necrosis factor (TNF), IL-6, and NO secretion in NFD macrophages (Figure S3C).

Figure 2 Hypercholesterolemia Attenuates the Inflammatory Phenotype of Macrophages without Reconfiguring Glycolysis and the TCA Cycle
Show full captionFigure viewer
To address whether distinct LPS-induced metabolic rewiring underlies the deactivated phenotype of HFD foam cells, we measured glycolysis upon acute and 24-hr LPS exposure. NFD and HFD macrophages showed comparable glycolytic rates and glucose uptake (Figure 2E, 2F, and S3D), indicating that the attenuated inflammatory phenotype of HFD macrophages is probably not caused by reduced glycolysis.
Next we examined whether differences in succinate, itaconate, α-ketoglutarate, or other metabolites could explain the attenuated pro-inflammatory function of LPS-stimulated HFD macrophages. PLS-DA identified distinct metabolic profiles upon LPS stimulation in macrophages from both groups (Figure 2G). We observed that LPS induced itaconate, succinate, and oxaloacetate levels to a similar extent in both NFD and HFD macrophages (Figure 2H). This suggests that the reduced inflammatory phenotype observed in HFD macrophages is not caused by a distinct LPS-induced TCA cycle reconfiguration. In addition to altered levels of different amino acids (Figures 2I) and increased levels of NADH in HFD macrophages (Table S2), several metabolites related to the PPP (marked with asterisks in Figure 2I) strongly contributed to the differential metabolic profile in LPS-stimulated NFD and HFD macrophages.
Hypercholesterolemia Diminishes the NRF2 and PPP in Macrophages
Metabolic analysis demonstrated an increased abundance of several PPP metabolites, including ribose-5P or ribulose-5P, sedoheptulose-7P, and glyceraldehyde 3-P upon LPS stimulation (Figure 3A). Interestingly, LPS-induced ribose-5P or ribulose-5P and sedoheptulose-7P levels were lower in HFD macrophages. Analyzing the two genes that encode glucose-6-phosphate dehydrogenase (G6PD) as the rate-limiting enzyme of the PPP in mice (Huminiecki and Wolfe, 2004) revealed that the LPS-induced elevation of G6pd2, but not G6pdx, was absent in HFD macrophages (Figures 3B and 3C). Moreover, Pgd (encoding 6-phosphogluconate dehydrogenase, which converts 6-phosphogluconate into ribulose 5-P in the PPP) was reduced in both naive and LPS-stimulated HFD macrophages (Figure 3B), whereas Pgd protein levels were only suppressed in naive HFD macrophages (Figure S4A). To validate whether suppression of the PPP in HFD macrophages (Figure 3D) could explain their attenuated LPS-induced inflammatory responses, we pharmacologically inhibited G6PD with dehydroepiandrosterone (DHEA) or 6-aminonicotinamide (6-AN). Supporting this notion, blockade of the PPP diminished the LPS-induced production of pro-inflammatory mediators in macrophages (Figure 3E). Because desmosterol-driven LXR activation regulates at least a part of the inflammatory phenotype of foam cells (Spann et al., 2012), we studied whether this pathway controls the PPP. Activation of LXR and its target genes with GW3965 did not affect PPP genes and metabolites (Figures S4B–S4D), backing the idea that both LXR-dependent and independent mechanisms contribute to the diminished inflammatory phenotype of foam cells (Spann et al., 2012).

Figure 3 Hypercholesterolemia Reduces LPS-Mediated Induction of the PPP in Macrophages
Show full captionFigure viewer
To uncover the LXR-independent mechanistic link between hypercholesterolemia, suppressed PPP, and inflammation, we further explored our RNA sequencing (RNA-seq) dataset. Pathways analysis revealed that the Nrf2 pathway was the most differentially regulated pathway between LPS-stimulated NFD and HFD macrophages (Figure 3F), and most genes of this pathway were downregulated in HFD macrophages (Figure 3G). Accordingly, Nrf2 protein levels were reduced in LPS-treated HFD macrophages (Figure 3H). Importantly, Nrf2 was found to be a regulator of the PPP in cancer cells (Mitsuishi et al., 2012) and analyzing expression data from Nrf2-deficient macrophages (GEO: GSE71695) revealed that several PPP genes, including Pgd, are downregulated in Nrf2-deficient macrophages (Figure S4E). Moreover, analysis of published chromatin immunoprecipitation (ChIP-seq) data (DDBJ: DRA003771) revealed binding of Nrf2 4 kb upstream of the Pgd locus (Figure 3I), suggesting a direct link between reduced Nrf2 activity and Pgd expression in HFD macrophages. Indeed, Pgd is suppressed in Nrf2-deficient macrophages and increased in macrophages that have lower levels of the Nrf2 repressor protein KEAP1 (Figure 3J). Accordingly, the LPS-induced production of sedoheptulose-7P and ribose-5P or ribulose-5P downstream of Pgd in the PPP was blunted in the absence of Nrf2 (Figure S4F). This suppressed Nrf2 signaling acts in parallel with other pathways, like the LXR pathway (Spann et al., 2012), and manipulating one branch does not recapitulate the deactivated phenotype observed in HFD macrophages. Indeed, Nrf2-deficient macrophages did not show overall suppressed LPS responses (Figure S4G).
Together, this demonstrates a link between reduced Nrf2 and a defective PPP in HFD macrophages and that the latter pathway supports inflammatory responses.
Discussion
Recent findings in the rapidly expanding field of immunometabolism underscored the importance of metabolic reprogramming during macrophage activation (Van den Bossche et al., 2017). However, most knowledge regarding this metabolic-immunologic crosstalk has emerged from in vitro-cultured macrophages, excluding different (e.g., microenvironmental and systemic) layers of regulation that are at play in vivo. This gave us the incentive to explore the influences of different systemic lipid environments on cellular macrophage metabolism and function.
Leukocytes from FH patients demonstrated reduced expression of genes related to OXPHOS. In mice, hypercholesterolemia was associated with reduced cholesterol biosynthesis in macrophages. Differences in cell type (total leukocytes versus macrophages) or species (human versus mouse) might underlie this discrepancy. Dhcr24, which encodes 24-dehydrocholesterol reductase, which converts desmosterol into cholesterol, was the most suppressed gene related to cholesterol biosynthesis in macrophages from HFD mice. This finding is in agreement with a previous study, and diminished Dhcr24 expression was found to result in the accumulation of desmosterol in HFD macrophages (Spann et al., 2012).
Isolated macrophages from hypercholesterolemic mice showed reduced maximal respiration and SRC. In T cells, SRC is positively correlated with their survival (van der Windt et al., 2012). Therefore, decreased SRC might increase the susceptibly to apoptosis in macrophage foam cells, potentially contributing to necrotic core development in atherosclerotic lesions (Moore et al., 2013).
It is well-accepted that atherosclerosis is a chronic inflammatory disease driven by elevated LDL cholesterol levels. The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial provides strong evidence in support of the inflammation hypothesis and demonstrated that neutralizing the pro-inflammatory cytokine IL-1β significantly reduces the rate of recurrent cardiovascular events (Ridker et al., 2017).
Confirming previous literature (Spann et al., 2012), we now observed that the LPS-induced secretion of inflammatory mediators was reduced in macrophages isolated from hypercholesterolemic mice. This might appear to be inconsistent with the inflammation hypothesis of atherogenesis. However, it is important to note that both in vivo-elicited HFD foam cells and in vitro LDL-exposed macrophages still produce considerable amounts of inflammatory cytokines upon activation, albeit to a lower extend than “normal” macrophages. Another explanation for the observed deactivated phenotype of foam cells could be the phenotypic diversity detected in plaques (Cochain et al., 2018). Not all plaque macrophages exhibit a pro-inflammatory phenotype, and there is a substantial subpopulation of macrophages with anti-inflammatory features (Kadl et al., 2010). In agreement with our observations, recent transcriptome analysis of macrophages from atherosclerotic aortae revealed that lipid-loaded plaque macrophages are less inflammatory than their non-foamy counterparts (Kim et al., 2018). We therefore favor the theory that, in addition to the systemic metabolic environment, microenvironmental cues regulate macrophage phenotypes in plaques (Spann et al., 2012) to promote the chronic inflammatory responses that are demonstrably driving atherogenesis.
Accumulation of cellular cholesterol leads to specific oxysterols and sterols that regulate the activity of LXR (Spann et al., 2012). LXRs bind to and prevent the removal of repressor complexes at TLR4-responsive genes, blunting their expression and exerting anti-inflammatory effects (Ghisletti et al., 2007). We now show that, in addition to LXR (Spann et al., 2012), LXR-independent impairment of the PPP contributes to the suppressed inflammatory responses in macrophage foam cells during hypercholesterolemia.
Interestingly, we discovered that 6-phosphogluconate dehydrogenase (Pgd) gene expression and downstream metabolites were blunted in HFD macrophages. In accordance, knockdown of PGD was found to reduce the oxidative PPP flux, NADPH:NADP+ ratio, and ribulose-5P and ribose-5P levels in human cancer cells (Lin et al., 2015). NADPH and ribose-5P generated in the PPP can support the inflammatory macrophage responses in different ways, including ROS production, anti-oxidant cellular defense, fatty acid synthesis, and nucleotide production (Nagy and Haschemi, 2015). Thus, reduced flux through the PPP as observed in HFD macrophages can cause attenuated inflammatory responses and ROS production. Furthermore, Pgd expression was already reduced in naive HFD macrophages, possibly creating a condition that causes impaired future LPS responses. Vice versa, the lower PPP might also be a consequence of an attenuated inflammatory phenotype in HFD macrophages and the consecutive lower demand for PPP-derived products that regulate inflammation and anti-oxidant cellular defense.
We identified the Nrf2-mediated oxidative stress response as the most suppressed pathway in LPS-stimulated HFD macrophages. Nrf2 emerged as a crucial regulator of the inflammatory responses in macrophages (Kobayashi et al., 2016; Mills et al., 2018). Interestingly, several PPP genes were previously identified as Nrf2 target genes in cancer cells (Mitsuishi et al., 2012). Here we emphasized the importance of the Nrf2 pathway in the regulation of the PPP in macrophages. Importantly, suppressed Nrf2 is not the only mediator of the HFD macrophage phenotype and probably acts in parallel with other mechanisms, like the desmosterol-induced LXR pathway that was described earlier (Spann et al., 2012). Indeed, LXR activation or Nrf2 deletion as such did not result in the deactivated HFD macrophage phenotype. Our observations agree with previous studies demonstrating normal IL-1β, TNF, and IL-6 expression in the absence of Nrf2 (Mills et al., 2018; Bambouskova et al., 2018; Kobayashi et al., 2016). Conversely, activation of Nrf2 in macrophages by pharmacological or genetic (low KEAP1 expression) means clearly dampens inflammatory responses (Kobayashi et al., 2016) and mediates the anti-inflammatory effects of the metabolite itaconate (Mills et al., 2018). Thus, low levels of Nrf2 do not affect LPS responses as such, but Nrf2 activation is clearly anti-inflammatory. It will be of interest to define the mechanism responsible for Nrf2 repression in macrophage foam cells.
Together, these observations show that hypercholesterolemia suppresses the Nrf2 and PPP in macrophages and deactivates their inflammatory phenotype. We demonstrate that systemic metabolic changes translate into rewired intracellular metabolic pathways in macrophages that are tailored to support their effector functions. This highlights the intricate interplay between inflammatory signaling and metabolic pathways.
STAR★MethodsKey Resources Table
REAGENT or RESOURCESOURCEIDENTIFIER
| Antibodies | ||
| anti-actin | Millipore | Cat# MAB1501; RRID:AB_2223041 |
| anti-mitofusin 1 (MFN1) | Abcam | Cat# ab57602; RRID:AB_2142624 |
| anti-mitofusin 2 (MFN2) | Sigma | Cat# WH0009927M3; RRID:AB_1842440 |
| anti-OPA1 | BD Biosciences | Cat# 612606; RRID:AB_612606 |
| anti-NRF2 | Cell Signaling | Cat# 12721; RRID:AB_2715528 |
| anti-PGD | Abcam | Cat# ab129199; RRID:AB_11144133 |
| Total OXPHOS Rodent WB Antibody Cocktail | Abcam | Cat# ab110413; RRID:AB_2629281 |
| anti-rabbit IgG/HRP (secondary) | Thermo Fisher Scientific | Cat# 32260; RRID:AB_1965959 |
| anti-mouse IgG/HRP (secondary) | Thermo Fisher Scientific | Cat# 32230; RRID:AB_1965958 |
| anti-mouse CD71-PE | BD PharMingen | Cat# 553267; RRID:AB_394744 |
| anti-mouse CD206-APC | Biolegend | Cat# 141707; RRID:AB_10896057 |
| anti-mouse CD273-PE | BD PharMingen | Cat# 557796; RRID:AB_396874 |
| anti-mouse CD301-Alexa Fluor-647 | Serotec | Cat# MCA2392A647T; RRID:AB_1101873 |
| rat IgG2a-PE (isotype control) | BioLegend | Cat# 400507 |
| rat IgG2a-APC (isotype control) | BioLegend | Cat# 400511 |
| anti-mouse CD11b-PE-Cy7 | BD PharMingen | Cat# 552850; RRID:AB_394491 |
| anti-mouse F4/80-APC-eFluor780 | eBioscience | Cat# 47-4801; RRID:AB_2637188 |
| anti-mouse CD16/CD32 (Fc-block) | eBioscience | Cat# 14-0161; RRID:AB_467132 |
| Chemicals, Peptides, and Recombinant Proteins | ||
| Penicillin-Streptomycin | Thermo Fisher Scientific | Cat# 15140-122 |
| L-glutamine | Thermo Fisher Scientific | Cat# 25030024 |
| Recombinant murine IL-4 | PeproTech | Cat# 214-14 |
| Lipopolysaccharides (LPS) | Sigma | Cat# L2637 |
| Oil Red O | Sigma | Cat# O0625 |
| Hematoxylin | Merck | Cat# 1.05175.2500 |
| Oligomycin (OM) | Sigma | Cat# 75351 |
| 2-deoxyglucose (2-DG) | Sigma | Cat# D6134 |
| Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) | Sigma | Cat# C2920 |
| Rotenone | Sigma | Cat# R8875 |
| Antimycin A | Sigma | Cat# A8674 |
| Pyruvic acid | Sigma | Cat# 107360 |
| Malic acid | Sigma | Cat# M0875 |
| Adenosine diphosphate (ADP) | Sigma | Cat# A5285 |
| MitoTracker Green FM | Thermo Fisher Scientific | Cat# M7514 |
| CM-H2DCFDA | Thermo Fisher Scientific | Cat# C6827 |
| 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) | Thermo Fisher Scientific | Cat# N13195 |
| RNA-free DNase | QIAGEN | Cat# 79254 |
| 6-Aminonicotinamide (6-AN) | Sigma | Cat# A68203 |
| Dehydroepiandrosterone (DHEA) | Sigma | Cat# D063 |
| GW3965 | Sigma | Cat# G6295 |
| Critical Commercial Assays | ||
| IL-6 ELISA | Life Technologies | Cat# CMC0063 |
| TNF ELISA | Life Technologies | Cat# CMC3013 |
| Griess reaction | Sigma | Cat# G4410 |
| BCA Protein Assay kit | Thermo Fisher Scientific | Cat# 23225 |
| RNeasy Mini Kit | QIAGEN | Cat# 74106 |
| Ovation Mouse RNA-Seq System | NuGEN | Cat# 0348-32 |
| High Pure RNA Isolation Kit | Roche | Cat# 11828665001 |
| iScript cDNA Synthesis Kit | Bio-Rad | Cat# 170-8891 |
| Quick-gDNA MiniPrep | Zymo Research | Cat# D3024 |
| Deposited Data | ||
| RNA-sequencing data | This paper | GEO: GSE107412 |
| Experimental Models: Organisms/Strains | ||
| Mouse: LdlrKO: B6.129S7-Ldlrtm1Her/J | The Jackson Laboratory | JAX:002207 |
| Mouse: Nrf2KO: B6.129P3-Nf2l2tm1Mym | Itoh et al., 1997 | N/A |
| Mouse: Keap1KD: B6.129P3-Keap1tm2Mym | Taguchi et al., 2010 | N/A |
| Mouse: WT: C57BL/6J | The Jackson Laboratory | JAX:000664 |
| Oligonucleotides | ||
| Primer sequences | This paper (Table S3) | N/A |
| Software and Algorithms | ||
| FlowJo | ThreeStar | N/A |
| GraphPad Prism 7 | GraphPad Software | N/A |
| Seahorse Wave | Agilent | N/A |
| Ingenuity Pathway Analysis | QIAGEN | N/A |
| R package: ggplot2 | Wickham, 2016 | https://cran.r-project.org/web/packages/ggplot2 |
| R package: ropls | Thévenot et al. (2015) | http://www.bioconductor.org/packages/release/bioc/html/ropls.html |
| R package: mixOmics | Rohart et al. (2017) | http://mixomics.org |
| STAR 2.5.2b | Dobin et al. (2013) | https://github.com/alexdobin/STAR/releases |
| SAM tools | Li et al. (2009) | http://samtools.sourceforge.net |
| HOMER | Heinz et al. (2010) | http://homer.ucsd.edu/homer |
| R package: DESeq2 | Love et al. (2014) | https://bioconductor.org/packages/release/bioc/html/DESeq2.html |
| R package: limma | Ritchie et al. (2015) | https://bioconductor.org/packages/release/bioc/html/limma.html |
| Other | ||
| Control normal fat diet (NFD) | Harlan Laboratories (Envigo) | Cat# 2016 (Teklad global 16% protein) |
| High fat diet (HFD) | Special diet Services | Code 824199 |
| 0.5 μM Fluoresbrite YG microspheres | Polysciences | Cat# 17152 |
| Thioglycollate medium | Fisher Scientific | Cat# 11782834 |
| RPMI-1640 medium | Thermo Fisher Scientific | Cat# 52400041 |
| RPMI-1640 Medium, no glucose | Thermo Fisher Scientific | Cat# 11879020 |
| Fetal Bovine Serum | Thermo Fisher Scientific | Cat# 10500 |
| NP-40 cell lysis buffer | Thermo Fisher Scientific | Cat# FNN0021 |
| Protease Inhibitor Cocktail | Sigma | Cat# 11873580001 |
| PhosSTOP | Sigma | Cat# 4906837001 |
| Bolt 4-12% Bis-Tris Plus Gels | Thermo Fisher Scientific | Cat# NW04120BOX |
| Nitrocellulose Membrane | Bio-Rad | Cat# 162-0094 |
| TWEEN 20 | Sigma | Cat# P1379 |
| SuperSignal West Pico PLUS Chemiluminescent Substrate | Thermo Fisher Scientific | Cat# 34580 |
| Fast SYBR Green Master Mix | Applied Biosytems | Cat# 4385618 |
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jan Van den Bossche (j.vandenbossche@vumc.nl).
Experimental Model and Subject DetailsMice
Female and male LdlrKO mice were obtained from Jackson Laboratory. LdlrKO mice were housed at the Animal Research Institute AMC (ARIA) and all animal experiments were conducted after approval (permit: DBC102861) by the Committee for Animal Welfare of the Academic Medical Center, University of Amsterdam. 6-month old adult mice were used for experiments and put on a control normal fat diet (NFD, 4% fat, Harlan Laboratories) or a high fat, high cholesterol diet (HFD, 16% fat, 0,25% cholesterol, Special Diet Services) for 10 weeks. Nrf2-knockout (Nrf2KO) (Itoh et al., 1997) and Keap1-knockdown (Keap1KD) (Taguchi et al., 2010) mice, and their wild-type (WT) counterparts, all 8-12-week old females on the C57BL/6 genetic background, were bred and maintained in the Medical School Resource Unit of the University of Dundee. Mice of the same sex were randomly assigned to both experimental groups in disposable Innovive 101 IVC cages in groups of 3 or 4.
Method DetailsIsolation of macrophages
After 10 weeks of NFD or HFD, LldrKO mice were euthanized by CO2 asphyxiation. Four days prior to sacrifice, mice were intraperitoneally injected with 3% thioglycollate medium (Fisher Scientific). Upon sacrifice, the peritoneum was flushed with 10 mL ice-cold PBS and collected peritoneal cells were cultured in RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin (GIBCO). After 3 h, non-adherent cells were washed away and adhered cells (typically consisting of 90%–95% CD11b+ F4/80+ macrophages, Figure S1D) were stimulated for 24 hours with 10 ng/ml LPS (Sigma) or 100 U/ml IL-4 (Peprotech), or were left untreated, and were used for further analyses. Blood cholesterol and triglyceride levels were measured by enzymatic methods using available kits (Roche). To determine lipid accumulated in peritoneal macrophages, tissue slides with cells were fixed in 4% formalin for 10 minutes and washed two times with PBS (with magnesium and chloride) before and after fixation. Subsequently, tissue slides were incubated in 60% isopropanol for 15 minutes before staining for 45 minutes with fresh 0.3% Oil Red O in 60% isopropanol. After staining, tissue slides were rinsed in 60% isopropanol, washed in distilled water, incubated for 1 minute with hematoxylin blued in tap water and rinsed with distilled water. Bone-marrow derived (BMDM) macrophages were generated from femurs and tibia from WT, Nrf2KO and Keap1KD mice and differentiated in RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin and 15% L929-conditioned medium for 7 days.
Metabolic extracellular flux analysis
Macrophages (1x105 cells/well) were plated on XF-96-cell culture plates (Seahorse Bioscience) and treated as specified. OCR and ECAR were assessed using the XF-96 Flux Analyzer (Seahorse Bioscience) as detailed before (Van den Bossche et al., 2015). Changes in ECAR in response to glucose (10 mM), OM (1.5 μM) and 2-DG (100 mM) injection were used to calculate all glycolysis parameters and OXPHOS characteristics were calculated from the OCR changes in response to OM (1.5 μM), FCCP (1.5 μM) and rotenone (1.25 μM) + antimycin A (2.5 μM) injection (Van den Bossche et al., 2015; Van den Bossche et al., 2016). The Seahorse Bioscience Mito Fuel Flex Test Kit was used to determine the dependency of cells for glucose, glutamine or fatty acid oxidation.
Respiratory measurements of isolated mitochondria
To isolate mitochondria, cell pellets were resuspended in 1 mL of MTE buffer (250 mM mannitol, 5 mM TRIS, 0.5 mM EDTA, pH 7.4). Macrophages were lysed using 10 passages through the cell cracker (European Molecular Biology Laboratory, Heidelberg, Germany). The homogenate was centrifuged 10 min at 1000 g, after which the supernatant was transferred to a new tube and centrifuged at 10000 g. The resulting supernatant was considered the cytosolic fraction. The final pellet containing the mitochondrial fraction was washed with 1 mL MTE buffer, centrifuged at 3600 g and resuspended in a minimal volume of MTE buffer. Equal amounts of mitochondria (0.5 μg well) were resuspended in MAS buffer (70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, and 1 mM EGTA; pH 7.2, plus 10 mM pyruvate and 1 mM malate as substrates), transferred to XF-96-cell culture plates, centrifuged at 2000 g for 20 min at 4°C and measured using a XF-96 Flux Analyzer (Seahorse Bioscience) to assess basal oxygen consumption (state 2), maximal coupled respiration or state 3 after injection of 4 mM ADP, state 4o after injection of 1.5 μM OM, maximal uncoupled respiration (state 3u) after injection of 4 μM FCCP and the respiratory control ratio (RCR = state 3/state 4o) in accordance to an established protocol (Rogers et al., 2011).
Liquid chromatography - mass spectrometry
Macrophages (5x105 cells/well) in 24 well plates were washed three times with 0,9% NaCl. Metabolism was quenched by adding 1 mL ice-cold methanol/water (1/1; v/v). The following internal standards were added, D3-aspartic acid, D3-serine, D5-glutamine, D3-glutamate, 13C3-pyruvate, 13C6-isoleucine, 13C6-glucose, 13C6-fructose-1,6-biphosphate, 13C6-glucose-6-phosphate, adenosine-15N5-monophosphate and guanosine-15N5-monophosphate (5 μM). 1 mL of chloroform was added, vortexed and centrifuged for 5 minutes at 14.000 rpm at 4°C. ∼800 μL of the “polar” top layer was transferred to a 1.5 mL tube, dried to dryness in a vacuum concentrator and dissolved in 100 μL methanol/water (6/4; v/v). For the analysis, we used a Thermo Scientific (U)HPLC system coupled to a Thermo Q Exactive (Plus) Orbitrap mass spectrometer (Waltman) with a SeQuant ZIC-cHILIC column at 15°C (PEEK 100 × 2.1 mm, 3.0 μm particle size, Merck). The mobile phase composed of (A) 9/1 acetonitrile/water with 5 mM ammonium acetate; pH 6.8 and (B) 1/9 acetonitrile/water with 5 mM ammonium acetate; pH 6.8, respectively. The LC program started with 100% (A) hold 0-3 min; ramping 3-24 min to 20% (A); hold from 24-27 min at 20% (A); ramping from 27-28 min to 100% (A); and re-equilibrate from 28-35 min with 100% (A), flow rate was 0.250 mL/min. The MS data were acquired in full scan, negative ionization mode with a mass resolution of 140.000. Interpretation of the data was performed in the Xcalibur software (ThermoFisher). Subsequent analyses were done in a R environment using the ggplot2, ropls and mixOmics packages (Rohart et al., 2017; Thévenot et al., 2015; Wickham, 2016).
Flow cytometry
To assess surface marker expression, cells (1.5x105 cells/well) in 96 well plates were deateched with citrate and transferred to V-bottom 96 well plates and stained with CD71, CD206, CD273, CD301 or isotype controls (all 1:250 diluted in PBS with 0,5% BSA and 2.5 mM EDTA) for 20 minutes at room temperature in the dark. After labeling, cells were washed with PBS with 0,5% BSA and 2.5 mM EDTA and finally resuspend in PBS with 0,5% BSA and 2.5 mM EDTA and measured on BD FACSCanto or a Beckman Coulter CytoFLEX, and analyzed using FlowJo (TreeStar). In order to quantify mitochondrial mass and ROS production, macrophages (105 cells/well) in 96 well plates were detached using citrate buffer (17 mM tri-Sodium citrate dehydrate and 135 mM potassium chloride in water) transferred to V-bottom 96 well plates and washed with PBS. Next, cells were resuspended in PBS with 200 nm MitoTracker Green or 20 μM CM-H2DCFDA (both ThermoFisher) and incubated for 30 minutes at 37°C (5% CO2). After incubation, cells were washed with PBS and mitochondrial mass and ROS production was measured using flow cytometry. To determine glucose uptake, macrophages (105 cells/well) were cultured in 96 well plates for two hours in RPMI-1640 lacking glucose and serum. Subsequently, 2-NBDG (ThermoFisher) was added for an additional incubation of 20 minutes in a final concentration of 25 μM. Next, cells were detached with citrate buffer, transferred to V-bottom 96 well plates and washed with PBS and analyzed using flow cytometry. To assess phagocytic activity, 105 macrophages were cultured for 1 h at 37°C (or 4°C as a control, Figure S3E) in the presence of Fluoresbrite YG microspheres (0.5 μM, Polysciences).
Immunoblotting
Immunoblotting for NRF2 and mitochondrial complexes was performed as detailed by (Mills et al., 2018) and (Wüst et al., 2016), respectively. For MFN1, MFN2, OPA1 and PGD immunoblotting, macrophages (1x106 cells/well) in 12 well plates were lysed in NP40 cell lysis buffer (ThermoFisher) supplemented with protease inhibitor cocktail (Sigma-Aldrich) and PhosSTOP (Sigma-Aldrich). Lysates were equalized on protein concentration after quantification with the BCA assay (ThermoFisher), separated on Bolt 4%–12% Bis-Tris gels (ThermoFisher) and transferred onto nitrocellulose membranes (Bio-Rad). After blocking for 1 hour with 5% milk powder (Campina) in Tris-buffered saline, TWEEN 20 (TBS-T), membranes were incubated overnight with primary antibodies against MFN1 (1:1000 dilution), MFN2 (1:200), OPA1 (1:1000) and PGD (1:1000) in 5% milk, TBS-T, followed by incubation for 1 hour with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:2000) in 5% milk, TBS-T and visualization with SuperSignal West Pico Chemiluminescent PLUS Substrate (Thermo Fisher Scientific).
Cytokine and NO production
IL-6 and TNF levels in the supernatant were measured by ELISA (Life Technologies) and NO production was assessed by a Griess reaction (Sigma-Aldrich) according to the supplier’s protocol.
RNA sequencing
Total RNA was isolated from peritoneal macrophages using a RNeasy Mini Kit with DNase treatment (QIAGEN). Strand-specific libraries were constructed from 100 ng total RNA using ‘Ovation RNA-Seq system’ following manufacturer instructions (NuGen Technologies). Samples were pooled and diluted to 10 nM and sequenced on an Illumina HiSeq 4000 instrument (Illumina) to a depth of ± 20 million single-ended 50 bp reads.
Bioinformatics
Reads were aligned to the mouse genome mm10 by STAR 2.5.2b with default settings (Dobin et al., 2013). BAM files were indexed and filtered on MAPQ > 15 with SAMTools 1.3.1 (Li et al., 2009). Raw tag counts and RPKM (reads per kilobase per million mapped reads) values per gene were summed using HOMER2′s analyzeRepeats.pl script with default settings and the -noadj or –rpkm options for raw counts and RPKM reporting, respectively (Heinz et al., 2010). Differential expression was assessed using the DESeq2 bioconductor package in an R 3.3.1 environment with gene expression called differential with a p value < 0.05 and an average RPKM > 1 in at least one group (Love et al., 2014). Presented RPKM values in scatterplots were tested using one-way ANOVA followed by Bonferroni’s post hoc comparisons test. Differential expression analysis on available microarray data (GEO: GSE13985) was executed using the limma package and gene expression was called differential with a p value < 0.05 (Ritchie et al., 2015). Differential expressed genes were analyzed in Ingenuity Pathway Analysis (Qiaqen) to identify deregulated pathways.
qPCR
RNA was isolated with High Pure RNA Isolation kits (Roche), cDNA was synthesized with iScript (Bio-Rad), and qPCR was performed using SYBR Green Fast mix (Applied Biosytems) on a ViiA7 (Applied Biosystems). Housekeeping genes Rplp0 and Ppia were used for normalization and used primer sequences are noted in the Table S3. DNA was extracted using the Quick-gDNA MiniPrep (Zymo Research) kit and primers for mt-Co1 and Ndufv1 were used to determine the mtDNA/gDNA ratio.
Quantification and Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). Number (n) and type (biological or technical) of replicates are indicated in the figure legends. Data were tested using a two-tailed Student’s t test (when comparing two groups) or one-way ANOVA followed by Bonferroni’s post hoc comparison to test multiple groups in GraphPad Prism version 7.0 software, as indicated in the figure legends. p values < 0.05 were considered significant, with levels of significance being indicated as follows: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant.
Data and Software Availability
The accession number for the RNA sequencing data reported in this paper is GEO: GSE107412.
Acknowledgments
J.V.d.B. received a VENI grant from ZonMW (91615052) and a Netherlands Heart Foundation junior postdoctoral grant (2013T003) and senior fellowship (2017T048). M.P.J.d.W. is an established investigator of the Netherlands Heart Foundation, is supported by grants from the Netherlands Heart Foundation and Spark-Holding BV (2015B002), the European Union (ITN grant EPIMAC and REPROGRAM [EU Horizon 2020]), and Fondation Leducq (16CVD-01), and holds an AMC fellowship. We acknowledge support from the Netherlands CardioVascular Research Initiative, Dutch Federation of University Medical Centers, the Netherlands Organisation for Health Research and Development, the Royal Netherlands Academy of Sciences (CVON 2011-19 and CVON 2017-20) and Cancer Research UK (C20953/A18644). We thank Tadeja Rezen, Peter Juvan, and Damjana Rozman for the GEO: GSE13985 dataset details.
Author Contributions
Conceptualization, J.V.d.B.; Methodology, J.V.d.B.; Formal Analysis, J.B., S.G.S.V., M.v.W., K.H.M.P., and J.V.d.B.; Investigation, J.B., S.v.d.V., S.G.S.V., D.G.R., R.C.I.W., A.E.N., S.W.D., M.E.W., E.V.K., and J.V.d.B.; Writing – Original Draft, J.B.; Writing – Review & Editing, J.B., S.G.S.V., D.S., R.H.H., L.A.O., A.T.D.-K., E.L., M.P.J.d.W., and J.V.d.B.; Visualization, J.B., M.v.W., and J.V.d.B.; Supervision, M.P.J.d.W. and J.V.d.B.; Funding Acquisition, M.P.J.d.W. and J.V.d.B. All authors read and approved the final manuscript.
Declaration of Interests
The authors declare no competing interests.
Supplemental Information (2)
Download all
Document S1. Figures S1–S4 and Tables S1–S3
Document S2. Article plus Supplemental Information
References
Bambouskova, M. ∙ Gorvel, L. ∙ Lampropoulou, V. ...
Electrophilic properties of itaconate and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis
Nature. 2018; 556:501-504
Cochain, C. ∙ Vafadarnejad, E. ∙ Arampatzi, P. ...
Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis
Circ. Res. 2018; 122:1661-1674
Dobin, A. ∙ Davis, C.A. ∙ Schlesinger, F. ...
STAR: ultrafast universal RNA-seq aligner
Bioinformatics. 2013; 29:15-21
Ference, B.A. ∙ Ginsberg, H.N. ∙ Graham, I. ...
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Eur. Heart J. 2017; 38:2459-2472
Ghisletti, S. ∙ Huang, W. ∙ Ogawa, S. ...
Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma
Mol. Cell. 2007; 25:57-70
Heinz, S. ∙ Benner, C. ∙ Spann, N. ...
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities
ReportVolume 25, Issue 8p2044-2052.e5November 20, 2018Open access
Download Full Issue
A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia
Jeroen Baardman1 ∙ Sanne G.S. Verberk2,9 ∙ Koen H.M. Prange1,9 ∙ … ∙ Esther Lutgens1,8 ∙ Menno P.J. de Winther1,8,9 ∙ Jan Van den Bossche1,2,9,10 j.vandenbossche@vumc.nl … Show more
Affiliations & NotesArticle Info

Download Full Issue
Show Outline
Highlights
•
Systemic metabolism affects immune cell metabolism
•
Hypercholesterolemia suppresses the PPP and Nrf2 pathway in macrophages
•
PPP inhibition and hypercholesterolemia deactivate inflammatory macrophage responses
•
The Nrf2 pathway regulates the PPP in an LXR-independent manner
Summary
Metabolic reprogramming has emerged as a crucial regulator of immune cell activation, but how systemic metabolism influences immune cell metabolism and function remains to be investigated. To investigate the effect of dyslipidemia on immune cell metabolism, we performed in-depth transcriptional, metabolic, and functional characterization of macrophages isolated from hypercholesterolemic mice. Systemic metabolic changes in such mice alter cellular macrophage metabolism and attenuate inflammatory macrophage responses. In addition to diminished maximal mitochondrial respiration, hypercholesterolemia reduces the LPS-mediated induction of the pentose phosphate pathway (PPP) and the Nrf2-mediated oxidative stress response. Our observation that suppression of the PPP diminishes LPS-induced cytokine secretion supports the notion that this pathway contributes to inflammatory macrophage responses. Overall, this study reveals that systemic and cellular metabolism are strongly interconnected, together dictating macrophage phenotype and function.
Graphical Abstract

Keywords
Introduction
In recent years, metabolic reprogramming arose as a crucial controller of macrophage activation (Van den Bossche et al., 2016, 2017). For instance, in response to pro-inflammatory stimuli such as the Toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS), macrophages show increased glycolysis, as demonstrated by an enhanced extracellular acidification rate (ECAR) (Van den Bossche et al., 2016). Moreover, LPS reconfigures the tricarboxylic acid (TCA) cycle in macrophages and induces itaconate and succinate accumulation (Jha et al., 2015; Tannahill et al., 2013). Itaconate is a key controller of inflammatory macrophage responses through its regulatory effect on succinate dehydrogenase and its activation of the anti-oxidant transcription factor Nrf2 (Lampropoulou et al., 2016; Michelucci et al., 2013; Mills et al., 2018). Succinate promotes inflammation by inducing interleukin 1β (IL-1β) expression (Mills et al., 2016; Tannahill et al., 2013) and can activate immune cells in the local environment upon secretion (Littlewood-Evans et al., 2016). Furthermore, the activity of the pentose phosphate pathway (PPP) is enhanced in LPS-stimulated macrophages, supplying precursors for nucleotide synthesis and nicotinamide adenine dinucleotide phosphate (NADPH), which is used for reactive oxygen species (ROS) production by NADPH oxidase, fatty acid synthesis, and anti-oxidant cellular defense (Nagy and Haschemi, 2015; Wu et al., 2008). So far, most knowledge regarding macrophage immunometabolism was obtained with in vitro-cultured bone marrow-derived macrophages and largely ignored the possible systemic and micro-environmental effects on macrophage metabolism and function in vivo (Norata et al., 2015). Exploring this neglected aspect of immunometabolism might identify therapeutic strategies to dampen chronic inflammatory diseases such as atherosclerosis, in which lipid-laden macrophage “foam cells” are crucial during all stages of the disease. Elevated levels of circulating low-density lipoprotein (LDL) cholesterol, as observed in patients with familial hypercholesterolemia (FH), are a prominent risk factor for developing atherosclerosis (Ference et al., 2017). FH is predominantly caused by loss-of-function mutations in the LDL receptor (LDLR) gene, leading to impaired hepatic uptake of LDL and, consequently, elevated levels of plasma LDL (Reiner, 2015). It has been shown that hypercholesterolemia affects the lipidome of macrophages and deactivates part of their inflammatory responses via activation of LXR (Spann et al., 2012). However, LXR-independent repression mechanisms still need to be defined. Here we confirm that hypercholesterolemia attenuates LPS-induced inflammatory macrophage responses and show that this deactivated phenotype is accompanied by a diminished Nrf2-mediated oxidative stress response and LXR-independent suppression of the PPP, indicating that systemic and cellular metabolism are directly intertwined, together regulating macrophage function.
ResultsHypercholesterolemia Translates into Altered Immune Cell Metabolism
Ingenuity Pathway Analysis (IPA) of published FH patient microarray data (GEO: GSE13985; characteristics in Table S1) identified oxidative phosphorylation (OXPHOS) and mitochondrial dysfunction among the top-ranked enriched canonical pathways (Figure 1A), and most differentially expressed genes belonging to those pathways were downregulated in leukocytes of FH patients (Figure 1B).

Figure 1 Hypercholesterolemia Affects Immune Cell Metabolism
Show full captionFigure viewer
To study the effects of systemic metabolic changes on immune cell metabolism in more detail, Ldlrko mice were fed a high-fat diet (HFD) to induce hypercholesterolemia and hypertriglyceridemia or a normal-fat control diet (NFD) (Figures S1A–S1C). Peritoneal macrophages from HFD mice were elicited as a validated in vivo model and source of foam cells (Spann et al., 2012). CD11b+F4/80+ peritoneal macrophages isolated from the HFD group were lipid-laden foam cells (hereafter referred to as “HFD macrophages”; Figures S1D and S1E) and compared with “NFD macrophages” to evaluate the effect of systemic metabolism on macrophage metabolism independent of microenvironmental cues present in atherosclerotic lesions. To study the effects of these different lipid environments on glycolysis and mitochondrial function in macrophages, we performed an extracellular flux analysis and revealed similar basal glycolysis and mitochondrial respiration in macrophages isolated from mice fed either diet (Figure 1C). Interestingly, HFD macrophages demonstrated lower maximal mitochondrial respiration and a reduced spare respiratory capacity (SRC) (Figure 1D) but showed no differences in non-mitochondrial oxygen consumption, ATP production, and proton leak (Figure S2A). Furthermore, both macrophage types showed similar fuel dependencies, with fatty acids being the main drivers of mitochondrial oxygen consumption (Figure 1E).
Because reduced mitochondrial mass results in decreased SRC in T cells (van der Windt et al., 2012), we assessed whether a lower mitochondrial abundance could explain the reduced SRC in HFD macrophages. Supporting this notion, HFD macrophages indeed showed a lower mitochondrial mass, as demonstrated by MitoTracker Green staining, mitochondrial DNA:genomic DNA ratio, and mitochondrial complex immunoblotting (Figures 1F and 1G and S2B). Together with the observation that similar amounts of mitochondria isolated from NFD or HFD macrophages display equal respiration (Figure 1H), our data strongly suggest that the reduced maximal respiration in HFD macrophages is mainly due to a decrease in mitochondrial mass. RNA sequencing revealed that genes related to mitochondrial biogenesis and dynamics were not altered in HFD macrophages; this was further confirmed by qPCR and immunoblotting (Figures S2C–S2E). Pathway analysis indicated that the top most enriched pathways were related to cholesterol biosynthesis, and associated genes were downregulated in HFD macrophages (Figures 1I and 1J).
Given the importance of metabolites such as itaconate, succinate, and α-ketoglutarate in regulating macrophage function (Lampropoulou et al., 2016; Liu et al., 2017; Michelucci et al., 2013; Mills et al., 2016, 2018; Tannahill et al., 2013), we next measured the levels of an extensive set of 63 metabolites. Partial least square discriminant (PLS-DA) analysis was used to discriminate NFD and HFD macrophages based on the measured metabolites. Interestingly, the abundance of several metabolites varied among NFD and HFD macrophages, with itaconate as the most distinctive metabolite (Figure 1K), whose abundance was lower in HFD macrophages (Table S2). Overall, hypercholesterolemia is associated with reduced mitochondrial mass and maximal respiration and affects the levels of metabolites such as itaconate.
Hypercholesterolemia Attenuates Inflammatory Macrophage Responses without Major Changes in Glycolysis or the TCA Cycle
Because itaconate regulates inflammatory macrophage responses (Jha et al., 2015; Mills et al., 2018) and was reduced in naive HFD macrophages, we investigated the effects of hypercholesterolemia on LPS-induced inflammatory macrophage activation. In parallel to the previously reported decreased expression of several inflammatory genes, we identified reduced secretion of pro-inflammatory cytokines as well as lower nitric oxide (NO) and lower ROS levels in HFD macrophages (Figures 2A–2C). Both types of macrophages exhibited similar phagocytic activity and comparable expression of Il10 and IL-4-induced genes and surface proteins (Figures 2D, S3A, and S3B). Together, this does not indicate a general inhibition of macrophage activation in the HFD group but shows that these cells undergo a deactivation process during which foam cells lose part of their LPS-induced inflammatory properties. Likewise, short exposure to oxidized or acetylated LDL in vitro also decreased subsequent LPS-induced tumor necrosis factor (TNF), IL-6, and NO secretion in NFD macrophages (Figure S3C).

Figure 2 Hypercholesterolemia Attenuates the Inflammatory Phenotype of Macrophages without Reconfiguring Glycolysis and the TCA Cycle
Show full captionFigure viewer
To address whether distinct LPS-induced metabolic rewiring underlies the deactivated phenotype of HFD foam cells, we measured glycolysis upon acute and 24-hr LPS exposure. NFD and HFD macrophages showed comparable glycolytic rates and glucose uptake (Figure 2E, 2F, and S3D), indicating that the attenuated inflammatory phenotype of HFD macrophages is probably not caused by reduced glycolysis.
Next we examined whether differences in succinate, itaconate, α-ketoglutarate, or other metabolites could explain the attenuated pro-inflammatory function of LPS-stimulated HFD macrophages. PLS-DA identified distinct metabolic profiles upon LPS stimulation in macrophages from both groups (Figure 2G). We observed that LPS induced itaconate, succinate, and oxaloacetate levels to a similar extent in both NFD and HFD macrophages (Figure 2H). This suggests that the reduced inflammatory phenotype observed in HFD macrophages is not caused by a distinct LPS-induced TCA cycle reconfiguration. In addition to altered levels of different amino acids (Figures 2I) and increased levels of NADH in HFD macrophages (Table S2), several metabolites related to the PPP (marked with asterisks in Figure 2I) strongly contributed to the differential metabolic profile in LPS-stimulated NFD and HFD macrophages.
Hypercholesterolemia Diminishes the NRF2 and PPP in Macrophages
Metabolic analysis demonstrated an increased abundance of several PPP metabolites, including ribose-5P or ribulose-5P, sedoheptulose-7P, and glyceraldehyde 3-P upon LPS stimulation (Figure 3A). Interestingly, LPS-induced ribose-5P or ribulose-5P and sedoheptulose-7P levels were lower in HFD macrophages. Analyzing the two genes that encode glucose-6-phosphate dehydrogenase (G6PD) as the rate-limiting enzyme of the PPP in mice (Huminiecki and Wolfe, 2004) revealed that the LPS-induced elevation of G6pd2, but not G6pdx, was absent in HFD macrophages (Figures 3B and 3C). Moreover, Pgd (encoding 6-phosphogluconate dehydrogenase, which converts 6-phosphogluconate into ribulose 5-P in the PPP) was reduced in both naive and LPS-stimulated HFD macrophages (Figure 3B), whereas Pgd protein levels were only suppressed in naive HFD macrophages (Figure S4A). To validate whether suppression of the PPP in HFD macrophages (Figure 3D) could explain their attenuated LPS-induced inflammatory responses, we pharmacologically inhibited G6PD with dehydroepiandrosterone (DHEA) or 6-aminonicotinamide (6-AN). Supporting this notion, blockade of the PPP diminished the LPS-induced production of pro-inflammatory mediators in macrophages (Figure 3E). Because desmosterol-driven LXR activation regulates at least a part of the inflammatory phenotype of foam cells (Spann et al., 2012), we studied whether this pathway controls the PPP. Activation of LXR and its target genes with GW3965 did not affect PPP genes and metabolites (Figures S4B–S4D), backing the idea that both LXR-dependent and independent mechanisms contribute to the diminished inflammatory phenotype of foam cells (Spann et al., 2012).

Figure 3 Hypercholesterolemia Reduces LPS-Mediated Induction of the PPP in Macrophages
Show full captionFigure viewer
To uncover the LXR-independent mechanistic link between hypercholesterolemia, suppressed PPP, and inflammation, we further explored our RNA sequencing (RNA-seq) dataset. Pathways analysis revealed that the Nrf2 pathway was the most differentially regulated pathway between LPS-stimulated NFD and HFD macrophages (Figure 3F), and most genes of this pathway were downregulated in HFD macrophages (Figure 3G). Accordingly, Nrf2 protein levels were reduced in LPS-treated HFD macrophages (Figure 3H). Importantly, Nrf2 was found to be a regulator of the PPP in cancer cells (Mitsuishi et al., 2012) and analyzing expression data from Nrf2-deficient macrophages (GEO: GSE71695) revealed that several PPP genes, including Pgd, are downregulated in Nrf2-deficient macrophages (Figure S4E). Moreover, analysis of published chromatin immunoprecipitation (ChIP-seq) data (DDBJ: DRA003771) revealed binding of Nrf2 4 kb upstream of the Pgd locus (Figure 3I), suggesting a direct link between reduced Nrf2 activity and Pgd expression in HFD macrophages. Indeed, Pgd is suppressed in Nrf2-deficient macrophages and increased in macrophages that have lower levels of the Nrf2 repressor protein KEAP1 (Figure 3J). Accordingly, the LPS-induced production of sedoheptulose-7P and ribose-5P or ribulose-5P downstream of Pgd in the PPP was blunted in the absence of Nrf2 (Figure S4F). This suppressed Nrf2 signaling acts in parallel with other pathways, like the LXR pathway (Spann et al., 2012), and manipulating one branch does not recapitulate the deactivated phenotype observed in HFD macrophages. Indeed, Nrf2-deficient macrophages did not show overall suppressed LPS responses (Figure S4G).
Together, this demonstrates a link between reduced Nrf2 and a defective PPP in HFD macrophages and that the latter pathway supports inflammatory responses.
Discussion
Recent findings in the rapidly expanding field of immunometabolism underscored the importance of metabolic reprogramming during macrophage activation (Van den Bossche et al., 2017). However, most knowledge regarding this metabolic-immunologic crosstalk has emerged from in vitro-cultured macrophages, excluding different (e.g., microenvironmental and systemic) layers of regulation that are at play in vivo. This gave us the incentive to explore the influences of different systemic lipid environments on cellular macrophage metabolism and function.
Leukocytes from FH patients demonstrated reduced expression of genes related to OXPHOS. In mice, hypercholesterolemia was associated with reduced cholesterol biosynthesis in macrophages. Differences in cell type (total leukocytes versus macrophages) or species (human versus mouse) might underlie this discrepancy. Dhcr24, which encodes 24-dehydrocholesterol reductase, which converts desmosterol into cholesterol, was the most suppressed gene related to cholesterol biosynthesis in macrophages from HFD mice. This finding is in agreement with a previous study, and diminished Dhcr24 expression was found to result in the accumulation of desmosterol in HFD macrophages (Spann et al., 2012).
Isolated macrophages from hypercholesterolemic mice showed reduced maximal respiration and SRC. In T cells, SRC is positively correlated with their survival (van der Windt et al., 2012). Therefore, decreased SRC might increase the susceptibly to apoptosis in macrophage foam cells, potentially contributing to necrotic core development in atherosclerotic lesions (Moore et al., 2013).
It is well-accepted that atherosclerosis is a chronic inflammatory disease driven by elevated LDL cholesterol levels. The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial provides strong evidence in support of the inflammation hypothesis and demonstrated that neutralizing the pro-inflammatory cytokine IL-1β significantly reduces the rate of recurrent cardiovascular events (Ridker et al., 2017).
Confirming previous literature (Spann et al., 2012), we now observed that the LPS-induced secretion of inflammatory mediators was reduced in macrophages isolated from hypercholesterolemic mice. This might appear to be inconsistent with the inflammation hypothesis of atherogenesis. However, it is important to note that both in vivo-elicited HFD foam cells and in vitro LDL-exposed macrophages still produce considerable amounts of inflammatory cytokines upon activation, albeit to a lower extend than “normal” macrophages. Another explanation for the observed deactivated phenotype of foam cells could be the phenotypic diversity detected in plaques (Cochain et al., 2018). Not all plaque macrophages exhibit a pro-inflammatory phenotype, and there is a substantial subpopulation of macrophages with anti-inflammatory features (Kadl et al., 2010). In agreement with our observations, recent transcriptome analysis of macrophages from atherosclerotic aortae revealed that lipid-loaded plaque macrophages are less inflammatory than their non-foamy counterparts (Kim et al., 2018). We therefore favor the theory that, in addition to the systemic metabolic environment, microenvironmental cues regulate macrophage phenotypes in plaques (Spann et al., 2012) to promote the chronic inflammatory responses that are demonstrably driving atherogenesis.
Accumulation of cellular cholesterol leads to specific oxysterols and sterols that regulate the activity of LXR (Spann et al., 2012). LXRs bind to and prevent the removal of repressor complexes at TLR4-responsive genes, blunting their expression and exerting anti-inflammatory effects (Ghisletti et al., 2007). We now show that, in addition to LXR (Spann et al., 2012), LXR-independent impairment of the PPP contributes to the suppressed inflammatory responses in macrophage foam cells during hypercholesterolemia.
Interestingly, we discovered that 6-phosphogluconate dehydrogenase (Pgd) gene expression and downstream metabolites were blunted in HFD macrophages. In accordance, knockdown of PGD was found to reduce the oxidative PPP flux, NADPH:NADP+ ratio, and ribulose-5P and ribose-5P levels in human cancer cells (Lin et al., 2015). NADPH and ribose-5P generated in the PPP can support the inflammatory macrophage responses in different ways, including ROS production, anti-oxidant cellular defense, fatty acid synthesis, and nucleotide production (Nagy and Haschemi, 2015). Thus, reduced flux through the PPP as observed in HFD macrophages can cause attenuated inflammatory responses and ROS production. Furthermore, Pgd expression was already reduced in naive HFD macrophages, possibly creating a condition that causes impaired future LPS responses. Vice versa, the lower PPP might also be a consequence of an attenuated inflammatory phenotype in HFD macrophages and the consecutive lower demand for PPP-derived products that regulate inflammation and anti-oxidant cellular defense.
We identified the Nrf2-mediated oxidative stress response as the most suppressed pathway in LPS-stimulated HFD macrophages. Nrf2 emerged as a crucial regulator of the inflammatory responses in macrophages (Kobayashi et al., 2016; Mills et al., 2018). Interestingly, several PPP genes were previously identified as Nrf2 target genes in cancer cells (Mitsuishi et al., 2012). Here we emphasized the importance of the Nrf2 pathway in the regulation of the PPP in macrophages. Importantly, suppressed Nrf2 is not the only mediator of the HFD macrophage phenotype and probably acts in parallel with other mechanisms, like the desmosterol-induced LXR pathway that was described earlier (Spann et al., 2012). Indeed, LXR activation or Nrf2 deletion as such did not result in the deactivated HFD macrophage phenotype. Our observations agree with previous studies demonstrating normal IL-1β, TNF, and IL-6 expression in the absence of Nrf2 (Mills et al., 2018; Bambouskova et al., 2018; Kobayashi et al., 2016). Conversely, activation of Nrf2 in macrophages by pharmacological or genetic (low KEAP1 expression) means clearly dampens inflammatory responses (Kobayashi et al., 2016) and mediates the anti-inflammatory effects of the metabolite itaconate (Mills et al., 2018). Thus, low levels of Nrf2 do not affect LPS responses as such, but Nrf2 activation is clearly anti-inflammatory. It will be of interest to define the mechanism responsible for Nrf2 repression in macrophage foam cells.
Together, these observations show that hypercholesterolemia suppresses the Nrf2 and PPP in macrophages and deactivates their inflammatory phenotype. We demonstrate that systemic metabolic changes translate into rewired intracellular metabolic pathways in macrophages that are tailored to support their effector functions. This highlights the intricate interplay between inflammatory signaling and metabolic pathways.
STAR★MethodsKey Resources Table
REAGENT or RESOURCESOURCEIDENTIFIER
| Antibodies | ||
| anti-actin | Millipore | Cat# MAB1501; RRID:AB_2223041 |
| anti-mitofusin 1 (MFN1) | Abcam | Cat# ab57602; RRID:AB_2142624 |
| anti-mitofusin 2 (MFN2) | Sigma | Cat# WH0009927M3; RRID:AB_1842440 |
| anti-OPA1 | BD Biosciences | Cat# 612606; RRID:AB_612606 |
| anti-NRF2 | Cell Signaling | Cat# 12721; RRID:AB_2715528 |
| anti-PGD | Abcam | Cat# ab129199; RRID:AB_11144133 |
| Total OXPHOS Rodent WB Antibody Cocktail | Abcam | Cat# ab110413; RRID:AB_2629281 |
| anti-rabbit IgG/HRP (secondary) | Thermo Fisher Scientific | Cat# 32260; RRID:AB_1965959 |
| anti-mouse IgG/HRP (secondary) | Thermo Fisher Scientific | Cat# 32230; RRID:AB_1965958 |
| anti-mouse CD71-PE | BD PharMingen | Cat# 553267; RRID:AB_394744 |
| anti-mouse CD206-APC | Biolegend | Cat# 141707; RRID:AB_10896057 |
| anti-mouse CD273-PE | BD PharMingen | Cat# 557796; RRID:AB_396874 |
| anti-mouse CD301-Alexa Fluor-647 | Serotec | Cat# MCA2392A647T; RRID:AB_1101873 |
| rat IgG2a-PE (isotype control) | BioLegend | Cat# 400507 |
| rat IgG2a-APC (isotype control) | BioLegend | Cat# 400511 |
| anti-mouse CD11b-PE-Cy7 | BD PharMingen | Cat# 552850; RRID:AB_394491 |
| anti-mouse F4/80-APC-eFluor780 | eBioscience | Cat# 47-4801; RRID:AB_2637188 |
| anti-mouse CD16/CD32 (Fc-block) | eBioscience | Cat# 14-0161; RRID:AB_467132 |
| Chemicals, Peptides, and Recombinant Proteins | ||
| Penicillin-Streptomycin | Thermo Fisher Scientific | Cat# 15140-122 |
| L-glutamine | Thermo Fisher Scientific | Cat# 25030024 |
| Recombinant murine IL-4 | PeproTech | Cat# 214-14 |
| Lipopolysaccharides (LPS) | Sigma | Cat# L2637 |
| Oil Red O | Sigma | Cat# O0625 |
| Hematoxylin | Merck | Cat# 1.05175.2500 |
| Oligomycin (OM) | Sigma | Cat# 75351 |
| 2-deoxyglucose (2-DG) | Sigma | Cat# D6134 |
| Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) | Sigma | Cat# C2920 |
| Rotenone | Sigma | Cat# R8875 |
| Antimycin A | Sigma | Cat# A8674 |
| Pyruvic acid | Sigma | Cat# 107360 |
| Malic acid | Sigma | Cat# M0875 |
| Adenosine diphosphate (ADP) | Sigma | Cat# A5285 |
| MitoTracker Green FM | Thermo Fisher Scientific | Cat# M7514 |
| CM-H2DCFDA | Thermo Fisher Scientific | Cat# C6827 |
| 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) | Thermo Fisher Scientific | Cat# N13195 |
| RNA-free DNase | QIAGEN | Cat# 79254 |
| 6-Aminonicotinamide (6-AN) | Sigma | Cat# A68203 |
| Dehydroepiandrosterone (DHEA) | Sigma | Cat# D063 |
| GW3965 | Sigma | Cat# G6295 |
| Critical Commercial Assays | ||
| IL-6 ELISA | Life Technologies | Cat# CMC0063 |
| TNF ELISA | Life Technologies | Cat# CMC3013 |
| Griess reaction | Sigma | Cat# G4410 |
| BCA Protein Assay kit | Thermo Fisher Scientific | Cat# 23225 |
| RNeasy Mini Kit | QIAGEN | Cat# 74106 |
| Ovation Mouse RNA-Seq System | NuGEN | Cat# 0348-32 |
| High Pure RNA Isolation Kit | Roche | Cat# 11828665001 |
| iScript cDNA Synthesis Kit | Bio-Rad | Cat# 170-8891 |
| Quick-gDNA MiniPrep | Zymo Research | Cat# D3024 |
| Deposited Data | ||
| RNA-sequencing data | This paper | GEO: GSE107412 |
| Experimental Models: Organisms/Strains | ||
| Mouse: LdlrKO: B6.129S7-Ldlrtm1Her/J | The Jackson Laboratory | JAX:002207 |
| Mouse: Nrf2KO: B6.129P3-Nf2l2tm1Mym | Itoh et al., 1997 | N/A |
| Mouse: Keap1KD: B6.129P3-Keap1tm2Mym | Taguchi et al., 2010 | N/A |
| Mouse: WT: C57BL/6J | The Jackson Laboratory | JAX:000664 |
| Oligonucleotides | ||
| Primer sequences | This paper (Table S3) | N/A |
| Software and Algorithms | ||
| FlowJo | ThreeStar | N/A |
| GraphPad Prism 7 | GraphPad Software | N/A |
| Seahorse Wave | Agilent | N/A |
| Ingenuity Pathway Analysis | QIAGEN | N/A |
| R package: ggplot2 | Wickham, 2016 | https://cran.r-project.org/web/packages/ggplot2 |
| R package: ropls | Thévenot et al. (2015) | http://www.bioconductor.org/packages/release/bioc/html/ropls.html |
| R package: mixOmics | Rohart et al. (2017) | http://mixomics.org |
| STAR 2.5.2b | Dobin et al. (2013) | https://github.com/alexdobin/STAR/releases |
| SAM tools | Li et al. (2009) | http://samtools.sourceforge.net |
| HOMER | Heinz et al. (2010) | http://homer.ucsd.edu/homer |
| R package: DESeq2 | Love et al. (2014) | https://bioconductor.org/packages/release/bioc/html/DESeq2.html |
| R package: limma | Ritchie et al. (2015) | https://bioconductor.org/packages/release/bioc/html/limma.html |
| Other | ||
| Control normal fat diet (NFD) | Harlan Laboratories (Envigo) | Cat# 2016 (Teklad global 16% protein) |
| High fat diet (HFD) | Special diet Services | Code 824199 |
| 0.5 μM Fluoresbrite YG microspheres | Polysciences | Cat# 17152 |
| Thioglycollate medium | Fisher Scientific | Cat# 11782834 |
| RPMI-1640 medium | Thermo Fisher Scientific | Cat# 52400041 |
| RPMI-1640 Medium, no glucose | Thermo Fisher Scientific | Cat# 11879020 |
| Fetal Bovine Serum | Thermo Fisher Scientific | Cat# 10500 |
| NP-40 cell lysis buffer | Thermo Fisher Scientific | Cat# FNN0021 |
| Protease Inhibitor Cocktail | Sigma | Cat# 11873580001 |
| PhosSTOP | Sigma | Cat# 4906837001 |
| Bolt 4-12% Bis-Tris Plus Gels | Thermo Fisher Scientific | Cat# NW04120BOX |
| Nitrocellulose Membrane | Bio-Rad | Cat# 162-0094 |
| TWEEN 20 | Sigma | Cat# P1379 |
| SuperSignal West Pico PLUS Chemiluminescent Substrate | Thermo Fisher Scientific | Cat# 34580 |
| Fast SYBR Green Master Mix | Applied Biosytems | Cat# 4385618 |
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jan Van den Bossche (j.vandenbossche@vumc.nl).
Experimental Model and Subject DetailsMice
Female and male LdlrKO mice were obtained from Jackson Laboratory. LdlrKO mice were housed at the Animal Research Institute AMC (ARIA) and all animal experiments were conducted after approval (permit: DBC102861) by the Committee for Animal Welfare of the Academic Medical Center, University of Amsterdam. 6-month old adult mice were used for experiments and put on a control normal fat diet (NFD, 4% fat, Harlan Laboratories) or a high fat, high cholesterol diet (HFD, 16% fat, 0,25% cholesterol, Special Diet Services) for 10 weeks. Nrf2-knockout (Nrf2KO) (Itoh et al., 1997) and Keap1-knockdown (Keap1KD) (Taguchi et al., 2010) mice, and their wild-type (WT) counterparts, all 8-12-week old females on the C57BL/6 genetic background, were bred and maintained in the Medical School Resource Unit of the University of Dundee. Mice of the same sex were randomly assigned to both experimental groups in disposable Innovive 101 IVC cages in groups of 3 or 4.
Method DetailsIsolation of macrophages
After 10 weeks of NFD or HFD, LldrKO mice were euthanized by CO2 asphyxiation. Four days prior to sacrifice, mice were intraperitoneally injected with 3% thioglycollate medium (Fisher Scientific). Upon sacrifice, the peritoneum was flushed with 10 mL ice-cold PBS and collected peritoneal cells were cultured in RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin (GIBCO). After 3 h, non-adherent cells were washed away and adhered cells (typically consisting of 90%–95% CD11b+ F4/80+ macrophages, Figure S1D) were stimulated for 24 hours with 10 ng/ml LPS (Sigma) or 100 U/ml IL-4 (Peprotech), or were left untreated, and were used for further analyses. Blood cholesterol and triglyceride levels were measured by enzymatic methods using available kits (Roche). To determine lipid accumulated in peritoneal macrophages, tissue slides with cells were fixed in 4% formalin for 10 minutes and washed two times with PBS (with magnesium and chloride) before and after fixation. Subsequently, tissue slides were incubated in 60% isopropanol for 15 minutes before staining for 45 minutes with fresh 0.3% Oil Red O in 60% isopropanol. After staining, tissue slides were rinsed in 60% isopropanol, washed in distilled water, incubated for 1 minute with hematoxylin blued in tap water and rinsed with distilled water. Bone-marrow derived (BMDM) macrophages were generated from femurs and tibia from WT, Nrf2KO and Keap1KD mice and differentiated in RPMI-1640 containing 25 mM HEPES, 2 mM L-glutamine, 10% FCS, 100 U/ml penicillin and 100 μg/ml streptomycin and 15% L929-conditioned medium for 7 days.
Metabolic extracellular flux analysis
Macrophages (1x105 cells/well) were plated on XF-96-cell culture plates (Seahorse Bioscience) and treated as specified. OCR and ECAR were assessed using the XF-96 Flux Analyzer (Seahorse Bioscience) as detailed before (Van den Bossche et al., 2015). Changes in ECAR in response to glucose (10 mM), OM (1.5 μM) and 2-DG (100 mM) injection were used to calculate all glycolysis parameters and OXPHOS characteristics were calculated from the OCR changes in response to OM (1.5 μM), FCCP (1.5 μM) and rotenone (1.25 μM) + antimycin A (2.5 μM) injection (Van den Bossche et al., 2015; Van den Bossche et al., 2016). The Seahorse Bioscience Mito Fuel Flex Test Kit was used to determine the dependency of cells for glucose, glutamine or fatty acid oxidation.
Respiratory measurements of isolated mitochondria
To isolate mitochondria, cell pellets were resuspended in 1 mL of MTE buffer (250 mM mannitol, 5 mM TRIS, 0.5 mM EDTA, pH 7.4). Macrophages were lysed using 10 passages through the cell cracker (European Molecular Biology Laboratory, Heidelberg, Germany). The homogenate was centrifuged 10 min at 1000 g, after which the supernatant was transferred to a new tube and centrifuged at 10000 g. The resulting supernatant was considered the cytosolic fraction. The final pellet containing the mitochondrial fraction was washed with 1 mL MTE buffer, centrifuged at 3600 g and resuspended in a minimal volume of MTE buffer. Equal amounts of mitochondria (0.5 μg well) were resuspended in MAS buffer (70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, and 1 mM EGTA; pH 7.2, plus 10 mM pyruvate and 1 mM malate as substrates), transferred to XF-96-cell culture plates, centrifuged at 2000 g for 20 min at 4°C and measured using a XF-96 Flux Analyzer (Seahorse Bioscience) to assess basal oxygen consumption (state 2), maximal coupled respiration or state 3 after injection of 4 mM ADP, state 4o after injection of 1.5 μM OM, maximal uncoupled respiration (state 3u) after injection of 4 μM FCCP and the respiratory control ratio (RCR = state 3/state 4o) in accordance to an established protocol (Rogers et al., 2011).
Liquid chromatography - mass spectrometry
Macrophages (5x105 cells/well) in 24 well plates were washed three times with 0,9% NaCl. Metabolism was quenched by adding 1 mL ice-cold methanol/water (1/1; v/v). The following internal standards were added, D3-aspartic acid, D3-serine, D5-glutamine, D3-glutamate, 13C3-pyruvate, 13C6-isoleucine, 13C6-glucose, 13C6-fructose-1,6-biphosphate, 13C6-glucose-6-phosphate, adenosine-15N5-monophosphate and guanosine-15N5-monophosphate (5 μM). 1 mL of chloroform was added, vortexed and centrifuged for 5 minutes at 14.000 rpm at 4°C. ∼800 μL of the “polar” top layer was transferred to a 1.5 mL tube, dried to dryness in a vacuum concentrator and dissolved in 100 μL methanol/water (6/4; v/v). For the analysis, we used a Thermo Scientific (U)HPLC system coupled to a Thermo Q Exactive (Plus) Orbitrap mass spectrometer (Waltman) with a SeQuant ZIC-cHILIC column at 15°C (PEEK 100 × 2.1 mm, 3.0 μm particle size, Merck). The mobile phase composed of (A) 9/1 acetonitrile/water with 5 mM ammonium acetate; pH 6.8 and (B) 1/9 acetonitrile/water with 5 mM ammonium acetate; pH 6.8, respectively. The LC program started with 100% (A) hold 0-3 min; ramping 3-24 min to 20% (A); hold from 24-27 min at 20% (A); ramping from 27-28 min to 100% (A); and re-equilibrate from 28-35 min with 100% (A), flow rate was 0.250 mL/min. The MS data were acquired in full scan, negative ionization mode with a mass resolution of 140.000. Interpretation of the data was performed in the Xcalibur software (ThermoFisher). Subsequent analyses were done in a R environment using the ggplot2, ropls and mixOmics packages (Rohart et al., 2017; Thévenot et al., 2015; Wickham, 2016).
Flow cytometry
To assess surface marker expression, cells (1.5x105 cells/well) in 96 well plates were deateched with citrate and transferred to V-bottom 96 well plates and stained with CD71, CD206, CD273, CD301 or isotype controls (all 1:250 diluted in PBS with 0,5% BSA and 2.5 mM EDTA) for 20 minutes at room temperature in the dark. After labeling, cells were washed with PBS with 0,5% BSA and 2.5 mM EDTA and finally resuspend in PBS with 0,5% BSA and 2.5 mM EDTA and measured on BD FACSCanto or a Beckman Coulter CytoFLEX, and analyzed using FlowJo (TreeStar). In order to quantify mitochondrial mass and ROS production, macrophages (105 cells/well) in 96 well plates were detached using citrate buffer (17 mM tri-Sodium citrate dehydrate and 135 mM potassium chloride in water) transferred to V-bottom 96 well plates and washed with PBS. Next, cells were resuspended in PBS with 200 nm MitoTracker Green or 20 μM CM-H2DCFDA (both ThermoFisher) and incubated for 30 minutes at 37°C (5% CO2). After incubation, cells were washed with PBS and mitochondrial mass and ROS production was measured using flow cytometry. To determine glucose uptake, macrophages (105 cells/well) were cultured in 96 well plates for two hours in RPMI-1640 lacking glucose and serum. Subsequently, 2-NBDG (ThermoFisher) was added for an additional incubation of 20 minutes in a final concentration of 25 μM. Next, cells were detached with citrate buffer, transferred to V-bottom 96 well plates and washed with PBS and analyzed using flow cytometry. To assess phagocytic activity, 105 macrophages were cultured for 1 h at 37°C (or 4°C as a control, Figure S3E) in the presence of Fluoresbrite YG microspheres (0.5 μM, Polysciences).
Immunoblotting
Immunoblotting for NRF2 and mitochondrial complexes was performed as detailed by (Mills et al., 2018) and (Wüst et al., 2016), respectively. For MFN1, MFN2, OPA1 and PGD immunoblotting, macrophages (1x106 cells/well) in 12 well plates were lysed in NP40 cell lysis buffer (ThermoFisher) supplemented with protease inhibitor cocktail (Sigma-Aldrich) and PhosSTOP (Sigma-Aldrich). Lysates were equalized on protein concentration after quantification with the BCA assay (ThermoFisher), separated on Bolt 4%–12% Bis-Tris gels (ThermoFisher) and transferred onto nitrocellulose membranes (Bio-Rad). After blocking for 1 hour with 5% milk powder (Campina) in Tris-buffered saline, TWEEN 20 (TBS-T), membranes were incubated overnight with primary antibodies against MFN1 (1:1000 dilution), MFN2 (1:200), OPA1 (1:1000) and PGD (1:1000) in 5% milk, TBS-T, followed by incubation for 1 hour with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:2000) in 5% milk, TBS-T and visualization with SuperSignal West Pico Chemiluminescent PLUS Substrate (Thermo Fisher Scientific).
Cytokine and NO production
IL-6 and TNF levels in the supernatant were measured by ELISA (Life Technologies) and NO production was assessed by a Griess reaction (Sigma-Aldrich) according to the supplier’s protocol.
RNA sequencing
Total RNA was isolated from peritoneal macrophages using a RNeasy Mini Kit with DNase treatment (QIAGEN). Strand-specific libraries were constructed from 100 ng total RNA using ‘Ovation RNA-Seq system’ following manufacturer instructions (NuGen Technologies). Samples were pooled and diluted to 10 nM and sequenced on an Illumina HiSeq 4000 instrument (Illumina) to a depth of ± 20 million single-ended 50 bp reads.
Bioinformatics
Reads were aligned to the mouse genome mm10 by STAR 2.5.2b with default settings (Dobin et al., 2013). BAM files were indexed and filtered on MAPQ > 15 with SAMTools 1.3.1 (Li et al., 2009). Raw tag counts and RPKM (reads per kilobase per million mapped reads) values per gene were summed using HOMER2′s analyzeRepeats.pl script with default settings and the -noadj or –rpkm options for raw counts and RPKM reporting, respectively (Heinz et al., 2010). Differential expression was assessed using the DESeq2 bioconductor package in an R 3.3.1 environment with gene expression called differential with a p value < 0.05 and an average RPKM > 1 in at least one group (Love et al., 2014). Presented RPKM values in scatterplots were tested using one-way ANOVA followed by Bonferroni’s post hoc comparisons test. Differential expression analysis on available microarray data (GEO: GSE13985) was executed using the limma package and gene expression was called differential with a p value < 0.05 (Ritchie et al., 2015). Differential expressed genes were analyzed in Ingenuity Pathway Analysis (Qiaqen) to identify deregulated pathways.
qPCR
RNA was isolated with High Pure RNA Isolation kits (Roche), cDNA was synthesized with iScript (Bio-Rad), and qPCR was performed using SYBR Green Fast mix (Applied Biosytems) on a ViiA7 (Applied Biosystems). Housekeeping genes Rplp0 and Ppia were used for normalization and used primer sequences are noted in the Table S3. DNA was extracted using the Quick-gDNA MiniPrep (Zymo Research) kit and primers for mt-Co1 and Ndufv1 were used to determine the mtDNA/gDNA ratio.
Quantification and Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). Number (n) and type (biological or technical) of replicates are indicated in the figure legends. Data were tested using a two-tailed Student’s t test (when comparing two groups) or one-way ANOVA followed by Bonferroni’s post hoc comparison to test multiple groups in GraphPad Prism version 7.0 software, as indicated in the figure legends. p values < 0.05 were considered significant, with levels of significance being indicated as follows: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns, not significant.
Data and Software Availability
The accession number for the RNA sequencing data reported in this paper is GEO: GSE107412.
Acknowledgments
J.V.d.B. received a VENI grant from ZonMW (91615052) and a Netherlands Heart Foundation junior postdoctoral grant (2013T003) and senior fellowship (2017T048). M.P.J.d.W. is an established investigator of the Netherlands Heart Foundation, is supported by grants from the Netherlands Heart Foundation and Spark-Holding BV (2015B002), the European Union (ITN grant EPIMAC and REPROGRAM [EU Horizon 2020]), and Fondation Leducq (16CVD-01), and holds an AMC fellowship. We acknowledge support from the Netherlands CardioVascular Research Initiative, Dutch Federation of University Medical Centers, the Netherlands Organisation for Health Research and Development, the Royal Netherlands Academy of Sciences (CVON 2011-19 and CVON 2017-20) and Cancer Research UK (C20953/A18644). We thank Tadeja Rezen, Peter Juvan, and Damjana Rozman for the GEO: GSE13985 dataset details.
Author Contributions
Conceptualization, J.V.d.B.; Methodology, J.V.d.B.; Formal Analysis, J.B., S.G.S.V., M.v.W., K.H.M.P., and J.V.d.B.; Investigation, J.B., S.v.d.V., S.G.S.V., D.G.R., R.C.I.W., A.E.N., S.W.D., M.E.W., E.V.K., and J.V.d.B.; Writing – Original Draft, J.B.; Writing – Review & Editing, J.B., S.G.S.V., D.S., R.H.H., L.A.O., A.T.D.-K., E.L., M.P.J.d.W., and J.V.d.B.; Visualization, J.B., M.v.W., and J.V.d.B.; Supervision, M.P.J.d.W. and J.V.d.B.; Funding Acquisition, M.P.J.d.W. and J.V.d.B. All authors read and approved the final manuscript.
Declaration of Interests
The authors declare no competing interests.
Supplemental Information (2)
Download all
Document S1. Figures S1–S4 and Tables S1–S3
Document S2. Article plus Supplemental Information
References
Bambouskova, M. ∙ Gorvel, L. ∙ Lampropoulou, V. ...
Electrophilic properties of itaconate and derivatives regulate the IkappaBzeta-ATF3 inflammatory axis
Nature. 2018; 556:501-504
Cochain, C. ∙ Vafadarnejad, E. ∙ Arampatzi, P. ...
Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis
Circ. Res. 2018; 122:1661-1674
Dobin, A. ∙ Davis, C.A. ∙ Schlesinger, F. ...
STAR: ultrafast universal RNA-seq aligner
Bioinformatics. 2013; 29:15-21
Ference, B.A. ∙ Ginsberg, H.N. ∙ Graham, I. ...
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Eur. Heart J. 2017; 38:2459-2472
Ghisletti, S. ∙ Huang, W. ∙ Ogawa, S. ...
Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma
Mol. Cell. 2007; 25:57-70
Heinz, S. ∙ Benner, C. ∙ Spann, N. ...
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities